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3. Abstract 
3.1 Deutsche Zusammenfassung 
Das Vorkommen und die Funktion von Z-DNA in Menschen wurde innerhalb der 
letzten Jahrzehnte erforscht und bestätigt[1-9]. Die Detektierbarkeit und damit ein 
tieferes Verständnis der Funktion von Z-DNA in lebenden Zellen oder gar ganzen 
Organismen wurde trotz vieler Forschungsarbeiten nicht erreicht. Man ist im 
Moment nicht in der Lage zu bestimmen, in welchem Zellstadium Z-DNA vorkommt 
und welche genaue Funktion es übernimmt. Der Fokus dieser Arbeit widmet sich dem 
Thema Detektierbarkeit von Z-DNA in lebenden Zellen über einen Ansatz, der durch 
rationelles Design von kleinen Molekülen diese speziellen Form Z-DNA darstellt.  
Der erste Schritt dieser Arbeit war das Auffinden von funktionierenden 
Metallkomplexen und das Testen dieser in Modelsystemen. Das Ziel war, eine 
spezifische Interaktion zwischen DNA und dem Metallkomplex zu definieren welche 
einfach zu detektieren, reproduzierbar und auch in vivo anwendbar ist. Da DNA in 
wässriger und salzhaltiger Umgebung vorkommt, wurden ein stabiles und 
wasserlösliches Porphyrin, 5,10,15,20-Tetramethylpyridinium-porphyrin, als 
Grundbaustein gewählt. Die Eigenschaften der Porphyrine kann man durch 
verschiedene zentrale Metalle beeinflussen. Verschiedene Kombinationen dieser 
Porphyrine mit und ohne Metallzentren wurden in Modelsystemen getestet. Balaz et 
al. haben im Jahr 2005 eine Studie veröffentlicht, in welcher sie Z-DNA mit einem 
Zink(II) 5,10,15,20-(methyl-pyridinium)-porphyrin mittels CD Spektroskopie spezifisch 
nachweisen konnten[10, 11]. Wir haben diese Resultate kurze Zeit später bestätigen 
können und die Effekte verschiedener Metallzentren wie Kupfer und Nickel getestet. 
Dabei stellte sich heraus, das die Metallzentren eine wichtige Rolle spielen und 
verschiedene Interaktionen wie zum Beispiel Interkalation, partielle Interkalation, 
oder seitliche Koordination mit DNA bevorzugen. Ein Stacking der Porphyrine um die 
DNA wurde auch beobachtet, welches massgeblich bei Molekülen mit axialen 
Liganden am Metallzentrum einher ging.  
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Um dieses System spezifischer in kompetitiver Umgebung wie Zellen zu machen und 
elektrostatische Interaktionen zwischen den Porphyrinen zu vermeiden, wurde dieses 
System weiterentwickelt zu einem Porphyrin  Netzwerk. Dieses sollte aus zwei Z-DNA 
detektierenden Einheit Metall-(methylpyridinium)-porpyhrin und einer starren 
Verbindung mit definiertem Abstand aufgebaut sein. Als Verbindungen der beiden 
Porphyrine wurde ein quadratisch planar koordinierendes Metallzentrum wie zum 
Beispiel Cisplatin gewählt. Dieses Molekül könnte mit der Eigenschaft als side-on 
koordinierendes Metalloporphyrin die spezifischen Eigenschaften der Z-DNA wie 
Basenabstand, Durchmesser und die exponierten Koordinationsstellen (wie zum 
Beispiel das N7 des Guanosins) nutzen und nur an diese Konformation der DNA 
binden. Die Synthese dieser Moleküle wurde durch die positive Ladung der einzelnen 
Bauteile erschwert und erforderte einen neuen Ansatz. Dabei wurde aber eine 
interessante Entdeckung gemacht.  
Fragmente dieser di-Porphyrin Systeme, ein Metalloporphyrin koordiniert an ein 
Cisplatin (Verbindungen 17 – 22) zeigten eine ausgeprägte Toxizität gegenüber 
humanen Krebszellen bei der Bestrahlung mit rotem Licht. Zwei menschliche 
Zelllinien wurden auf Toxizität der verschiedenen Verbindungen 17 – 22 getestet und 
mit Standards wie Cisplatin verglichen. Viele Porphyrine sind fluoreszierende 
Verbindungen sind und werden als photoaktive Substanzen verwendet. Sie können 
Strahlung wie zum Beispiel rotes Licht, welches Melanoma durchdringen kann, 
nutzen, um Singlett Sauerstoff zu erzeugen, welches als hochaktive Spezies schweren 
Schaden in den Zellen anrichten kann. Die Bestrahlung für 10 Minuten mit gekühltem 
Licht vervielfachte die Toxizität um das bis zu 78 fache bei dem toxischsten Molekül 
22 mit einer Konzentration IC50 von 0.08 M. Um diesen Effekt besser zu verstehen 
und Verbesserungen am System vornehmen zu können wurden erste Zellstudien 
durchgeführt, welche auf den bleichenden Effekt durch die Entwicklung von Singlett 
Sauerstoff hindeuten. 
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3.2 English Abstract 
The presence and function of left-handed Z-DNA in the human organism has been 
proved throughout the last two decades[1-9]. The detectability of Z-DNA in living cell 
has nevertheless not been achieved and one is not able to observe the processes that 
happen during and after the formation of Z-DNA. The focus of this work originated 
from the rational design of molecules able to interact with Z-DNA in living organisms.  
Starting from studies of metal complexes interacting and inducing Z-DNA, the aim of 
this thesis was to develop a modular system that can interact with the Z-DNA and be 
observed for its specific interaction. Since DNA was the target and the interaction 
should occur in natural surroundings, the water-soluble porphyrin 5,10,15,20-
tetramethylpyridinium-porphyrin with various central metal centers was chosen as a 
starting molecule and its properties tested in different model systems. Balaz et al. 
reported in 2005 the recognition of Z-DNA in a model CD spectrometry setup by the 
addition of Zinc (II) 5,10,15,20-(methyl-pyridinium)-porphyrin to a previously induced 
Z - DNA form of poly d(GC)[10, 11]. We reproduced these experiments with different 
central metals such as copper and nickel to find out that the central metal ion plays 
an important role in this interaction. The results revealed different behaviors of the 
porphyrins ranging from side-on coordination, intercalation or partial intercalation of 
the porphyrin system to stacking of the porphyrin around the DNA depending on the 
coordination sphere around the central metal ion. 
To make this system more specific towards only Z-DNA recognition and also to avoid 
electrostatic interaction between the porphyrin and the DNA, we developed of a 
system based on a porphyrin array. This consisted of a two-(methyl-pyridinium)-
porphyrins and a linker in between (for the compounds please refer to chapter 4, 
Figure 4.41). The idea was to build a molecule that could recognize the specific 
properties of Z-DNA like rigidity, base to base distance, coordination sites and 
sequence specific properties. The synthesis of this system turned out to be very 
difficult due to the highly charged molecules that had to be combined. A porphyrin 
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array consisting of a cisplatin corner and two positively charged porphyrins was 
synthesized.  
Fragments of this porphyrin system, one metalloporphyrins coordinated to a cisplatin 
(compounds 17 – 22), showed very interesting characteristics when cancer cells were 
exposed to these compounds in the presence of red light. Two human cancer cell 
lines were treated with 6 lead compounds and the toxicity determined in various 
conditions. Since porphyrins are fluorescent and can act as photoactive compounds, 
the influence of red light that could penetrate skin was tested. The metal free 
porphyrin compound 19 was as toxic in the dark as the reference cisplatin, a well-
known anti-cancer agent. All compounds showed an increased toxicity when exposed 
to red light for 10 minutes. The Pt-porphyrin compounds 20 – 22 showed a significant 
toxicity towards both cell lines in the dark, which characterizes their behavior as 
cisplatin analogs. When these compounds were exposed to red light for 10 minutes, 
the toxicity increased up to 78 times and reached IC50 concentrations down to 0.08 
M. The spectroscopic properties of the porphyrins absorbed the red light very 
effectively. To further understand the mechanism of these phototoxic effects, 
preliminary cell uptake studies showed a bleaching effect which could be due to the 
evolution of singlet oxygen.  
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4. Interaction of Metallo – Porphyrins with Different Conformations of DNA 
4.1 DNA – an introduction 
4.1.1 The early days of DNA research 
Deoxyribonucleic acid (DNA) is a very unique molecule. DNA consists of numerous 
sequences of nucleobases that decode the genome. DNA represents the plan for all 
functionalities carried out in the human body. It possesses a high flexibility and thus 
can rotate around the sugar phosphate backbone, a process needed for the process 
called transcription, in which DNA is transcribed into RNA to further translate to 
proteins. In order to regulate the transcription process, DNA can constitute different 
conformations, which will be the topic in Chapter 5, which deals with the special left 
– handed Z-DNA. 
 
Figure 4.1 Schematic drawing of DNA in the 1953 as we know it today[12]. 
In the late 19th century, the discovery of our gene material was initiated by Mendel's 
work with common garden peas, pisum sativum. His discoveries led him to the 
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hypothesis that physical characteristics are the result of the interaction of discrete 
particles, which we now call genes. His theory was, however, widely disregarded by 
scientists at that time. In the last quarter of the 19th century, microscopists and 
cytologists, interested in the process of cell division, developed both the equipment 
and the methods needed to visualize chromosomes and their division in the 
processes of mitosis[13, 14] and of meiosis[15]. Shortly after, many scientists were 
convinced that the hereditary material (as defined by Mendel) and chromosomes 
must be the same. Later, chemical analysis of chromosomes showed them to be 
composed of both DNA and protein. The question arose, which substance carried the 
hereditary information? For many years most scientists favored the hypothesis that 
protein was the responsible molecule because of its vast complexity when compared 
with DNA. After all, DNA is only composed of 4 nucleobases while protein is 
composed of 21 amino acids, and DNA molecules are linear while proteins range from 
linear to multiple branched to globular.  
It seemed clear that the relatively simple structure of a DNA molecule could not carry 
all of the genetic information needed to account for the so diversified life on earth. In 
the early 1950's, evidence showing that DNA must be the chromosomal component 
that carries hereditary information was observed. In 1952, Alfred Hershey and 
Martha Chase used radioactive labeling to grow a particular type of phage, known as 
T2, in the presence of two different radioactive labels so that the phage DNA 
incorporated radioactive phosphorus 32P, while the protein incorporated radioactive 
sulphur 35S. Their analysis showed that most of the 32P-label was found inside of the 
cell, while most of the 35S was found outside. This suggested to them that the 
proteins of the T2 phage remained outside of the newly infected bacterium while the 
phage-derived DNA stayed in the cell. They then showed that the phage derived DNA 
caused the infected cells to produce new phage chromosomes. This elegant work 
showed conclusively that DNA is the molecule which holds the genetic information.  
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The physical structure of the DNA molecule and its resulting functionality was subject 
to be discovered, since it was not clear how such a simple molecule could decode the 
full information on such a complex species as a human being.   
In the late 1950s, only a few groups were working on determining the structure of 
DNA, among these was a group led by Linus Pauling[16, 17], and two groups in Britain 
from the University of Cambridge. A key inspiration in the work of all of these teams 
was the discovery in of Pauling in 1948 that many proteins included helices[12] which 
he found from X-ray patterns. Even in the initial crude diffraction data from DNA (see 
Figure 4.3 for a later version of a simple x-ray pattern), it was clear that the structure 
involved helices. Watson and Crick came up with a model that was restricted to what 
chemically and biologically was reasonable. In 1952, Chargaff discovered that two 
nucleotides pairs, adenine and thymine, guanine and cytosine, were always present 
in equal proportions.  
 
Figure 4.2 DNA structure prediction of Linus Pauling which turned out to be wrong. Taken from 
L. Pauling[12] later version of a simple x-ray pattern. 
Watson and Crick began to postulate double helical arrangements, and concluded 
that reversing the directionality of one strand provides an explanation for Chargaff's 
results, which also had the effect of ensuring that the distance between the 
phosphate chains did not vary along a sequence. They could prove from an X-ray 
pattern obtained by Franklin that the constant distance between bases must have a 
value of 2 nanometers[18]. The same pattern also gave them the 3.4 nanometer-per-
10 bases “pitch” of the helix. Watson, Crick and Wilkins were awarded the Nobel 
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Prize in medicine in 1962 for discovering the molecular structure of DNA. Figure 4.3 
shows the DNA model presented by Watson and Crick in 1952[19].  
 
Figure 4.3 DNA model of Watson and Crick. Pictures taken from [19]. The hydrogen bonds the way 
Watson imagined them in 1953. 
Today, DNA is well known and characterized. It is organized as two complementary 
strands which are made up of a phosphate-sugar backbone and a nucleobase in a 
periodic sequence. In between the bases of the two complementary strands are 
hydrogen bonds (Watson – Crick bonds) that can be separated[20-22]. In Figure 4.4, the 
phosphates (circles) are bound to the sugars (ribose – shown in black). In between 
the bases, the hydrogen bonds can be seen, whereas the number of the bonds 
depends on the bases (written inside of the bases, A – adenine, C – cytosine, G – 
guanine, T – thymine)[23]. DNA offers numerous possible binding sites for metals 
(Figure 4.3, right) whereas soft metals tend to coordinate to the nucleobases and 
hard metals to the backbone[24]. 
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Figure 4.4 left: Hydrogen bonds in detail on the left and the double helical structure of B - DNA 
on the right. Picture taken from www.chemistrydaily.com; right: DNA strand presented as a chain of 
nucleotides, sugar and phosphate. The arrows present the possible binding sites for metals. 
 
4.1.2 DNA and its role as a target of molecular chemistry 
DNA, in its function as storage of the genes, has been a target for molecular 
approaches in medicine for a long time. The vision to control the function and 
expression of the genes and to block certain genes was the origin of personalized 
medicine. Since 25 years, several approaches were started to culminate in the 
decoding of the human proteome in 2001 by Celera and its founder Craig Venter[25]. 
Since that time, molecular diagnostics and direct target approaches towards certain 
regions or conformations of the DNA have been published[2, 3, 26-30]. The focus has 
always been the isolation and detection of a specific regions or conformations of DNA 
and later also of RNA. 
The isolation of specific DNA targets within genomes is critical for a variety of 
research. Recently, considerable effort has been spent to isolating microsatellite 
sequences. Microsatellites are sequences containing a low level of sequence 
complexity comprised of short tandem repeats of two to five base pairs. They are 
often a marker of choice for population genetics studies mainly due to their higher 
mutation rate[26, 31]. 
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Various approaches to target DNA were developed. DNA can be targeted via three 
different interactions: intercalation, groove (major or minor) binding or covalent 
binding[32-34]. The strongest interaction was found in the 1980s when Rosenberg 
discovered the interaction between platinum and DNA[35]. This topic is further 
discussed in Chapter 6. 
 
Figure 4.5 Interaction of oxaliplatin with a DNA fragment crystallized by Spingler et al.[36, 37] 
DNA can also be targeted via a groove binding mode. Since the B- conformation of 
the DNA forms 2 kinds of deep and wide grooves, both major and minor grooves can 
be targeted. The major groove is a primary target which is also used for drugs such as 
methyl green[38] or DAPI[39-42], the Hoechst stain[43, 44]. The minor groove can be 
approached by proteins such as TBP[45-48] or small molecules such as Hoechst 33258 
(Figure 4.7). 
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Figure 4.6 Molecular model of ethidium cation intercalating between two base pairs. This image 
was taken from http://en.wikipedia.org/wiki/File:DNA_intercalation2.jpg (created in 2005 
using VMD software). 
 
Figure 4.7 top: Hoechst molecule (magenta) bound to the major groove of DNA. Taken from PDB 
264D “Three dimensional crystal structure of the A-tract DNA dodecamer” (picture 
http://en.wikipedia.org/ wiki/Hoechst_stain). Bottom: cylindrical structure binding to the minor 
groove. Below depicted is the organic structure [33, 44, 49, 50]. Picture taken from Hannon et al[49]. 
  25 
Another interaction type is most commonly used in biology for staining purposes – 
the intercalation. The most prominent intercalator is ethidium bromide [51-53] (see 
Figure 4.6). Intercalators have an appropriate size and chemical nature that fits in 
between base pairs of DNA. These ligands are commonly polycyclic, aromatic, and 
planar, and therefore often make good stains. Intensively studied DNA intercalators 
include berberine, proflavine, daunomycin, doxorubicin and thalidomine. They can be 
used for chemotherapeutic treatment to inhibit replication of DNA in fast growing 
cancer cells.  
 
4.1.3 Different conformations of DNA 
For many natural species, symmetry plays an important role. Symmetry can be 
observed in eukaryotic systems such as human beings as well as in simple prokaryotic 
systems such as algae. In the picture below, Japanese researchers produced an axial 
non-natural symmetry to a snail shell by modifying a set of genes of this snail. 
 
Figure 4.8 Symmetrical snail shells produced by Japanese researchers in 2009 (taken from 
www.spiegel.de).  
Even in the basic structures of living organisms, symmetry plays a vital role. It is 
observed in proteins forming symmetrically shaped ion channels, as well as in DNA. 
Double stranded DNA occurs in at least 3 different conformations of which all were 
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traced in vivo[54]. The most common conformation of the DNA in vivo is the B- form, a 
right – handed double helix characterized by a wide major groove and a narrow 
minor groove[55]. Its counterpart is the left handed Z-DNA. The major groove of the B-
DNA is easily accessible to proteins which are important for the replication of DNA. 
The base pairs are situated perpendicularly to the helix axis and the sugar pucker is 
C2´ - endo. The bases are staked upon each other and the backbone forms a smooth 
curve. B-DNA is favored at low salt concentrations under physiological conditions, 
especially in a highly water containing environment (above 95%). It is believed to be 
the native conformation occurring in the chromosomes[3, 25, 56, 57]. The double helix is 
narrower and more elongated than the other right handed A-conformation. In B-
DNA, the helix makes a turn every 3.4 nm, and the distance between two neighboring 
base pairs is 0.34 nm. Hence, there are about 10 pairs per turn. The antiparallel 
strands make two grooves of different widths, referred to as the major groove and 
the minor groove, which may facilitate binding specific proteins.  
   
Figure 4.9 Comparison of the different types of DNA: A – DNA (left), B-DNA (middle) and Z-DNA 
(right). Pictures taken from the Image Library of Macromolecules of the University Jena. 
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The biological functions of the sequences of the nucleic acids are mainly based on the 
ability of the nucleic bases to undergo specific interactions. But DNA is a very flexible 
and dynamic molecule that can assume a variety of inter-converting forms. Figure 4.9 
shows an overview of the three conformations. The A-form is found for the most RNA 
molecules and RNA – DNA duplexes [58]. It is characterized by a shorter, therefore 
wider helix with a deep and narrow major groove which cannot be easily accessed by 
proteins. The wide and shallow minor groove of the A-DNA is easier accessible to 
proteins, but the information content there is lower than in the major groove. The A- 
form is the favored conformation in low water concentrations. The alignment of the 
bases is not as perfect as with the B- form as the bases are tilted to the helix axis. The 
sugar pucker is C3´- endo because in RNA, the 2´- OH inhibits the C2´- endo 
conformation. 
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Figure 4.10 A comparison of A-, B- and Z-DNA. In the upper picture, the side view is presented 
with the data for the helix raise during one full turn and the number of bases needed for that. In the 
picture below, on the right side, the cross section of the DNA forms and, on the left, another side 
view is shown. Pictures taken from the lecture notes of Prof. Roland Sigel.  
 
 
Figure 4.11 Sugar Pucker of B- (left) and Z- (right) DNA. The structure of guanosine in B-DNA and 
Z-DNA. The sugar is oriented so that the plane defined by C1’-O1’-C4’ is horizontal. Atoms lying 
above this plane are in the endo conformation. In B-DNA (left), the glycosidic bond between the N9 
position of the purine ring and C1’ carbon of the ribose sugar is in the anti-position and the 
deoxyribose contains a C2’ endo pucker. When Z-DNA (right) forms, the guanine rotates around the 
glycosidic bond into the syn position and the deoxyribose forms a C3’ endo pucker. The sugar pucker 
change results in a different distance between the phosphate groups (Picture taken from Rich et 
al.[6]). 
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The most interesting DNA double helix structure is the Z-conformation. The name of 
this structure comes from the zig – zagging of the phosphates. It is a left – handed 
double helix which is also found in vivo. It is much longer and narrower than the A- 
and B- conformation. This form of DNA is found especially for alternating purine - 
pyrimidine sequences in very high salt concentrations, some base substitutions or in 
alcohol [59]. The need for alternating purines and pyrimidines to form Z-DNA is due to 
the stacking of the bases. It is the dinucleotide unit, not the mononucleotide that is 
the repeating unit of this structure, for example there is good stacking within the GpC 
dinucleotide, but not between the (CpG). There is no real major groove found in this 
structure and the minor groove is very narrow[9, 60]. The bases are nearly 
perpendicular to the helix axis. The Zig – Zag backbone pattern arises from an 
alternating conformation of the bases relative to the deoxyribose sugar. In Z-DNA, 
the nucleotides alternate between the standard anti – conformation and the more 
compact syn-conformation with the base essentially sitting on top of the deoxyribose 
ring. This alternating pattern of anti / syn nucleotide conformations is strictly adhered 
in all the crystal structures of Z-DNA [61]. Thus, it is the alternation in the backbone 
and not the sequence that defines Z-DNA. Therefore, the guanine takes a syn-position 
and its sugar pucker is C3´- endo whereas cytosine takes the anti – position and its 
sugar pucker makes the C2´- endo conformation[62]. There is a slow exchange of the 
proton which should be provided for the guanine to form the Watson – Crick base 
pair because the hydrogen of the N2 – amine of guanine binds to the phosphate of 
the backbone (5´- PO)[63]. The syn – conformation of the guanine of Z-DNA and the 
anti – conformation of the B-DNA are shown in Figure 4.11[55].  
The positions of the bases differ greatly in the different conformations of DNA. Since 
the position of the bases is essential for the ability of proteins or metals to bind on 
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the DNA strand, a closer look at the accessibility of the bases is shown 
 
Figure 4.12. In the B- form (left), the location of the base pair is centered in the helix 
with the phosphate backbone organized around the periphery of the helix. The bases 
in Z-DNA are positioned towards the outside of the helix so that certain sites are 
more chemically reactive and easier accessible to metals than in B-DNA. The N7 and 
C8 positions of the guanine in Z-DNA, are exposed to the surrounding environment 
[61]. 
 
Figure 4.12 View along the axes of B- (left) and Z- (right) DNA each consisting of the sequence 
d(CGCG). The major groove is oriented to the right in both cases. The arrows point to the exposed N7 
of guanine. 
 
Several factors influence the B-Z equilibrium, which depends upon the DNA itself 
(intrinsic factors) and the environment (extrinsic factors)[64]. In the following section, 
both the intrinsic and extrinsic factors will be discussed. 
Oligonucleotides containing alternating purine – pyrimidine sequences adopt the Z- 
conformation. The base sequence that favors Z-DNA is alternating poly d(GC), but 
also poly d(AT) can form the Z-DNA, although poly d(AT) is quite resistant to adopt 
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the left handed conformation. The tendency of alternating purines – pyrimidines to 
convert into the Z-form is d(GC) > d(AC) = d(GT) >> d(AT)[64-66]. Methylation of C5 of 
cytosine causes the Z-form to be more easily formed[67]. Since the methylation of 
cytosine occurs often in eukaryotic DNA as a form of regulating gene expression, this 
could be a hint of the function of Z-DNA[67-69].  
The discovery of Z-DNA itself was unusual in that it was the first crystal structure of 
any double – stranded oligonucleotide. There had been spectroscopic evidence that 
there was something like a left – handed form, but this could not be proved until the 
crystal structure was solved. The Z-DNA conformation was first observed in very high 
concentration of salts (>2.5 M NaCl)[59]. The Z-form is destabilized by the charge 
repulsion of the negative phosphate groups. High concentrations of monovalent 
cations (Na+, K+, Li+, etc.) can compensate the charge and therefore stabilize Z-DNA. 
More effective are multivalent cations such as polyamines or [Co(NH3)6]
3+, that are 
able to decrease the electrostatic repulsion and supply hydrogen bonding[70, 71]. 
Negative supercoiling has been found to be one of the most important factors in the 
stabilization of Z-DNA. To achieve the transcription of a particular gene, the 
polymerase goes along the DNA strand following its helical path. This movement 
would require a rotation of the transcription complex around the DNA axis. It was 
calculated that the rotation speed to of this transcription proteins would be too high 
to be reached by a complex structure like the transcription apparatus. In this case, 
the DNA has to be translocated past the stationary polymerase and rotate around its 
own axis while doing so. Both in eukaryotes and prokaryotes, the DNA is attached to 
cellular structures and the existence of these points of anchorage would prevent the 
free rotation of the DNA, resulting in the over winding of the DNA (positive 
supercoiling) ahead of the enzyme and the unwinding of the DNA (negative 
supercoiling) behind it (Figure 4.13)[72, 73]. 
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Figure 4.13 The mechanism of transcription and the formation of negative supercoiling. R is the 
transcription ensemble consisting of the polymerase, the nascent RNA, and proteins bound to the 
RNA. When R is moving from left to right without turning around the DNA, the portion in front of the 
polymerase becomes over wound (positive supercoiling), the portion behind the enzyme becomes 
under wound (negative supercoiling) (Picture taken from Peck et al[72]). 
 
4.1.4 Formation of Z-DNA 
Fuertes reviewed the many molecular mechanisms proposed for the B- to Z-DNA 
transition. The considerable number of proposed models shows the high interest of 
the scientific research in the field and also shows how much it is still unknown[74].   
One of these models for the transition from B- to Z-DNA involves flipping the base 
pairs upside down. During the process, deoxycytidine stays in its anti-conformation, 
due to the rotation of the sugar and the base; whereas deoxyguanosine changes into 
the syn conformation, since only the base rotates. 
 
Figure 4.14 Zipper model for the B- to Z-DNA transition in negatively supercoiled closed circular 
DNA. The initiation step is the formation of the B-Z junction (J). Four melted base pairs can be found 
in these junctions[62]. 
R  
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Z-DNA is a higher energy conformation than B-DNA. Thus Z-DNA will only occur when 
plasmids are torsionally stressed, being stabilized by negative supercoiling[4, 73]. 
The analysis of 137 fully sequenced human genes demonstrated that sequences 
which could easily form Z-DNA were found in 98 cases. The most surprising was the 
fact that these sequences were 10 times more frequent in 5’ than in 3’ regions[75]. 
This would fit with the hypothesis that the energy to form Z-DNA in vivo is provided 
by the transcription[73]. 
 
Figure 4.15 B- Z DNA junction was crystallized in the presence of the binding domain hZADAR1 
from the human editing enzyme, double-stranded (ds)RNA adenosine deaminase (ADAR1), to 
stabilize the Z conformation. This crystal structure showed one base pair flipped out from the DNA 
helix. a) Schematic diagram of the DNA sequence and protein positions.  Flipped out bases are A0 
and T0´. b) 2Fo – Fc omit map of the DNA junction, calculated using native data at 2.6 Å
[30].  
Z-DNA can also be induced in vitro. The first factor influencing the Z-DNA formation is 
the selected DNA sequence, as mention above. Also, Z-DNA can be stabilized by high 
salt solutions[59]. Since in Z-DNA phosphates residues are closer to each other than in 
B-DNA, by introducing positively charged ions, the repulsion among phosphates is 
reduced. As a consequence, using multivalent cationic species lead to the formation 
of Z-DNA at lower concentrations of this species. Polyamines, such as spermine, or 
[Co(NH3)6]
3+ are good examples of cationic species inducing Z-DNA[70, 71].  
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Chemical modification of DNA can also influence the Z-DNA formation. Poly d(GC) can 
more easily adopt the Z- conformation by bromination or methylation of cytosine at 
C5 position or by bromination of guanine at the C8 position[8, 64-67]. It has to be 
mentioned that methylation of cytosine at the C5 is relatively common in eukaryotic 
DNA and there seems to be a correlation between methylation of a gene with the 
regulation of the transcription for that gene[6]. 
Several groups have studied the possible correlation between chromosomal 
breakpoints in human tumors to potential Z-DNA forming sequences[76, 77]. Vásquez et 
al. observed that the deletions or rearrangements generated in mammalian cells are 
mainly replication independent and are likely initiated by repair processing cleavages 
surrounding the Z-DNA forming sequence. Vásquez et al. proposed that these types 
of genomic alterations are related to the chromosome breaks and gene 
translocations that map near Z-DNA forming sequences in human leukemia and 
lymphoma[78].    
 
Figure 4.16 Isomerization of hemicatenated molecules. Molecules linked in a homologous 
sequence of d(GC) can invert one pair of arms with respect to the other by isomerization[79]. 
Kmiec observed that homologous pairing in vitro between plasmids requires the 
presence of Z-DNA in both plasmids, and the reaction seems to start within the Z-
DNA stretches. At the region of homology, the two DNA rings become intertwined. 
The reaction is governed by superhelicity. The pairing starts within the d(GC)n 
sequence, in the Z-DNA form, and not at the unwound B-Z junction. A crucial 
observation was that a Z-DNA specific binding protein could block the whole process. 
Plasmids with d(GC)n
.d(CG)n could be paired with plasmids with the same sequence. 
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However, these same plasmids could not be paired with plasmids containing 
d(GT)n
.d(CA)n in the Z – conformation (Figure 4.16)
[79]. 
 
4.1.5 Circular dichroism[80] 
When light passes through an absorbing optically active substance, not only the left 
and right circularly polarized rays travel at different speeds, but also the two rays are 
absorbed to a different extend. The difference in absorption between the left and the 
right circularly polarized rays is called circular dichroism. 
The bases are the chromophoric groups in DNA. The bases themselves have a plane 
of symmetry, therefore are not optically active. However, the sugar can induce a CD 
in the absorption bands of the chromophoric bases. Due to this, the intensity of the 
CD is low, since it is a secondary effect of the asymmetric sugar inducing a CD and not 
the bases themselves, which are symmetric. However, for nucleic acids, it is different. 
The hydrophobic planes of the bases tend to stack in water to minimize their 
exposure to the solvent. The electronic transitions of the chromophoric bases can 
interact with each other giving a CD spectrum of high intensity. As mentioned above, 
DNA can adopt different conformations. Since CD is dependent on base-base 
interactions, this technique can very easily discriminate among the different DNA 
conformations. 
The intensity of the DNA CD bands in the long-wavelength (220-300nm) region is 
unexpectedly low. This is due to the cancellation of the many bands occurring in this 
region. Bands occurring at lower wavelengths (<200nm) have higher intensity and are 
much more sensitive to the DNA melting or the GC content of a specific sequence.  
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Figure 4.17 Circular dichroism of B-DNA (red) and Z-DNA (blue). Concentration of the DNA 
solution was 0.1 mM. 
In the long-wave region, B-DNA presents a positive band at 275nm and a negative 
one around 250nm. The CD of Z-DNA is almost a mirror image of the B-DNA, with a 
negative band at 290nm and a positive one at 260nm. However this mirror image is 
just fortuitous and has nothing to do to the base to base interactions in Z-DNA 
compared with B-DNA (Figure 4.17).  
 
4.1.6 Possible biological functions of Z-DNA. 
Because the backbone chains of B- and Z-DNA run in opposite directions, B-DNA 
cannot be converted to Z-DNA by simply twisting on the two ends of the helix; a more 
elaborate mechanism must be involved. Figure 4.18 shows this conformation change 
from B- to Z-DNA including the intermediate stages[81]. DNA encodes biological 
information in at least two different ways: the sequence of the bases specifies the 
composition of proteins and its shape provides information to regulate the cell life. 
One of the biggest changes occurs when going from the right-handed B-DNA double 
helix to the slightly thinner and elongated left-handed Z-DNA conformation[4, 9]. It is 
established that DNA sequences that have the potential to adopt the Z-DNA 
conformation were found in biological systems[4]. Evidence of the existence of Z-DNA 
in vivo has been reported in recent years and it has been shown that the B- and Z-
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form can coexist in an equilibrium of B- and Z- conformations in plasmids[82], in 
metabolically – active mammalian cells[83] and in polygene chromosomes from 
Drosophila[6, 84].  
 
Figure 4.18 The transition from B- to Z-DNA and the reversal of the chain sense[62]. Starting from 
B-DNA (a): in the first step the phosphoribose backbone is extended. The bases are allowed to flip 
through the helix axis as the backbone is rotated from a right-handed to a left-handed direction (b). 
The helix then can be compacted again (c) to form Z-DNA (d and e) (Picture taken from Ho and 
Mooers[62]). 
Z-DNA is a higher energy conformation than B-DNA and it is assumed that the energy 
necessary to form it in vivo is generated by the transcription process. The sequences 
that are able to induce Z-DNA, the alternating purine – pyrimidine sequence, are 
often found in eukaryotic genomes. For example Wolf et al.[85] showed that a long 
stretch of an alternating purine – pyrimidine sequence is found in the intron of the 
human corticotropin-releasing hormone (CRH) gene and that this sequence is found 
in the Z-DNA conformation in the transcribed gene. 
Therefore Z-DNA is estimated to function as a regulator of gene expression[4]. This 
could become a new approach in anti-cancer therapy. Tumor cells are characterized 
by a higher replication rates than normal cells and require a higher reproduction of 
proteins and enzymes which can only be achieved by a higher rate of transcription of 
the DNA. Additionally to the regulatory function, the transcription – induced Z-DNA 
may provide information about the specific sequence where enzymes are located on 
the DNA. 
 
a b c d e 
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Figure 4.19 Example of Z-DNA occurring in a biological process. Interaction of ADAR1 with 
double-stranded RNA and Z-DNA. The Z-DNA binding site of the domain of ADAR1 is named Zab, and 
its subdomain, Zα, can recognize the characteristic features of left-handed DNA: the zig – zagging 
phosphates backbone, and the protruding C8 of the alternating syn guanosine[4, 86]. Picture taken 
from Dr. Spingler.  
Each conformation of DNA has its own biological role in the regulation of the life of 
the cell[68, 73, 87]. To understand their biological effects, gathering information about 
any of these conformations is very important. DNA provides its genetic information in 
at least two different ways. The most important is given by the sequence of the 
nucleotides which specifies the composition of proteins. The second way of providing 
information is through its shape and conformation. DNA itself can regulate its own 
gene expression by enabling or blocking the transcription complexes to read the 
information of the sequence[4]. Z-DNA provides an interesting research area, since Z-
DNA is such an unusual conformation of DNA with very controversial biological 
functions which are not yet proven. To selectively bind to Z-DNA and to be able to 
recognize the Z- conformation can be achieved since this form is different from all the 
other conformations. The special geometrical conformation of Z-DNA and its specific 
sequence of nucleobases can provide areas where complexes can strongly and 
specifically bind.  
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4.2  Abilities of Porphyrins to detect DNA 
4.2.1 Interactions with Z - DNA 
The interaction of porphyrins and related molecules with DNA was described as early 
as 1979 and followed by intensive studies by Pasternack et al[88-90]. He exposed DNA 
to different porphyrins and found in that positively charged porphyrins have unique 
behaviors. Apart from the obvious ability to intercalate in between the bases because 
of the flat nature of the molecules, two different modi of interaction were described 
early on.  
 
Figure 4.20 Example of an A2B2 – type porphyrin having three modi of interaction with DNA if 
moiety R is sterically non – demanding. The solubility of the porphyrins and thus ability to interact 
with components of the cells is due to the positive charge of the moieties. 
The side on mode of interaction was mostly observed by symmetrical positively 
charged porphyrins, the attrition of porphyrins in the grooves of the DNA structure 
was mainly described for A2B2 - type porphyrins (Figure 4.20) in which the R moieties 
are sterically non – demanding[91-95]. Experiments with calf thymus DNA showed a 
substantial competition of positively charged porphyrins against ethidium bromide (a 
well-known intercalator and staining agent of DNA and cells) [91, 94, 96, 97]. These studies 
focused on fluorescence spectroscopic analysis as well as UV vis. Other studies in the 
late 80s and early 90s tried to determine the interaction of the various flat molecules, 
amongst these also phthalocyanines, porphyrins and acridines with DNA. X – Ray 
analysis and later on molecular modeling confirmed the interaction and also lead to 
several pharmaceutical applications based on these molecules[92, 98, 99]. For the 
interaction with B-DNA, it was found that the porphyrin has a precise center of 
symmetry with the N-methylpyridinium groups inclined to the central porphyrin at 
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angles of 66-72°. It has been shown that only the CpG site can have full ligand 
intercalation, since the thymine methyl group sterically hinders intercalation at the 
TpA sites. Modeling also indicates the importance of electrostatic effects in the low-
energy forms of intercalated and part-intercalated complexes at both sequences. 
These molecules are also well studied towards their specific characteristics and 
widely used for other applications such as flat screens and are thus well understood. 
Nevertheless, synthesis studies of porphyrins and related molecules are still 
published due to the difficult steps involved to obtain a reasonable yield and to make 
more complex porphyrins accessible. Nature uses porphyrins as well in essential 
building blocks such as hemoglobin or chlorophyll. Balaz et al. proposed a side on 
binding mode for all non-intercalating porphyrins and coordination to N7 of the 
DNA’s guanosine if the central metal center contains a vacant binding site. 
 
4.2.2 Interaction of porphyrins with G – Quadruplexes 
Porphyrins can also interact with different conformations of DNA. About 10 years 
ago, Wheelhouse et al. discovered that cationic porphyrins could stabilize G-
quadruplex structures at the end of chromosomes and thereby inhibit the telomerase 
[100, 101]. They used extended porphyrins with bulky or long side arms as 
chromophores to fit on top of the quadruplex structure. At the ends of chromosomes 
are regions of DNA called telomeres which have the function to replicate 
chromosome ends using the enzyme telomerase, because the enzymes that replicate 
DNA cannot copy the extreme 3′ ends of the chromosomes.  
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Figure 4.21 Top view on a G – Quadruplex structure with the central potassium ion in green. 
Picture taken from Wikipedia: Quadruplexes. 
Human telomeres are nucleoprotein complexes containing the repeated DNA 
sequence d(GGGTTA)n (n = 100 - 3,000) that is paired with its complement strand, 
except for a short (24 - 400 base) single-stranded 3' overhang. Telomeric DNA gets 
shortened by each successive round of cellular replication, possibly resulting in a 
molecular clock that limits the total number of replication cycles a normal cell can 
undergo. These quadruplex structures have become an active field of the anti – aging 
and cancer research and several patents have been filed to protect various 
approaches to stabilize this unique conformation[100, 102-104]. Molecules that bind to G-
quadruplex structures may inhibit cancer growth by at least two mechanisms which 
have a common basis: the stabilization of the G – quadruplex structure. 
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Figure 4.22 Comparison of different DNA motifs in G – rich sections of the DNA. Picture taken 
from http://www.bioorganic-chemistry.com/research.html. Possible interaction of porphyrins with 
quadruplex DNA. 
 
4.3 Background and motivation for this work 
Aim of the project was to detect the presence and location of the Z-DNA within the 
cells. Although sequences that can adopt Z-DNA are widely present in human DNA, 
the biological role for Z-DNA is not really understood yet. Short fragments of Z-DNA 
have been found in both prokaryote and eukaryote cells. These Z-DNA regions could 
have a crucial role in the expression of some genes[54, 87, 105-107]. The initial idea of the 
project was to find a specific binding molecule that would preferably interact only 
with Z-DNA also in vivo. Balaz et al proposed a zinc porphyrin to detect Z-DNA and a 
side on coordination of the central zinc towards N7 of the porphyrin[11]. This concept 
was taken as a basis to determine the location of Z-DNA in living cells. It is still not 
understood in which stage of the cell cycle, Z-DNA is occurring and how this effect the 
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expression level of certain proteins. It could become important for the specific 
treatment of cancer types to be able to block or stabilize or at least monitor some 
conformations of DNA such Z-DNA[26, 108-110].  
 
4.4 Results and Discussion – Interaction of Porphyrins with DNA 
4.4.1 Interaction of metallo – porphyrins with different conformations of DNA 
The development of more complex porphyrins includes also the introduction of a 
core metal center. This metal determines whether an axial coordination hinders an 
intercalation (and therefore favors a side on coordination), but it also controls its 
spectroscopic properties. For example, the difference of the Q – band can shift up to 
70 nm (from 550 nm to 620 nm) upon the exchange of cobalt to a zinc center. These 
changes can be observed via different methods. In Table 4.1, an overview of the 
interaction of porphyrins (visibly active) with DNA is summarized. These effects will 
be further discussed in the description of the results[111]. 
 Viscosity CD Visible: 
Intensity of 
the Soret band 
Visible: Shift 
of the Soret 
band 
Intercalator Increase Negative signal (near the 
Soret band) 
Hypochromicity Red 
Outside 
stacking 
Slight 
decrease 
Conservative signal (= up 
and down peaks of almost 
equal intensity near the 
Soret band) 
Hypochromicity Slight red 
Outside 
binding 
without 
stacking 
Decrease Positive signal (near the 
Soret band) 
Hyperchromicity Red 
Table 4.1 Spectroscopic changes due to different porphyrin-DNA interactions according to Prof. 
Luigi G. Marzilli including a description of the different modes of interaction of porphyrins and DNA. 
The intercalation causes the greatest change in the visible UV spectra with a red shift of the Soret – 
and Q – band.  
 
  44 
4.4.2 Interaction of lead porphyrins with guanosine 
First, the interaction of the porphyrin molecules towards 5’-guanosine 
monophosphate (5’-GMP) was followed by UV titration. As shown in Figure 4.25, the 
types of coordination and electrostatic interactions are not quite as manifold 
compared to the interaction with DNA. Nevertheless, there are 3 different kinds of 
interaction and combinations of the three possible. This experiment was chosen to 
determine the most suitable molecules to be followed by a study with poly d(GC). As 
a simpler model system, the titration of porphyrin versus guanosine (G) was also 
carried out, but only weak interactions could be detected (see Table 4.2, left side).  
Starting point was the synthesis of the DNA interacting moiety, the 5,10,15,20-
tetrapyridyl-porphyrin, followed by a methylation and metallation step to obtain the 
5,10,15,20-tetra-(4-methyl)pyridinium-porphyrin. The interaction of these molecules 
was tested as a model system towards the second step of this project, the formation 
of the Z-DNA specific porphyrin array. The synthesis of the basic porphyrin molecules 
and the following steps towards the water soluble [112-116], four fold methylated 
species was published[117, 118]. Nevertheless, optimization of the tedious workflow and 
the cleaning and separation of the final porphyrins was required. We choose a one-
pot synthesis described by Lindsey et al. and Fleischer et al. for the porphyrin 
synthesis [117, 119]. The methylation was carried out as described in the literature using 
methyl iodide. The metallation was performed by reacting the water-soluble, tetra-
methylated porphyrin with the acetate salts of either zinc, copper, or nickel (Scheme 
4.1).  
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Scheme 4.1 Reaction scheme to obtain the 5,10,15,20-tetra-(4-methyl)pyridinium-porphyrin. 
The methylation was carried out according to a slightly modified procedure described 
in literature, by treating the porphyrin with methyl iodide in DMF for 24h[120, 121]. 
After precipitation with acetone/ether and washing with acetone and cold water, the 
introduction of a metal into the porphyrin was carried out in water at 50°C using a 
water soluble metal salt (nitrate, tetrafluoroborate) and stirring for 24h. The yield in 
both reactions was almost quantitative yielding high purity as shown in the HPLC 
trace (Fig. 4.23). 
  
Figure 4.23 HPLC traces of the synthesis of 5,10,15,20-tetramethylpyridinium-porphyrin. After 1 
hour (top) a vast variety of mono-, cis- & trans-di, tri-, and tetramethylated porphyrin is synthesized. 
After 20 hours, only a small fraction of the trimethylated species is seen, which will after an 
additional 4 hours turn fully react towards the tetramethylated porphyrin. 
 
In the crystal structure below, porphyrin 10 was crystallized from water with the help 
of dioxane. The vacant space in the center of the porphyrin can nicely be seen. Only 
two counter ions are shown.  
MeI, 20h,  
DMF, 50°C 
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Figure 4.24 Povray plot of porphyrin 10 crystallized from a dioxane/water mixture. Elipsoids are 
drawn at 50% probability. Hydrogen ions are omitted for clarity.  
These molecules were exposed under different conditions to bases, oligonucleotides 
and DNA in both the B- and Z- conformation. The stability constants (pK) were 
calculated according to the concentration G or 5’-GMP added (corrected by the 
dilution factor). Different central metal ions caused changes in the UV vis signal but 
were comparable for the stability constants. The Soret maxima of compounds 10 
H2TMPyP, 11, NiTMPyP, and 14, ZnTMPyP are shown in Table 4.2. All Soret bands lay 
in the region between 400 – 440 nm. The interactions of the porphyrins showed, as 
expected, different spectroscopic behaviors. For compounds 10 H2TMPyP, and 11, 
NiTMPyP, the Soret maxima shifted upon titration of 5’-GMP up to 6 – 8 nm into the 
red. The interaction of compound 10, H2TMPyP and compound 11, NiTMPyP with the 
5’-GMP can therefore be characterized as a mostly electrostatic driven interaction 
because there are no other interactions plausible. Compound 10, H2TMPyP does not 
have a vacant coordination site and compound 11, NiTMPyP has two occupied axial 
binding sites. In the case of the compound 14, ZnTMPyP, the situation is different 
since zinc can suit 2 axial coordinating ligands. The formation of a shoulder at 445 nm 
is an indication of a formation of a second species caused by a coordination of 5’-
GMP towards the central metal ion of the porphyrin. The possible interactions 
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determined by this experiment are summarized in Figure 4.25. According to the axial 
ligands of the central ion, the electrostatic interaction gains importance.  
 
Figure 4.25 Possible interactions of zinc porphyrin with GMP, from left to right: electrostatic 
interaction of positively charged pyridinium moiety, coordinative interaction of the central zinc ion 
with N7 of guanine, electrostatic interaction of positively charged pyridinium moiety and oxygen(O6) 
of the base. 
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Table 4.2 Comparison of the interaction of H2TMPyP 10, NiTMPyP 11, and ZnTMPyP 14 with 
guanosine (left) and 5’-guanosine monophosphate (right). Conditions: 10-5 M M(II)TMPyP ( M(II) = 
H2, Ni, Zn) aq. was titrated with either G or 5´-GMP (0–40 eq.) at pH 6.5 (NaCac-Buffer).
 Dilution 
effects were corrected 
Surprisingly, in the case of the nickel porphyrin, the electrostatic effect dominated 
over the possible coordination of nickel towards the N7 of guanine. Obviously, the 
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nickel’s axial ligands coordinated better than the guanosine. The formation of a 
shoulder beside the Soret band in case of the zinc porphyrin 14 can only be explained 
by the appearance of a new species, formed by the coordination of the zinc center to 
the N7 of guanine. Zinc porphyrins in most cases feature only one, but strong axial 
ligand building up a square planar pyramid. Even a water molecule can become a 
ligand (see chapter 5, Figure 5.14, and Table 5.2). 
 
4.4.3 Interactions of porphyrin treated poly d(GC) with Z- inducing agent 
Porphyrins are interacting in various modes with DNA as mentioned in Table 4.2. To 
discriminate in between the effect of the Z-inducing agent and the porphyrins 10, 11, 
and 14 towards the different conformations of DNA, two types of experimental 
setups were carried out. The Z-DNA inducing agent was chosen to be spermine rather 
than metals or high salt concentrations due to its non-binding properties. 
The pKa values for spermine are 11.50, 10.95, 9.79 and 8.90
[122], which makes it a four 
cation at pH = 7.0. It is the most effective and smallest (apart from metal ions such as 
zinc) inducing agent and it does not compete with the metal centers of the 
porphyrins. Spermine is a natural compound involved in cellular metabolism found in 
all eukaryotic cells and is an essential growth factor in some bacteria. Spermine is 
associated with nucleic acids and is thought to stabilize helical structure. As a buffer 
system, we chose the well-established sodium cacodylate buffer due to its non – 
coordinating character and reasonable buffer capacity at around pH 5.5 – 7.5[123]. In 
the first experiment, B-DNA was treated with the corresponding porphyrin followed 
by the attempt to induce Z-DNA. The experiment was monitored by CD spectroscopy 
to determine the change of the corresponding conformation of poly d(GC). In the 
second experiment, the DNA in its B-DNA form was treated with spermine to induce 
Z-DNA followed by the treatment of equivalents of the corresponding metal 
porphyrins.  
  50 
The B-DNA treated with increasing amounts of the metal free porphyrin 10, which 
can intercalate into DNA, resulted in a small uplift of the signal at 290 nm and 
developing a negative signal in the region of 435 nm. At a concentration of 0.2 
equivalents porphyrin versus the number of base pairs, 0.1 equivalents spermine 
were added (Graph 4.1). The spectra strongly increased in both regions. The negative 
band at 435 nm further increased and an additional positive signal at 470nm 
appeared. Shortly after the addition of the potential Z-DNA inducing agent, the DNA 
precipitated although not yet neutralized. It is clear that the DNA remained in a right 
– handed helical conformation. Obviously the spermine caused some of the 
porphyrin to stack around the DNA.  
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Graph 4.1 CD spectra of poly d(GC) in its B- conformation (black), treated with molecule 10 
followed by the addition of the Z-DNA inducing agent spermine. Concentration of poly d(GC) = 
0.1mM (in base pair), Buffer: 1 mM sodium cacodylate pH 7.0.  
The same experiment with molecule 11 showed a different effect. After the addition 
of the porphyrin, the band at 425 nm of the porphyrin, which has become chiral, 
occurs without a large change in the region of the DNA (220 – 320 nm, see Graph 
4.2). The only change is a slight decrease of the signal at 290 nm which indicates a 
distortion of the DNA (red, Graph 4.2) upon side on conformation or an intercalative 
mode. This would also explain the effect of the spermine towards the DNA: upon 
addition, only the DNA region is changed towards a more compact conformation of 
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the DNA (purple), the missing hump at 305 nm indicates a more narrow structure of 
the DNA.  
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Graph 4.2 CD spectra of poly d(GC) in its B- conformation (black), treated with molecule 11 
followed by the addition of the Z-DNA inducing agent spermine. Concentration of poly d(GC) = 
0.1mM (in base pair), Buffer: 1 mM sodium cacodylate pH 7.0. 
Spermine could not induce Z-DNA likely due to the semi – intercalative and side on 
conformation of the porphyrin towards the DNA. A different, even more complex 
result was obtained from the experiment carried out with the zinc porphyrin 14 
(Graph 4.3). Upon addition of the porphyrin, no conformational change is observed in 
the DNA region. Also the band at 435 nm is very small and shows the characteristic 
up and down of the side on coordination. After adding spermine to the solution, the 
signal of the DNA flips completely (220 – 320 nm). Since the signal in the DNA region 
changes upside down, we assume left – handed helix. The weak signal around 435 nm 
remains. The exact interpretation of these results is difficult.  
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Graph 4.3 CD spectra of poly d(GC) in its B- conformation (black), treated with molecule 14 
followed by the addition of the Z-DNA inducing agent spermine. Concentration of poly d(GC) = 
0.1mM (in base pair), Buffer: 1 mM sodium cacodylate pH 7.0. 
It shows that the effect of the porphyrin in combination with the Z- inducing agent 
spermine is not straight forward. The porphyrin can interact in various modi with the 
DNA and effect its conformation and ability to change this conformation. No Z-DNA 
could be induced with the pre – treatment of DNA with intercalative and semi – 
intercalative porphyrin, as expected. The zinc porphyrin cannot intercalate and favors 
a side on coordination or interaction with DNA and thus can allow a Z-DNA formation. 
 
4.4.4 Interactions of lead porphyrins with previously induced Z- conformation 
of poly d(GC) 
The interaction of molecules 10, 11, and 14 with poly d(GC) were carried out similarly 
compared to the experiments described above. Aim of these experiments was to a) 
identify which compound is able to detect Z-DNA conformation of poly d(GC), b) 
which type of interaction dominates, c) how the competition of positively charged 
inducing agents hinder the interaction of porphyrins with DNA, and d) if the results 
are comparable with the known literature examples.  
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When previously induced Z-DNA was treated with compound 10, H2TMPyP, it flipped 
back to its B- conformation[124, 125]. The intercalating molecule forces poly d(GC) back 
into its lower energetic state, because due to its higher strain on the backbone, the Z-
form does not tolerate an intercalation and flips back into its more relaxed B-
conformation. After this conformational change after the addition of surprisingly few 
0.08 equivalents, more equivalents of 10 were added. A conformation was formed 
we interpret as a distorted right handed helix with porphyrins intercalating and 
stacking around the helix. Due to the high charge and maximum capacity of 
intercalation reached, the double stranded poly d(GC) might be forced to provide 
even more inter-base space and therefore distort itself. The poly d(GC) could not be 
forced back to its Z- conformation at the addition of spermine. After the addition of 
even more porphyrin (at 0.25 equivalents) the DNA precipitated. Nevertheless, a 
small signal at 445 nm upon addition of the porphyrin revealed a CD signal related to 
the change at the Soret band of the porphyrin. This indicates a distortion and change 
of the surrounding of the porphyrin. 
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Graph 4.4 CD spectra of poly d(GC) in its B-conformation (black), induced into its Z- 
conformation followed by the treatment of 10. Concentration of poly d(GC) = 0.1mM, Buffer: sodium 
cacodylate pH 7.0. 
Nickel porphyrin 11 was added to a solution of previously induced Z-DNA. In Graph 
4.5, the addition of the porphyrin can be followed, indicating a combination of a side 
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– on interaction and intercalation of the porphyrin with the DNA. The Z-DNA signal at 
around 290 nm becomes more positive upon addition of 11. Also the positive signal 
at 255 nm undergoes a red shift and slightly changes in intensity. At 435 nm, the 
Soret band of 11, a small negative signal occurs upon addition of around 0.15 
equivalents of the nickel porphyrin. If the Z-form is still present is difficult to 
determine due to the party intercalative and thus reversing of the conformation back 
to the B- form. The fact that the central nickel atom does have a vacant coordination 
site creates multiple binding mode possibilities which cannot be sufficiently 
determined by CD spectroscopy. Nickel porphyrin 11 is only able to partly intercalate 
because it can coordinate an anion at its axial position. The raise of the band at 435 
nm indicates though that the porphyrin might be suited for Z-DNA detection. 
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Graph 4.5 CD spectra of poly d(GC) in its B- conformation (black), induced into its Z- 
conformation followed by the treatment of 11. Concentration of poly d(GC) = 0.1mM, Buffer: sodium 
cacodylate pH 7.0. 
Following this pattern, the zinc porphyrin 14 was chosen as a non-intercalating 
molecule due to its axial water molecule (see Table 5.2)[11, 126-128]. Compound 14 was 
added to poly d(GC) in its Z- conformation and monitored via CD spectroscopy. Upon 
addition of 0.12 equivalents of 14, a small band at 440 nm can be observed which 
correlates with the structural distortion and change of rotation angle and chirality of 
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the central metal of the porphyrin. The Z-DNA signal of the DNA is only undergoing 
small changes upon the addition of the porphyrin which proves the intact Z- 
conformation[11].  The DNA related CD signals from 220 – 320 nm are only changed a 
bit such as a small red shift of the signal at 255 nm and an increase of the signal at 
290 upon addition of the signal. Apart from these small changes, the biggest change 
is the raise of the band at 440 nm which can be used as an internal probe for the 
detection of Z-DNA[10, 129-132]. The double signal (up and down) is an indicator of a side 
on conformation or even coordination to the DNA which is detected (statistically) 
equal with regard to its detection direction. The zinc porphyrin suits best to detect Z-
DNA in a model solution and was chosen as the lead compound for the follow on 
studies[88-90, 95, 111, 133]. 
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Graph 4.6 CD spectra of poly d(GC) in its B- conformation (black), induced into its Z- 
conformation followed by the treatment of 14. Concentration of poly d(GC) = 0.1mM, Buffer: sodium 
cacodylate pH 7.0. 
In comparing of the relevant Soret bands of the tested compounds shows, that the 
treatment of the zinc porphyrin with the Z-conformation of poly d(GC) shows the 
most significant changes which enable us to detect the presence of Z-DNA. 
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Figure 4.26 Overview of the different interactions of the lead porphyrins with B- and Z-DNA 
conformations after or before treatment with spermine. 
 
4.4.5 Calculations of the coordination of zinc porphyrin towards DNA 
Interestingly, very different interactions patterns of the different porphyrins interact 
with DNA were obtained. With the help of a computational model established in the 
lab of Prof. Dr. Jürg Hutter, the different electronic states of the porphyrins were 
modeled with different axial ligands. In a second step, the minimum repulsion of 
compound 14 interacting with different conformations of DNA was calculated.  
Porphyrin 14 was modeled to determine the distances of the water molecule to the 
central zinc center. Surprisingly, the energetic lowest conformation of the porphyrin 
was a slightly distorted, non-planar conformation with a distortion angle of 7° 
between the pyrrole rings. 
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Figure 4.27 Calculated structure of zinc porphyrin 14 with 2 water molecules in the axial position 
of the central metal ion. The distortion of the porphyrin is 7° within the pyrrole rings. The program 
CP2K was run with the following parameters: Marvin Sketch, Blyp-Funktional (Standard), triplez2p, 
Basis, Plainwave Density Cutoff: 280 Rydberg, in vacuo. 
The energetic HOMO and LUMO levels of porphyrin 14 were also calculated. The 
LUMO levels are located on the periphery of the molecule. This characteristic is 
mostly derived by the positive charge located at the methylated nitrogen atoms of 
the pyridines. Most electron density is located around the central porphyrin ring and 
the central metal ion (Figure 4.28). 
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Figure 4.28 Top: LUMO, LUMO -1, and LUMO -2 levels of porphyrin 14 with 2 axial water 
molecules calculated by CP2K. Bottom: HOMO, HOMO+1, HOMO +2 levels of porphyrin 14. The red 
molecules in the middle represent the axial water molecules covering the central zinc atom. 
The same result was observed for porphyrin 14 with two axial chloride anions. The 
LUMO levels are located around the peripheral pyridyl residues and the HOMO levels 
in the center. The main difference is that the HOMO relocates around the axial 
chloride anions (Figure 4.29). The calculations towards a better understanding of the 
interaction of the porphyrin and the polyanion DNA are therefore leading towards 
the conclusion, that an electrostatic interaction between the negatively charged 
backbone of the DNA and the positively charged periphery of the porphyrin is the 
most likely scenario of interaction. This is contradictory to previous experimental 
evidence in the literature[99, 134-138]. 
 In the literature, it is for example suggested, that a similar copper complexes, which 
contains leaner residues, can bind to DNA by different binding modes via electrostatic 
interaction and by intercalation of the aromatic ring into the base pairs of DNA. The 
functional groups on the side chain of the macrocycle play a key role in deciding the 
mode and extent of binding of the copper complexes to DNA[136]. A similar case can 
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be expected for the interaction of zinc and copper porphyrin 14 and 11 when 
exposed towards B- or Z-DNA.  
 
 
 
Figure 4.29 Top: LUMO, LUMO -1, and LUMO -2 levels of porphyrin 14 with 2 axial chloride 
molecules calculated by CP2K. Bottom: HOMO, HOMO+1, HOMO +2 levels of porphyrin 14. The red 
molecules in the middle represent the axial water molecules covering the central zinc atom. 
As Pasternack et al. already proposed in the 1990’s, various interaction possibilities 
are possible[88-90, 95, 97, 111, 138-140]. The energetically lowest interaction of water – 
soluble zinc porphyrin 14 was calculated to be a side on electrostatic interaction 
(Figure 4.30. The porphyrin bridges 6 base pairs and thus can electrostatic interact 
with the phosphor-sugar backbone. The possible distance between the pyridinium 
residues and the phosphate varies around 3.15 to 3.3 Å. The occupancy of porphyrin 
vs. DNA base pairs can, in this mode of interaction reach a ratio of 1:5. The distance 
in between the central metal ion and the N7 or a phosphate is calculated to be too 
far for an interaction. Balaz et al. proposed a binding of the zinc to N7 of the guanine 
which seems to be incorrect[11]. The non-electrostatic interacting pyridyl residues are 
not interaction or even intercalating into the DNA which is interesting because the 
DNA would change conformation from Z- back to the B-form. A closer distance of the 
residue towards the deep groove can be estimated due to the proximity of the freely 
rotating, positively charged pyridinium groups and the negatively charged minor 
groove[141, 142]. 
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Figure 4.30 Calculated lowest repulsion of the energetic interactions of porphyrin with Z-DNA. 
The basic Z-DNA structure was derived from a crystal structure of Z-DNA.  
 
4.4.6 Z-DNA detecting molecules 
In order to combine the functionality of the porphyrins with a feature that would 
direct these multiple – charged molecules to the Z-form of the DNA rather than other 
conformations was the original main focus of this work. The concept chosen was to 
target a very specific differentiation between B- and Z-DNA: their diameter (see 
Figure 4.31).  
The aim of this project is to synthesis a porphyrin – based molecule interacting only 
with the-form, ideally also in complex biological samples. The motivation was that 
there was no Z-form specific molecule proven to be specific in vivo. Balaz et al. could 
show that a model system based on a positively charged zinc porphyrin favors its 
interaction with Z-form over B- form[11, 142, 143]. It was also proven, that a 
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spectroscopic specificity towards the different conformations is given, when certain 
negatively charged nickel porphyrins are present at the conversion from B- to Z-DNA 
induced by spermine, which is a tetra – positively charged molecule[10]. We tested 
various combinations of metallated porphyrins and their interactions with both B- 
and Z-DNA. From that, a 3 dimensional approach was developed to enable an 
interaction with Z-DNA solely. Before that, the model system and its interaction with 
DNA was studied in experiment and calculated with the help of Prof. Hutter’s Group 
(University of Zürich, see previous chapter) 
 
Figure 4.31 Comparison of diameter of B-DNA towards Z-DNA[2, 61]. The diameter is increasing to 
23 Å and 19 Å respectively upon addition of the outer-sphere water molecules. 
The idea was to build an array of two porphyrins bound to a peripherally coordinated 
metal center each and rigidly bridged in a right angle via an organic residue to form a 
U-formed structure that would only be able to enclose the Z-DNA but not a B-DNA 
structure due to its diameter (see Figure 4.31). The objective was to determine 
whether a small molecule can recognize Z-DNA in a complex biological mixture. The 
following features were defined as necessary to achieve the goal: 
- positively charged 
- recognized by Z-DNA by targeting its characteristic properties 
- possible metal coordination to Z-DNA (N7 of guanine)  
- detectable via CD, UV and fluorescence spectroscopy  
- changes of environment detectable 
- limited interaction with other molecules controlled by charge 
- water-soluble  
18 Å 
20 Å 
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Figure 4.32 Schematic explanation for the diameter approach. The B-DNA does not fit in 
between the claws of the poly-porphyrin array. 
The work of Balaz et al. showed that it was possible to find structures with these 
properties. As described above, the concept of the porphyrin arrays was developed 
according to the results previously obtained in the experiments with the mono 
porphyrin species. Thereby, the distance between the two flanking porphyrins and 
the rigidity of the molecule was the focus. We chose a platinum cornerstone in order 
to obtain a rigid right angle able to attach to various linker forms. The linker should 
be inert towards DNA (no charge, no coordination sites, no chirality) and rigid to keep 
the original 90° angle. The length of the linker determined the distance between the 
metal centers of the porphyrin, which was set to be 22 Å to fit only the Z-DNA 
conformation, and not around the B- form.  
B-DNA 
Z-DNA 
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Figure 4.33 Schematic drawing of the lead molecule determining the distance between the 
metal centers of the corresponding neighboring porphyrins. The linker has to fulfill the task to keep 
the platinum centers at a given distance. Below: Different conformations of the proposed lead 
molecule due to the flexibility of the linker. 
The arms or claws were chosen to be zinc porphyrins because of the known 
interactions with DNA, and the non – intercalation characteristics (see Figure 4.33). It 
was important to be able to follow the distance between the metals in the 
  
22 
Å
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porphyrins. We assumed that the different conformations and thus different 
distances of the metal cores of the porphyrins will be observable by fluorescence 
spectroscopy according to the Dexter energy transfer. The introduction of 2 different 
metal centers (nickel and zinc, or cobalt and zinc, copper porphyrins are non – 
fluorescent) and thus changed spectral properties will be observable.  
The variability of the linker and the effect of the whole system was part of the 
investigation. It was assumed that a chiral linker or a linker that only allowed only one 
conformation by sterically hindering the other would have a different interaction with 
DNA. The synthetic challenge to assemble such molecules was simplified according to 
a modular system. The different units of the lead molecule were supposed to be 
exchangeable. The side arms were chosen to be porphyrins. The right angle unit 
choice was won by a platinum corner with different ligands completed by a variety of 
linking or bridging units. These had to be rigid, aromatic and ideally allow the right 
distance in between the corner and thus porphyrin units.  
 
4.4.7 Porphyrins as side arms: an odyssey 
Porphyrins chosen to fulfill the properties to interact with DNA (water soluble, 
positively charged) had to be rigidly bound to the Pt – unit. In this scenario, we first 
tried to synthesize a threefold methylated 5,10,15-tri-(methylpyridinium)-20-mono-
pyridyl-porphrin 8 with zinc as a central metal ion. To fit this porphyrin and connect it 
to the corner building block, a vacant binding side was needed. As shown in Figure 
4.33, we initially chose this to be a non-methylated pyridyl residue. The difficulty was 
to only tri – methylate a molecule that can be methylated four times. Since the 
methylation is kinetically dependant on the solubility of the thus successively more 
positively charged molecule, a non – methylatable, non – protic solvent like DMF was 
chosen. The methylation took from 20 min up to 24 h depending on temperature and 
solvent. Two different methylating agents could be used to perform the reaction in 
this conditions and solvents: methyl iodide and trimethyl oxonium.  
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Figure 4.34 Using different methylating agents to tri – methylate 5,10,15,20-pyridylporphrin 8. 
Reactions were performed at 65°C to realize fast reaction times; for each reaction, 10 equivalents of 
the corresponding methylating agent were added.  
In all reactions, a complex mixture was resulting to form mono-, cis and trans di-, tri- 
and tetra- methylated species. This mixture was tried to be separated by HPLC 
protocols in preparative - and semi preparative – amounts. However, it was not 
possible to separate more than a few milligrams of the tri - methylated species from 
the mixture. This was not enough to exchange the counter anion and to proceed with 
the reaction with the platinum corner.  
Tetra-Me
4+
 
Tri-Me
3+
 
cis+trans-Di-Me
2+
 
Mono-Me
+
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Other means of separation such as CPC (Centrifugal Partition Chromatography), thin 
layer chromatography as described the literature and thick layer chromatography 
could not separate this mixture as well[113, 144, 145]. The chemical approaches to block 
one pyridine residue by i.e. a cobalt pentamine complex were also accompanied by 
the difficult separation of multiply positive charged cations.  
To overcome those separation issues, a different, chemical approach had to be 
found. We synthesized different A3B porphyrins with A residues being able to 
methylate and B residues being not methylatable and have a vacant binding site. The 
most attractive B residue was the cyanophenyl building block which forms a strong 
coordination to platinum complexes. 
 
Figure 4.35 Synthesis of A3B porphyrins to with a vacant binding site. Tri – methylation of 
porphyrins with a vacant coordination site to bind to the platinum cornerstone. The lead molecule 
with a central metal ion and a vacant tri-pyridyl-cyanophenyl-porphyrin.  
As lead molecules, we synthesized the novel molecules 15, 16 and 17 with different 
central metal ions which were linked to the corner building blocks (see also chapter 5 
for further applications). These molecules feature a free rotating binding site which 
will linearly coordinate to a metal ion. The synthesis was performed via two different 
approaches. In the statistic approach, a 3:1:5 ratio of 4-pyridyl-aldehyde, 4-
cyanobenzaldehyde, and pyrrole was stirred in propionic acid at 165°C followed  a 
three step purification setup and chromatography to separate the 6 products[117, 146, 
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147]. The second approach was a modified variety of a synthetic approach provided by 
Lindsey et al[148-151]. For a detailed description please refer to chapter 7. The yield of 
all reactions towards the porphyrins was porphyrin – like poor at around 0.5 – 3 %.  
 
4.4.8 Corner Building Blocks 
The corner building blocks had the task to form a 90° angle in between the side arm 
and the bridge in order to form a rigid structure. The molecule of choice was a 
platinum complex with square planar coordination sites of which 2 were occupied by 
strongly binding ligands. The vacant binding sites had to open up the right angle and 
keep the side arms in place.   
Different ligands of the central platinum were chosen to modify the stability of the U 
– vs. S – shape of the porphyrin array.  
      
Figure 4.36 Selection of corner building blocks with different characteristic properties towards 
stabilizing a sterically hindered U shape. 
The molecules and their ligands[152-155] were synthesized according to literature 
procedures[156-162]. The coordination towards the side arms was initiated by the 
precipitation of silver chloride. Different metals were tested but the kinetic stability 
of the platinum complexes (and palladium complexes) was superior towards other 
approaches[162-166].  
 
3
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4.4.9 Synthesis of the Bridges 
To complete the lead molecule, an appropriate, straight bridging molecule had to be 
synthesized. Two different approaches were followed (see Figure 4.37) 
       
Figure 4.37 Two different, rigid bridging units to stabilize the lead molecule. Left: Slim porphyrin. 
Right: Series of (poly) – aryls having peripheral pyridyl residues. 
In the first approach, an ABAB porphyrin with two trans to each other located 
coordination sites was synthesized. This slim porphyrin has a poor solubility and was 
synthesized according to literature proceeds starting form a 4-pyridyl-aldehyde to 
obtain a pyridyl-dipyrrole (PDP) which is then further reacted with trioxane (cyclic 
trimer of formaldehyde which is less reactive) to form the cyclic porphyrin[118, 167-170].  
The second bridging unit, the linear 4,4'-biphenyl-4,4'-diyldipyridine 35, was 
synthesized according to the Suzuki coupling reaction (see below) in which a boronic 
acid is reacted with diaryl-dihalogenide. The dipyridyl was obtained in overall yields 
between 0 – 71%. One possible reason for the failure of some of the reaction 
procedures could be obtained by crystallography. As shown in Figure 4.39 the 4-
boropyridyl-pinacolester formed cross links to the neighboring boron atom which 
might explain the observed un-reactivity. This was previously mentioned in the 
literature[166, 177-179]. 
 
  69 
 
R2 Solvent  Base Catalyst Yield  
pinacol di-ester  MeOH / Toluene  Na2CO3, P(t-Bu)3  Pd(PPh3)4  0  
pinacol di-ester Dimethoxyethane  KOtBu  Pd(PPh3)4 0  
pinacol di-ester Toluene  K3PO4  Pd(PPh3)4 10
a  
OH EtOH / HBr  Bu4N(OAc)  Pd(PPh3)4  10
b  
OH Ether  K3PO4  NiCl2(dppp)  0  
OH Toluene Na2CO3  Pd(Cl)2dppf 71
a 
Figure 4.38 Suzuki reaction with different catalysts and with various reaction conditions. R1 was 
in most cases I, in some Br with no influence on the following reactions. All reactions were carried 
out under argon [171-176]. aisolated yield, bnon-isolated yield (by GC-MS). 
We overcame this trouble by using the palladium catalyst Pd(Cl)2dppf together with 
the boronic acid of pyridine. The reaction times where somewhat longer but the yield 
much higher with this approach. 
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Figure 4.39 Crystal structure of 4-boropyridyl-pinacolester obtained after the catalytic reaction 
with the diaryl crystallized from chloroform/hexane solution. Boron of the pinacol ester is 
coordinated to the N of the pyridyl residue.  
The coordination of these bridges was tested in a model system. According to Fujita 
et al.[173, 174, 180], a self – assembly upon addition of a trans – coordinating ligand can 
assemble towards a square. An activated en – palladium corner was added to a 
solution of 4,4’-bipyridyl and crystallized in an aqueous vs. methanol solution.  
 
Figure 4.40 Reaction scheme and Pd4(4,4’-bipyridyl)4 square crystallized. Counter ion are 8 
nitrates. 
The assembly of the porphyrin array was sketched out as depicted in the synthesis 
plan.  One problem difficult to overcome was the order of the successive reactions. 
First, the corner and bridge form a barbell followed by the addition of the side arm 
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porphyrin. The second option is a formation of a porphyrin – corner adducts and 
combines them with the bridge. In both synthetic approaches, several difficult steps 
have to be taken. There is a drastic difference of solubility of the flat, organic bridge 
and the water soluble, positively charged (activated) the platinum corners which have 
to become water soluble after the reaction in order to coordinate with the porphyrin. 
This coordination was crucial and made the first synthetic approach easier to tackle. 
It was not possible to form a water soluble tetra – aryl bridge coordinated to 
coordinated platinum corners. The follow on reaction was not possible. The same 
problem occurred when using the slim porphyrin 30 as bridge. The solubility was too 
poor.  
 
Figure 4.41 Synthesis plan for one way towards the lead molecule. All reactions were carried out 
in the dark. 
It was possible to an L – shape with two side arm porphyrins and a platinum corner. 
The water soluble [Pt(NH3)2(H2O)2]2
+ was added to an aqueous solution of porphyrin 
19 to form molecule 31, an L – shaped porphyrin array which has a charge of 8+. After 
purification via HPLC chromatography (see Figure 4.42), a yield of 26% could be 
obtained. Given the fact that the reaction took place between two highly positively 
charged molecules, this was surprising. Nevertheless, it was not possible to form a U 
– shaped molecule with a non – water soluble bridge.  
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Figure 4.42 Reaction scheme and analytical data of the L – shaped porphyrin array which is eight 
fold positively charged. Ion exchange chromatography could separate the positively charged 
mixture. 
 
4.5 Conclusion and Outlook  
Metalloporphyrins interact in characteristic pattern with different conformations of 
DNA. Various metalloporphyrins were synthesized and exposed to different model 
systems to study their interaction with oligonucleic acids. It was found that the metal 
free porphyrins 10 and 17 do intercalate into DNA and thus stabilize the B- form. 
Other porphyrins containing central metal ions such as copper can intercalate or 
coordinate to DNA in a side – on fashion. A very unique behavior is observed when 
the interaction of porphyrins containing central metal ions with axial ligands was 
tested. Especially a central zinc ion in the porphyrin showed a unique behavior 
towards Z-DNA only.  
chromatograp
  73 
The idea to demonstrate this in more difficult biological matrices with a combined 
approach unifying interaction specificity and sterically hindrances into one concept 
was unsuccessful due to chemical solubility issues. The foreseen lead molecule would 
have also combined the possibility to detect what the claws are reaching around due 
to their fluorescence properties.  
To further test the properties of the porphyrins, the interaction of the 
metalloporphyrins coordinated to one corner building block cisplatin (see molecules 
20 – 22) and the interactions towards cancer cells resulted in a new and exciting 
approach as described in chapter 5. 
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5.  Photoactive Metalloporphyrins for a Combined Chemo- and 
Photodynamic Therapy 
5.1 Abstract 
We introduced a new class of photoactive platinum-porphyrin conjugates, with a light 
dependent cytotoxicity down to 0.08 M (IC50) for compound 22. As photosensitizer 
of choice, cationic porphyrins were selected due to their water solubility, known cell 
and nucleus uptake, and the possibility to exchange the central metal to tune its 
characteristic absorption properties. Those complexes feature a very stable covalent 
bond between the photosensitizer and the cisplatin residue, and have a characteristic 
fluorescence behavior. We could convincingly show that their absorbance spectrum 
can be tuned to be useful for photodynamic therapy. The highly positively charged 
photo sensitizer makes the compounds water soluble and facilitates a cell uptake as 
was also shown for similar cationic porphyrin. The thus possible electrostatic or 
coordination to DNA (mitochondrial and well as chromosomal DNA) was studied in 
cell uptake studies. 
We have prepared several novel porphyrin-cisplatin conjugates which were fully 
characterized and analyzed for their behavior towards different human cancer cell 
lines (Scheme 5.6.)[181]. In contrast to the already reported phthalocyanine-cisplatin 
conjugates[182], the platinum complexes 20 - 22 have two leaving groups: the one 
chloride and the ammine trans to the cyano-ligand, which is N-bound to the platinum 
metal center. In a recent publication, it could been shown that the cyanide anion (N- 
or C-bound to the platinum) has the stronger trans effect than the amine[157, 159]. This 
was also observed in the case of our platinum – containing conjugates using mass 
spectrometric measurements.  
The cytotoxic effect of the molecules 17 - 22 was determined with and without 
irradiation of red, water-cooled light (3200 lux) at different durations and found to 
differ dramatically when irradiated. Shining light with a wavelength greater than 600 
nm on the incubated cells increased cytotoxicity of the molecules up to a factor of 57! 
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The most effective photocytotoxic molecule, 22, shows an IC50 value of 0.08 M 
against the A2780 cell line.  
Additionally to the classical determination of the physical properties, the stability of 
those molecules 17 - 22 in human serum was tested in a model system. This was 
carried out by monitoring the decomposition behavior and affinity of the molecules 
towards Human Serum Albumin (HSA) over time. It was shown that the non – 
platinum containing molecules 17 - 19 did not interact with HSA whereas the 
platinated conjugates 20 - 22 did show a significant coordination to HSA. 
 
5.2 Introduction 
Despite an impressive progress in the field of the chemotherapy, there is still the 
immediate need for multifunctional drugs that combines the advantages of 
photodynamic therapy and platinum based chemotherapy[38, 183-186]. In 2008, the 
pharmaceutical company Sanofi was selling the third generation drug oxaliplatin for 
more than 1.4 billion Euros[187-190]. Since the beginning of the 1990’s photodynamic 
therapy has extended the medicinal possibilities to fight cancer, especially for cancer 
types that can be reached with red light. So far there are only few reports about 
combined photodynamic chemo therapies to enhance for a synergistic effect [191-197].  
5.2.1 Cisplatin 
The anti-cancer activity of cis-diaminedichloroplatinum(II) (cisplatin, Figure 5.3) was 
accidentally discovered by the group of Barnett Rosenberg in 1969[35, 198]. They 
realized that certain platinum salts, which were accidentally formed from a platinum 
electrode, used to apply an electric field to bacterial Escherichia Coli, strongly 
inhibited cell division but had no influence on cell growth. Later they found out that 
this was also true for eukaryotic cells such as solid tumor cells. As a result, cisplatin 
rapidly entered clinical trials and thus received FDA approval in 1979 for use as an 
anticancer drug[199]. Despite efforts to launch more platinum based anticancer 
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drugs[200], cisplatin is the most widely used platinum anticancer drug and is especially 
effective against testicular[201], head, neck, non-small-cell lung, and cervical 
cancers[202]. Cisplatin is cell cycle unspecific and often used in combination with other 
cytotoxic drugs to enhance its effect[35].  
 
Figure 5.1 Cisplatin and its way into the cell. Different ligands are exchanged when entering a 
surrounding with a different chloride concentration.  
5.2.2 Second and Third Generations of cisplatin analogues 
Although cisplatin is a very effective anticancer drug, it has many undesirable side 
effects, in addition inherent and acquired resistances reduce its clinical efficacy. A 
number of less toxic second generation compounds have been synthesized, most 
notably carboplatin[203]. Carboplatin is less ototoxic but the neurotoxic effects are 
more prominent and are thus dose-dependent. 1R,2R-(diaminocyclohexane) 
oxalatoplatinum(II) (oxaliplatin, Figure 5.3) is a third generation platinum 
compound[204] that produces the same kind of inter- and intrastrand DNA cross-links 
as cisplatin, but its neurotoxicity is the most common dose – limiting side effect[205].  
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Figure 5.2 Cross-linking of the cisplatin with DNA and its coordination sites. Picture taken from a 
presentation of PD Dr. Bernhard Spingler. 
Oxaliplatin, in combination with 5-fluorouracil, has been first approved in Europe, 
Asia, Latin America[206] and in 2002 in the USA[207] for the treatment of metastatic 
colorectal cancer[191, 208-210]. Cis-, carbo-, and oxaliplatin are the only three platinum 
based anti-cancer drugs that are applied worldwide. In some countries, 
heptaplatin[211], nedaplatin[212], and lobaplatin[213] have been additionally 
approved[188, 214]. 
 
 
Figure 5.3 Worldwide (top) and regionally (bottom) used commercial platinum drugs. 
Many research groups have trid, and some succeeded, to expand the success of these 
platinum drugs to different cancer types or the ones that have become resistant 
against e.g. cisplatin[215-224]. Nevertheless, there is a great need to transfer the success 
of cisplatin in treating a limited number of cancer types to other types of cancer. The 
long list of side effects further limits its field of use: one of the major concerns of 
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cisplatin is its nephrotoxicity (kidney damage). The renal function of the patient has 
to be monitored via the patient’s creatinine clearance. The renal damage is 
additionally counteracted with increased hydration and dieresis[187, 225, 226]. This dose 
limiting toxicity is derived from a reactive oxygen species which, in mouse models, 
were shown to be enhanced by the removal of free radical agents. The second major 
side effect of cisplatin is its influence on the nervous system (neurotoxicity). A cost 
issue during the treatment with cisplatin is the need to perform nerve conductivity 
measurements before and during the chemotherapy, since the neurotoxic effects are 
not understood and irreversible[227, 228]. Nausea and vomiting are additional side 
effects which occur since cisplatin is one of the most emetogenic chemotherapy 
agents[229, 230]. The best solution against this side effect is the add-on of prophylactic 
aniemetics, i.e. granisetron, in combination with corticosteroids to enable treatment 
with the needed dosage. Other dramatic side effects of the drug are alopecia (hair 
loss), ototoxicity (loss of hearing)[231] and troubles with the electrolyte level[232].  
 
Figure 5.4 Way into cell of cisplatin and its possible targets within a cell. The transportation to 
the outside is also depicted. Picture taken from Nat. Rev. Cancer. 2007, 573. 
The reasons for those side effects are not well understood, but the main concern 
about the treatment with cisplatin is its cell unspecific uptake and damage. With the 
development of new platinum based drugs, chemists and physicians try to avoid 
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those side effects to make the treatment more cancer cell specific[233]. The chemistry 
of d8-Pt2+ compounds such as cisplatin is a reason for its unspecific behavior towards 
DNA. It is constituted by a square planar geometry, with two amine and two chloride 
ligands each in cis coordination. Cisplatin has a low solubility of only 1 mg / ml 0.9% 
aqueous saline solution[234] and is usually applied to the patient in a DMSO/saline 
solution. Cisplatin is hydrolyzed in water by losing a chloride ligand and coordination 
of a water molecule to the platinum. This cis-[(NH3)2PtCl(H2O)]
+ is highly reactive due 
to its pKa of 6.55
[235]. 80% of the mono-active form of cisplatin is in the deprotonated 
(mono-hydroxo) form at the physiological conditions (pH 7.4)[192, 236-238]. Despite other 
possible binding sites, i.e. RNA, proteins, microfilaments, cellular DNA has been 
shown to be the primary target of cisplatin. Due to its unique chemistry, cisplatin is 
protected from early reaction in the bloodstream until its passage to the cell 
membrane by the relatively high concentration (>100 mM) of chloride which keeps it 
in the non-reactive dichloro form. With the uptake in the cell, the salt concentration 
of the new environment (<20 mM) enables cisplatin to lose one chloride ligand to 
form the proposed active cis-[(NH3)2PtCl(H2O)]
+ species, which binds preferably to the 
N7 of guanine rather than N7-adenine or N3-cytosine[209, 239-242]. First, the mono-
adduct is formed, the major adduct being formed in the subsequent step to form a 
1,2-intrastrand cross-link between the N7 of the adjacent purine residue, either in an 
d(GpG) - fashion or less frequently, d(ApG)[210, 243, 244]. Different coordination behavior 
is mostly known for cisplatin binding to different types of RNA.[245-248] With the 
formation of those 1,2-intrastrand cross-links, the DNA conformation is altered to 
form a bend in the duplex helix and in some cases even an unwinding of the two 
strands[237, 249-255]. Those platinated regions and bends in the DNA duplex can be 
recognized by proteins, and can lead to cellular death by apoptosis or necrosis due to 
its interference with the normal functions of the proteins during transcription of the 
cells[256-258].  
Cells can become resistant against cisplatin, and either very high dosage has to be 
applied or an alternative treatment has to be found. There are several mechanisms 
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known that make cells drug resistant. Increased DNA repair is a mechanism to 
remove platinated DNA pieces or platinum induced lesions with the help of specific 
repair proteins, i.e. XPE-BF[215, 259, 260] which was found to increase cisplatin resistance. 
Another example is ERCC1 which is expressed more frequently in cisplatin resistant 
cells than in cells sensitive to cisplatin. Another mechanism known is, that cells avoid 
uptake or even remove the drug, which results in a reduced accumulation of the drug 
in the cells. This is not fully understood, but different mechanisms of cell uptake can 
be a hint to understand this behavior: drugs pass into the cell either by passive 
diffusion or by active transport systems. In the cell membranes and the interior of 
cells, sulfur containing macromolecules, such as metallothioneins or glutathione are 
present. Heavy metals are known to trigger the production of metallothioneins and 
strongly bind to those proteins, which are believed to be one of the detoxification 
mechanisms of the cells[199, 242, 252, 261-266]. Cisplatin binds to metallothioneins with a 
maximum of 10 platinum atoms per protein[267, 268].  
The cytotoxicity of cisplatin most likely involves the interaction of certain cellular 
proteins with the cisplatin-modified DNA.[269] Several X-ray crystal structures of a 
cisplatin-modified DNA complexed with HMG1, polymerase or histone proteins have 
been reported[255, 270, 271]. A novel feature of the first mentioned protein-DNA complex 
is the intercalation of a phenylalanine between the two cross-linked guanosine 
residues[270]. 
Cisplatin is also used in combination therapy. Recent research directions have 
expanded the  knowledge about these promising new therapies[272]. One study 
showed that there is low cross resistance of cisplatin-sensitive and -resistant human 
ovarian cancer cells against cisplatin in combination with intercalative drugs[224].  
Furthermore, cis- and carboplatin have been covalently linked with functional 
molecules. These linkages can be permanent or intentionally hydrolytically labile[273]. 
Fluorescent cisplatin conjugates allowed tracking of the platinum complexes in 
cisplatin resistant and sensitive A2780 human ovarian carcinoma cells[219, 220]. The 
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group of Gibson has studied various conjugates of carboplatin with either folate[274] 
or a nucleus localizing sequence (NLS)[275]. Despite higher cancer cell uptake, the 
conjugates proved to be less cytotoxic than carboplatin. Gadolinium complexes have 
been tethered to platinum complexes via a substituted malonate linker, which 
hydrolysed with a half-life of 3 days. The conjugates had a comparable toxicity than 
carboplatin with less side effects[273]. 
 
5.2.3 Photodynamic Therapy with Porphyrins[197, 276-280] 
Photodynamic therapy (also called PDT, photo radiation therapy, phototherapy, or 
photo chemotherapy) is a revolutionary treatment aimed at detecting and treating 
cancer without surgery or chemotherapy.  It is based on the discovery that certain 
chemicals known as photosensitizing agents can kill cells when exposed to a 
particular type of light. Nowadays, PDT is mostly conducted in damaging cancer cells 
with fixed-frequency laser light in combination with a photosensitizing agent. Besides 
cancer, PDT has further developed to become an efficient therapy for other 
complications such as cardiovascular, chronic skin diseases, i.e. psoriasis. Advantages 
of the photodynamic therapy are that it is a well-defined surface treatment with no 
or few effects of the neighboring cells [183, 191, 193, 196, 197, 279, 281-283]. The treatment does 
not have to be invasive and can be repeated several times in contrast to 
radiotherapy. Limiting factors are that the surface or tumor has to be reached by a 
light source, so it is mainly used to treat areas on or just under the skin, or in the 
lining of internal organs. While the drug can travel throughout the body, the 
treatment only works when irradiated by light, so PDT cannot be used to treat 
extensive cancers. The current drugs available also leave people very sensitive to light 
for a time, requiring special precautions. 
The first hint for a photodynamic therapy came with the increased knowledge of 
“Porphyria ”, which is a collection of diseases in which pigments then called porphyria 
accumulate in the skin, bones, and teeth that turn caustic on exposure to light[284]. 
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Many porphyria, are innocent in the dark but transferred by sunlight into caustic 
toxins. While struggling to find a cure for porphyria, scientist in the late 1850s came 
to realize that porphyrias could be not just a problem but also a tool for medicine[285-
287]. If a porphyria is injected into cancerous tumor, it can be activated by light to 
destroy the tissue. As a consequence, scientists during the late 1850s began to unlock 
the puzzle as to why certain biological substances such as chlorophyll (chlorin) and 
heme show unique colors and behave like porphyria. Close structural similarity 
between heme and chlorin was demonstrated by Verdeil in 1844, followed by Hoppe-
Seyer in 1880[94, 95, 104, 288-291]. Soon it became clear, that porphyrins (from the Greek 
word for purple) play a vital role in life’s processes. Porphyrins were defined as 
bioinorganic components consisting of a cyclic tetrapyrrole macrocycle having 26 p - 
electrons. In nature, apart from their most prominent role as a carrier of oxygen in 
the hemin molecules, porphyrin-type molecules with a specific interior metal ion are 
found in cytochromes, peroxides and catalases, chlorophyll (involved in plant 
photosynthesis). 
Photodynamic therapy (PDT) was first applied in 1900 when Raab et al. showed the 
cytotoxic effect of light towards infusoria when treated with acridines[292]. The first 
application to human skin cancer was performed by von Tappeiner and Jesionek in 
1903[293], when applying white light to irradiate topical eosin. In 1924, Policard 
observed fluorescence of porpyhrins in cells and consequently, Auler and Banzer later 
described the cell uptake of porphyrins, first in plants and later, into human tumor 
cells in 1942[294].  Porphyrin containing compounds continued to be a major agent in 
the photodynamic therapy. In 1948, selective accumulation of porphyrins in vivo 
were described by Figge, followed by a report by Rassmussan-Taxdal observing a 
selective localization of porphyrin in tumors in 1955[295]. Porphyrins were also used 
for the detection of tumors and monitoring its growth as discovered by Lipson and 
Blades in 1960. Dougherty treated the first skin cancer patients with a porphyrin-
based PDT drug in 1975[279], which came into clinical trials in 1978. This was the first 
PDT going for a drug approval. In 1990, Photofrin, a porphyrin based drug got FDA 
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approved and made it onto the market[162, 183, 185, 192, 238, 282, 296-300]. First only thought 
to be applicable for skin cancers and malignomal tumor cells, drugs were developed 
towards an application on various kinds of surface near cancers, such as early- and 
late-stage lung cancers, bladder cancer, colon or ovarian cancers to name a few[279, 
285, 299, 301]. 
The most commonly used photo sensitizers are porphyrins or phthalocyanines, of 
which more than eighty different natural molecules are known. The fact that 
porphyrins can be used in combination with almost any metal opens a vast variety of 
electronic, spectral and structural properties. All porphyrin-like compounds have a 
strong absorption band around 400nm called Soret – band. Unfortunately this 
absorption band is not useful for PDT because blue light does not penetrate very 
deeply into tissue; thus the weaker satellite absorption bands (Q bands) between 
500nm and 800nm are used for treatment. These Q bands equally contribute for 
fluorescence as the Soret – band does[10, 302-305].  
The properties of porphyrins are ideal for photo sensitizers for PDT since they are 
non-toxic and a selective uptake in tumor cells in high concentrations is described. 
Margaron et al. have reported that prophyrins are, being amphiphilic, generally more 
photo dynamically active than symmetrically hydrophobic or hydrophilic 
molecules[306]. Due to the very strong absorbance of light and transfer this energy to 
surrounding oxygen molecules, toxic singlet oxygen species and free radicals are thus 
formed upon irradiation[279, 307-309]. Singlet oxygen, the predominant cytotoxic agent 
produced during PDT is a highly reactive form of oxygen that is produced by inverting 
the spin of one of the outermost electrons. These chemicals are very reactive and can 
damage proteins, lipids, nucleic acids and other cellular components. 
5.2.4 Mechanism of Porphyrin Excitation  
The generation of singlet oxygen can be described in the following steps: excitation of 
the porphyrin to the singlet excited state (1P*) made possible by the strong 
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absorption in the near red UV region (Figure 5.5, simplified Jablonski diagram)[284, 310-
313]. The singlet excited porphyrin can decay back to the ground state with release of 
energy in the form of fluorescence - enabling identification of the tumor tissue. If the 
singlet state lifetime is suitable, which is the case for many porphyrins, the singlet 
state can be converted into the triplet excited state (3P*).  This energy can be 
transferred to another triplet state (according to the spin-transfer rules). One of the 
very few molecules with a triplet ground state is dioxygen, which can be found in 
most cells. Energy transfer takes place to afford highly toxic singlet oxygen (1O2) from 
ground state dioxygen (3O2 ), provided the energy of the 
3 P* molecule is higher than 
that of the product 1O2.  
 
Figure 5.5 Simplified Jablonski diagram depicting the energy levels of the porphyrin on the left and 
dioxygen on the right, respectively. 
There are 2 different types of photoreactions for the PDT (Scheme 5.1): Type-I 
photoreaction describes an electron transfer from the photo sensitizer to a substrate 
or directly to the dioxygen. The Type-II photoreaction is constituted of an energy 
transfer from the excited state of the photo sensitizer to the dioxygen to yield singlet 
oxygen.   
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Scheme 5.1 An overview of type I and II photoreactions: P resembles the photo sensitizer, 1P its singlet 
ground state, 
3
P* the triplet excited state, P
-
 is the reduced photo sensitizer, P
+
 the oxidized form, S is a 
substrate molecule, S
+
 its oxidized form, O2 resembles dioxygen (triplet ground state), O2
–
  is the superoxide 
anion, O2. is the superoxide radical, 
3
O2 is triplet ground-state oxygen , 
1
O2 in a singlet excited state, and SO is 
an oxygen adduct of a substrate. 
The general procedure of PDT includes the injection of the photosensitizing agent 
into the bloodstream of the patient. The drug is then absorbed by cells all over the 
body and later, the cancer cells are treated by exposing this surface to laser light 
(usually 10 – 30 minutes). The photosensitizing drug absorbs the light to form singlet 
oxygen that oxidizes the DNA, proteins, and membranes of the irradiated cells which 
are thus destroyed. Another application method is the treatment of a tumorous 
surface with a cream with is then locally irradiated after uptake of the photodynamic 
agent into the cells (up to 16h depending on the carrier substrate).  
Mitochondria have become the central processing organelles in the majority of 
apoptotic pathways. Signals from cell surface receptors or from damaged sites 
converge on mitochondria, leading to permeabilization of both mitochondrial 
membranes, dissipation of the inner membrane potential and release of several 
apoptosis-related proteins, normally located inside the mitochondria. This process 
can also be triggered by targeted irradiation of the corresponding receptor proteins 
in proximity of the photo sensitizer (Figure 5.6). The release of apoptosis-related 
proteins results from the formation of a channel known as the permeability transition 
pore complex (PTPC). Another receptor, AIF is localized in the mitochondria and 
released in response to light stimuli. This apoptosis-inducing factor moves directly to 
the nucleus, where it produces chromatin. The hydrolytic reactions of apoptosis are 
catalyzed by a family of proteases termed caspases. The caspases are cysteine 
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proteases present in cytosol and activated by mitochondrial proteins.  The combining 
effects of irradiation and the reaction of the surface receptors favor and accelerate 
the apoptotic behavior of mitochondrial protein cascades.  
 
Figure 5.6 Apoptotic mechanism in mitochondiral membranes upon irradiation with light [225]. 
 
5.2.5 Porphyrins and their Biological Behavior 
Porphyrins and metalloporphyrins possess a high binding-affinity to cellular 
components, membranes, proteins and DNA. Living cells as well as dead cells are 
stained rapidly by different porphyrins. Appropriate illumination at around 420 nm, in 
some cases of metalloporphyrins up to 550nm, generates an emission of red 
fluorescence and generates toxic oxygen species. In vivo administration of various 
porphyrin sensitizers to tumor bearing animals and humans resulted in uptake of the 
porphyrins in the tumors, while the normal surrounding tissues had a low comparable 
porphyrin concentration[90, 314-316]. 
As further developments, water soluble porphyrins were introduced, such as the 
tetra cationic 5,10,15,20-tetrakis(N-methyl-4-pyridinium)-porphyrin (Figure 5.7, 
TMPyP), which was found to localize in the nuclei of human leukemia cells. 
Furthermore upon UVA irradiation, it efficiently induces apoptosis[317]. Wu et al. claim 
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that some cationic porphyrins were killing HeLa cells with IC50 values down to 6 nM 
concentrations[183]. However, they did neither protect the cells from heating, as this is 
normally done[318] nor did they use any specified light source, since PDT is normally 
done with light that has a wavelength greater than 600 nm in order to penetrate 
deeper in the cancerous tissue.  
 
Figure 5.7 Water soluble 5,10,15,20-tetrakis(N-methyl-4-pyridinium)-porphyrin used as a photo 
reactive reagent to damage DNA[317]. 
 
5.2.6 Approved Drugs containing Porphyrins  
In December 1995, the U.S. Food and Drug Administration (FDA) approved a 
photosensitizing agent called Porfimer sodium, or Photofrin (Figure 5.8), to relieve 
symptoms of esophageal cancer that is causing an obstruction and for esophageal 
cancer that cannot be satisfactorily treated with laser alone[162, 297, 300]. In January 
1998, the FDA approved Porfimer sodium for the treatment of early non-small cell 
lung cancer in patients for whom the usual treatments for lung cancer are not 
appropriate. Still today, the most commonly used photo sensitizer is Photofrin. 
Recently, the FDA has recommended that BPDMA, marketed under the name 
Visudyne (injection), be approved for use in therapy, which is essentially a porphyrin 
based PDT to destroy the defined newly formed tissue in the retina. The ideal photo 
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sensitizer would have its absorption maxima at wavelengths longer than 600nm to 
achieve optimal penetration in deeper laying tissue and organs. 
 
Figure 5.8 Commercial photo sensitizer Photofrin. 
Different ways to apply this combinational therapy are tested, combining new laser 
types and photo sensitizers to treat potentially cancers that are located further below 
the skin or inside an organ. One important new aspect is also the combination of 
known classical chemotherapy and relatively new approaches like PDT to achieve 
optimal treatment of cancer with lesser side effects. 
 
 
Figure 5.9 Schematic drawing of a possible application of the photo sensitizer via systemic 
administration with later irradiation of the tumor with light. 
The market for photodynamic therapy is still rather small. Table 5.1 gives an overview 
on the cancer types which can be treated with the corresponding therapy including 
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the number of patients. The market estimate of approximately 250’000 suitable 
patients suggests that if safe and effective PDT treatments were available then 
annual sales well in excess of $100 million are possible. 
Cancer Type Patient Number PDT  suited 
Head and Neck  
(oral cavity, esophagus) 
150’000 based upon a US incidence of 17.7 
per 100’000 
10% = 15’000 
Lung cancer 
500’000 based upon a US incidence of 
170’000 
Estimated 10% = 
50’000 
Bladder 150’000 based upon a US incidence of 53’000 5% = 7’500 
Gastric 
Second most common cancer in Far East 
120’000 pa. In the West around 300’000 pa 
Estimated 10% = 
30’000 
Cervical 
40’000 based upon a US incidence of around 
13’000 
Estimated 10% = 
4’000 
Non melanoma skin 500’000 based upon a US incidence Estimated 80’000 
Barrett's esophagus  
(pre-cancerous) 
1 million based upon a US incidence 5% = 50’000 
Total  approx. 250’000 
Table 5.1 Overview on the number of patients estimated to benefit from a specific 
photodynamic therapy. Numbers derived from various sources of the official homepage of the NDA 
and NIH. 
5.2.7 Combinatorial Therapies 
There have been several studies evaluating the combination of PDT and “classical” 
chemotherapy[195]. First studies were done in the late nineties[319]. These and later 
studies could show that a combination of PDT and cisplatin was much more effective 
in killing murine tumors or mouse lymphoma cells respectively than any therapy 
alone[300]. Sadler et al. have introduced platinum(IV) diazide complexes, that upon 
UVA light irradiation are being activated to form the reactive Pt2+ complex (Scheme 
5.2)[160, 186, 226, 286, 320, 321]. 
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Scheme 5.2 Reaction of platinum(IV) diazide complexes and dinucleotides exposed to UVA light. 
Figure adopted from ref [226].  
Another study showed that PDT combined with cytotoxic chemotherapy is well 
tolerated in mice bearing either the RIF-1 tumor or the EMT-6 tumor[191]. However, 
the Photofrin-induced photodynamic therapy-resistant cell line (RIF-1) is cross-
resistant to cisplatin[192]. Another study showed that photodynamic therapy 
complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer 
cells [38]. In the same line, mouse squamous cell carcinoma were exhibiting enhanced 
susceptibility to photodynamic therapy when they were treated simultaneously with 
low doses of cisplatin[296]. Mechanistic studies revealed that low doses of cisplatin 
together with a Photofrin based photodynamic therapy lead to disjointed cell cycle 
phase-related activity. This accounted for the synergistic outcome of the combination 
therapy[185]. There was also a report about an enhanced apoptotic effect of combined 
photodynamic therapy and carboplatin[225]. 
Many research efforts were evaluated to find photo sensitizer that were covalently 
linked to DNA damaging metal complexes[322]. Initial work mainly was performed in 
the group of Brunner. Their first conjugate failed to be more phototoxic than cisplatin 
co-administrated with the porphyrin[238]. Follow-up compounds had phototoxicity 
down to the lower M concentration[168, 323-328]. Munakata and co-worker synthesized 
water soluble tetrakis-(2-aminophenyl)-porphyrins that were coordinated to 4 trans-
diamino-chloro-platinum units[329]. In Figure 5.10, the most recently published 
covalently conjugate between a photodynamic therapeutic agent (phthalocyanine) 
and cisplatin is shown [182]. Their phototoxicity after a relatively long exposure of one 
hour is in the sub micro molar concentration range. It needs to be noted that these 
conjugates are actually di-platinum complexes with both metals having only one 
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leaving group. Whether these di-platinum complexes will result in mono-adducts to 
DNA, which are easily repaired, or di-adducts, which are much more difficult to be 
repaired in the cell, remains to be explored.  
 
Figure 5.10 Example of a covalently linked cisplatin with a photodynamic therapeutic agent [182]. 
The cytotoxicity of conjugates of water-soluble porphyrins together with cisplatin 
analogues was studied without evaluating a possible PDT effect[330-333].  
 
5.3 Motivation and objective of this project 
In order to successfully treat cancer that occurs near a surface, we combined the 
advantages of photodynamic therapy conducted via water-soluble porphyrins with 
the well-known behavior of cisplatin. On the one hand, the porphyrin residue 
contributes its properties to the complete system, by a) adding its ability to enter 
cells while functioning as a carrier system for the covalently bound cisplatin, b) as a 
very effective photo sensitizer with tunable excitation properties related to the 
central metal ion and c) its function (in case of the non-metal containing and the d8-
metal containing ones) as a possible intercalator, which is considered as a binding 
mechanism and d) it’s tremendously improved water solubility[334]. It’s highly positive 
charge contributes to its affinity towards negatively charged biological structures 
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such as DNA, deprotonated proteins and possibly cell membranes and the 
phospholipid bilayer. Cisplatin was attached to the porphyrin because of its known 
anticancer properties. When attached to i.e. DNA and irradiated, the generation of 
singlet oxygen in the proximity of biological molecules will create greater damage 
than in more remote areas in the cells. The same is true for the binding of cisplatin to 
the cell membrane or the mitochondria. 
In Figure 5.11, the 6 lead molecules are shown. They all consist of a central porphyrin 
unit with 3 4-methyl-pyridinium and one para-cyanophenyl residues, which functions 
as a covalent link to platinum or stays innocent if no metal is attached. The 
prophyrins are aromatic, essentially flat, with a 3+ charge in case of the non-
platinated and 4+ in case of the platinated species (no chloride dissociation 
assumed). From the organic synthesis, iodide species were received. These counter 
anions were exchanged using an anion exchange column and set to be nitrate due to 
high solubility and innocent behavior towards cells or DNA.  
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Figure 5.11 Synthesized cationic porphyrins without and with an attached cis-
diamminechloroplatinum(II) unit and different central metal ions.[181] 
 
5.4 Results and Discussion 
5.4.1 Synthesis and Characterization  
Despite a great number of well-known and previously synthesized porphyrins, the 
synthesis of the 5,10,15-methylpyridinium-20-para-benzonitrile-porphyrin nitrate 
was only described seldom in literature[335]. The synthesis of the porphyrins was 
carried out according to or slightly modified the known procedures in porphyrin 
chemistry. The first approach was the direct synthesis according to Adler and Longo 
starting with single components of the porphyrins (pyrrole, para-cyanobenzaldehyde, 
4-pyridinaldehyde) and refluxing them in propionic acid under air for 40 minutes 
yielding a mixture of polypyrroles, 6 different porphyrins in statistical compositions of 
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their aromatic residues and other compounds which had to be separated via 
repeated column chromatography[147]. The yield was traditionally very low (~ 1%) and 
the clean-up very tedious. 
 
Scheme 5.3 Statistical Synthesis of A3B - type Porphyrins. 
The other, synthetically more challenging procedure was to go via the route 
described in Scheme 5.4. Starting from the dipyrromethane (DPM, if R1=pyridine 
DPP), which is then reacted further in a Gringard promoted reaction with an aryl-
chlorocarboxylic compound to the dipyrro-triaryl-diol[149, 336, 337]. This is processed to a 
stabilized tin – di(n-butyl) form which is thus reduced to the alcohol and instantly 
reacted to the closed ring porphyrin using again a dipyrromethane (DPM, if R2= para-
cyanobenzaldehyde DPpBN). This reaction yielded in each step around 30-50% of the 
desired product and totally yielded 12% of the porphyrin, although using a lot of 
purification and separation work. 
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Scheme 5.4 Synthesis of the A3B - type porphyrin via a stabilizing tin intermediate. 
The synthesis of the cisplatin-porphyrin compounds was carried out according the 
general protocols used to prepare cisplatin adducts by activating cisplatin by the 
precipitation of one chloride atom to produce a vacant site that is thus reacted with 
the cyano-group of the porphyrin. This reaction took several days or even weeks due 
to the two positively charged compounds that have to be reacted. The reaction was 
monitored via HPLC and the yield was high. 
 
Scheme 5.5 Reaction of the activated cisplatin with a porphyrin residue (R1 = 4-Me-pyridyl) 
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We prepared porphyrin compounds 17 – 22 which were fully characterized according 
to standard methods, including 1H-, 13C-, 195Pt-NMR, ESI-MS, HPLC, AAS, UVvis, and 
MALDI-MS. These compounds all originated from the 5,10,15-methylpyridinium-20-
benzonitril-porphyrin nitrate and contained different central metal ions, i.e. Cu2+ or 
Zn2+ and/or a cisplatin 4-methylpyridinium residue bound covalently to the nitrogen 
of the benzonitrile residue of the porphyrin. The seemingly simple preparation of 
mono activated cisplatin is rather low yielding as a survey of the literature shows[209, 
266, 338-340]. The reaction times for those platinated porphyrins were up to 20 days until 
the complete conversion was obtained. Nevertheless, we succeeded in synthesizing 
the mono porphyrin cisplatin adducts 17 – 22 in 88-92% yield. 
During the characterization of the compounds, it was found that these complexes 
have superior spectral properties upon previous porphyrin complexes regarding their 
absorption and fluorescence. The special absorption properties of these compounds 
culminated in compound 22 which had a standard Soret band at around 440 nm but a 
strong series of Q bands reaching form 565 to 680, a region which provides this 
compound 22 with good properties to be excited by irradiation through skin.  
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Figure 5.12 Absorption spectrum of Porphyrin 22. Arrow points to the large Q-band at 565 nm. 
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Already in 1930, Reed and Bachem proposed, that UV light above 550 nm could reach 
the corium of the skin in their description of the skin penetration of children. The 
visible light can thus excite the porphyrin 22 to become an active photosensitizer. 
   
 
Figure 5.13 Schematic drawing of the skin layers and the UV energy travelling into the specific 
layers of the skin. Picture was taken from www.cambrige-campus.co.uk/skin-
layer/UVtransmission. 
The spectral properties of the compounds did not change upon platination. Related 
DFT calculations showed that the influence of the central metal ion on the N 
(benzonitrile residue) is very small and thus the covalent platination does not have an 
influence on the electronic properties of the overall molecule. The HOMO and LUMO 
energy levels of compound 17 of the N atom of the CN show a minimal lower eV than 
the zinc containing compound 19. The same is true for all metal containing 
porphyrins as well as for their solvated central metal ions. But the influence is rather 
small towards the N of the cyano residue. The different reaction times and kinetic 
properties for the platination reaction of the molecules 17 – 19 cannot be explained 
with the influence of the central metal ion. This happened to be rather due to 
solvatation effects of the porphyrin complexes. Since platinum complexes in general 
react rather slowly, the reaction times for the platination reached from 2 days to 14 
days for a 100% platination. An anion effect can be neglected because the reaction 
was carried out once with nitrate and once with tetrafluoroborate as counter anion. 
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The DFT calculations do explain though why the UVvis spectrum for the sister 
compounds 17 & 20, 18 & 21, 19 & 22 are not different. The effect of the coordinated 
cisplatin towards the spectral properties is too low. 
A second observation related to chapter 4 could also be partly explained. The 
energies for the solvatation are showing a direct connection to the number of water 
molecules counted to the central metal ion. Compound 19 shows a large increase in 
E for the dissolution of the first as well as for the second water molecule and thus 3 
fold increased in stability from no to two coordinated water species (see Table 5.2). 
The first and second water molecule of copper compound 18 is not quite as strongly 
bound to the copper compared to the zinc containing compound. The copper 
molecule is known as an intercalator which was also observed for the compound 12 
described in chapter 4.[11, 99, 111, 136, 302, 304, 314, 341] There the observed intercalative 
properties lead to the conclusion of a semi-intercalation or a combination of a side-
on coordination and intercalation. The fact that compounds 19 and 22 are not 
intercalating but rather coordinating to DNA can also be explained with those 
numbers. The influence of the axially coordinated water molecules is rather strong as 
discussed previously[11]. 
  Porph-
2H 
17 
Porph-Cu 
18 
Porph-Zn 
19 
Porph-
Cu(H2O) 
Porph-
Zn(H2O) 
Porph-
Cu(H2O)2 
Porph-
Zn(H2O)2 
Energies (Hartrees) Electronic energy E -2172.65 -2367.68 -2237.15 -2444.12 
-
2313.60 
-2520.54 -2390.02 
 Solvent-corrected 
(H2O) energy Esolv -2173.05 -2368.08 -2237.56 -2444.52 
-
2313.99 -2520.95 -2390.43 
 E (kcal/mol)
a
 - - - -3.96 -6.12 -4.73 -9.56 

a
E  = Esolv[Porph-M(H2O)n] – Esolv[Porph-M] – nEsolv(H2O)   
MO energy (eV) / % 
of N atom of CN 
L+11 0.14 
(36%) 
0.14 
(40%) 
0.11 
(41%) 
0.15 
(40%) 
0.12 
(41%) 0.17 (34%) 0.16 (41%) 
 L+5 -1.88 
(13%) 
-1.86 
(13%) 
-1.87 
(14%) 
-1.83 
(13%) 
-1.85 
(14%) 
-1.79 
(13%) 
-1.79 
(13%) 
 LUMO (L) -3.52 -3.4 -3.41 -3.37 -3.41 -3.31 -3.35 
 HOMO (H) -6.05 -6.1 -5.97 -5.93 -5.87 -5.74 -5.64 
 H-1 -6.28 -6.15 -6.14 -6.04 -6.08 -5.93 -5.92 
 H-2 -7.18 -7.08 -7.24 -6.88 -7.17 -6.62 -6.99 
 H-6 -7.89 -7.66 
(13%) 
-7.62 -7.47 
(9%) 
-7.55 -7.36 -7.29 
 Mulliken charge on N atom of CN -0.115 -0.116 -0.116 -0.116 -0.107 -0.118 -0.113 
 E(HOMO-LUMO) [eV] 2.53 2.70 2.56 2.56 2.46 2.43 2.29 
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Table 5.2 Selected DFT data for porphyrin compounds 17, 18, and 19 and their mono- and 
diaquated- species. 
       
 
Figure 5.14 HOMO (left) and LUMO (right) orbital level of Cu compound 18 (top, one axial water 
molecule) and Zn compound 19 (bottom, two axial water molecules). 
 
5.4.2 Stability of Platinum-Porphyrin Complexes in Water and Serum 
For applications under biological conditions, it has to be secured, that the applied 
compounds are stable and not affected by the biological environment otherwise they 
might lose their functionality in vitro and in vivo. The serum stability is one important 
measure, as well as the internal stability of the compound itself. 
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The total concentration of albumin in plasma is around 60% of the total protein 
concentration, globulin (35%) and fibrinogen (4%) contribute to the rest of the highly 
abundant proteins. Lower abundant proteins only make up 1% of the total protein 
concentration. Albumin solutions are therefore taken as a model system to mimic 
cellular plasma conditions.  
The covalent bond from the benzonitrile residue of the porphyrin to the platinum is 
strong and could not be broken upon the irradiation of light (>550 nm, 6000 lux, from 
a xenon lamp, up to 20 hours, with or without water cooling) nor exposure to oxygen. 
The stability tests were carried out in MEM medium, RPMI medium as well as in 
water. Additionally, to the standard characterization, the platinum content was 
determined by AAS (Atomic Absorption Spectroscopy) and found to be 1 equivalent 
compared to the molecule before and after the irradiation. 
 Measured 
Abs. 
Reference  0.215 (2) 
20 0.213 (3) 
21 0.219 (4) 
22 0.209 (1) 
 
Table 5.3 AAS Normalized standard and the corresponding averaged measured concentrations 
of 50 ppm after 3 repetitions of the measurement. Reference solution was taken from Sigma-Aldrich 
and diluted to 50 ppm. 
It is known that cisplatin, especially in its activated form, binds rapidly and almost 
irreversible to human albumin present in its serum (HSA)[187, 342]. Since HSA contains 
cystein residues which are exposed to the solvent and it was shown in many studies 
that cisplatin binds to these covalently as shown, there are several binding modes 
possible towards HSA. Non-covalent linkage is usually a fast and reversible process 
detectable shortly after incubation. Electrostatic interactions are also reversible and 
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can thus be neglected due to slightly acidic conditions (pH = 5.0) during the 
experiments. Covalent coordination which is essentially irreversible and caused by a 
de-chlorination of the cisplatin-adduct and thus slow reaction evolves with time. Such 
covalent links can occur by either an unlikely separation of the platinum from the 
porphyrin or the combination and coordination of activated platinum toward a 
cystein, methionine, or histidine of the protein. The different resulting molecules 
could thus be observed due to their characteristic spectra via HPLC measurements. It 
was assumed, and later also tested, that the positively charged porphyrins alone 
regardless of the central metal center, do not interact with HAS (pIHSA(25°C) = 4.7). 
Thus, the electrostatic interaction could be neglected. 
 
Figure 5.15 Colorful porphyrins 17 - 22 (from left to right).HPLC probes taken during reaction. 
It should be noted, that all compounds 17 – 22 were stable in water, BSA media and 
also in acidic or saline solutions (up to pH1 and 1mM, respectively) over a period of 
weeks. Compounds 20, 21, and 22 showed a minor decomposition component when 
analyzed in a C18 – Nucleodur HPLC column with the typical 0.1% TFA buffer solution 
versus MeOH, which was due to the cisplatin – residue losing one chloride[181]. This 
behavior could be eliminated by the use of a saline solution (500 mg NaCl in 1l H2O, 
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~10mM) which reverses the dechlorination. This behavior could also be observed 
during the stability test, which was carried out in a 0.1% TFA solution.  
 
 
Figure 5.16 Comparison of HPLC properties of compound 22 run at a) normal 0.1% TFA buffer 
system and b) 10mM saline buffer system.  
Size exclusion usually quantify the ratio of human serum albumin bound/unbound to 
substrates, but due to restrictions and complications during the use of the size 
exclusion columns with the highly positively charged porphyrin molecules, the 
stability tests were carried out as follows: a 1 : 1 solution of HSA (13 mg ml-1) and a 
0.1 mM solution of the compound were dissolved in a phosphate buffer (0.1 M, pH 
7.4, 0.8% NaCl) and its reaction monitored over time with an HPLC system using a C18 
– Nucleodur column (flow rate 0.7 ml/min, max. pressure 175 bar) with gradient 1[181, 
343]. The effect of lipophilicity and size were taken into account to discriminate 
between the products. The traces were recorded with a photo diode array focusing at 
280 nm to monitor the HSA to determine its relative concentration and at 420 nm in 
order to observe the free porphyrin (at around 6.5-8 min, depending on the metal 
and Pt – residue) and the reaction product formed from HSA and the porphyrin at 
around 10.9 minutes. The gradient was prolonged to 20 minutes for this experiment 
to re – equilibrate the column again at 10% MeOH/0.1% TFA/H2O.  
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Figure 5.17 HPLC at 420 nm traces of the lead molecule 22 and its interaction with HAS at a) start 
and b) 48h. Free 22 was observed as the first signal. The formation of the HSA – 22 adduct is visible 
by the second signal appearing.  
The observation of the reaction was carried out for 48 hours and monitored every 1 
hour for the first 4 hours, then every 2 hours and later every 3 hours. The first rapid 
increase of bound Pt – Porphyrin (20, 21, and 22) towards HSA in the first 4 hours is 
due to hydrophilic interactions which accelerate the reaction. The latter process 
represents a covalent binding of the compounds to HSA. The compounds 20, 21, and 
22 showed a clear affinity and covalent bond to HSA but only 8% (22), 18% (20) and 
25% (21) were covalently bound within 48 hours, which makes the compounds 
reasonable stable in HSA. All other compounds were stable apart from the loss of a 
chloride as discussed above. 
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Figure 5.18 Lead molecules 17 – 22 and their interaction with HSA at 480 nm. It was observed 
that the platinum – free molecules (17, 18, and 19) did not interact with HSA whereas the ones with 
a Pt – residue (20, 21, and 22) showed a slight amount of covalently bound Pt – HSA species. 
5.4.3 Porphyrin Complexes and their interaction with DNA 
Porphyrins have a unique absorption characteristic with a strong absorption 
maximum called Soret band at around 420 nm for non-metallated and around 435 
nm for metallated species. The Q – bands, absorbing light from 450 – 650 nm depend 
on the outer sphere of the porphyrin, are also very characteristic and contribute 
additional absorbing properties, which will be of importance hereof. This absorption 
characteristic makes all porphyrins highly light absorbing, enabling them to easily get 
into a higher excited (triplet) state from which they decay emitting a strong 
fluorescence at  650 – 720 nm, although a number of paramagnetic central metal 
ions, i.e. copper can quench the fluorescence totally and also limit the absorption 
properties. Non-paramagnetic metal ions make porphyrins highly fluorescent. In our 
example, Zn2+ compound 22 has a very intense series of Q – bands at 530 nm. 
Peripheral bound metals, such as cisplatin compounds in our case, do shift especially 
the Q – bands into the red, which improves the absorption in deeper skin layers. Zinc 
and Nickel porphyrins were showed a high fluorescence behavior, copper porphyrins 
did not. Platinated zinc porphyrin has an, for prophyrins, exceptional high first Q – 
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band absorbance (8.2 × 104 cm−1M−1) at a wavelength of 563 nm – which is a factor 
that contributes to the high photo – induced cytotoxicity of this complex when 
irradiated. Porphyrin compounds 17 - 21 have lower intrinsic absorbance bands 
intense enough to be used in photodynamic therapy, although copper porphyrins 18 
and 21 are non-fluorescent as discussed in the literature for the related compound 
CuTMPyP (Fig. 5.19)[344]. 
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Figure 5.19 Steady state excitation (em = 680 for 17-21, 640 for 22) and emission (ex = 420 for 
17-21, 430 for 22) fluorescence spectra of porphyrins 17-22.[181] 
Porphyrins are fairly flat molecules, which dominates their interactions with the 
environment. The effect of the central metal ions strongly affects the physical 
properties of the molecule. Some (mostly natural) porphyrins contain amine- or 
carboxy- residues that make them more versatile and capable of binding to various 
receptors. In most cases discussed, especially regarding aqueous chemistry, the 
charge of the porphyrin is decisive. We choose a positively charged system to 
facilitate the binding towards poly-anions such as DNA or RNA, the usual target when 
working with cisplatin – analogue. The ability to further bind to other molecules is 
limited for the simple porphyrin systems which only contain a central metal ion. 
Compound 17 cannot bind to any other species except to strong Lewis acids via its 
Lewis acceptor, the benzonitrile. A possible binding site is the interior of the 
porphyrin ring, which can be assessed by a metal ion such as i.e. Mg2+. Other metals 
enter the center of the porphyrin and thus built very strong covalent linkages to the 
Excitation mission 
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porphyrin. Metallated porphyrins 18 and 19 are more versatile, including the 
possibility to exchange the central metal ion’s axial ligands. In mass spectrometric 
measurements, only copper showed an adhesive behavior towards counter ions such 
as nitrate or chloride. 
 
Figure 5.20 Colorful play with porphyrin compounds 17 – 22 at various pH values and in different 
solvents. 
To study the activity of the compounds towards their cisplatin – like behavior, 
interaction of compounds 20, 21 and 22 with 2’-desoxyguanosine was studied. 
Compounds 20, 21 and 22 do have several vacant or accessible binding sites in 
aqueous conditions. The reaction was carried out in a solution containing 10mM 
phosphate buffer at a pH = 7.4 with 1% NaCl, in order to mimic physiological 
conditions. A tenfold excess of 2’-desoxyguanosine was applied to the compounds. 
The product formation was monitored by measuring ESI – MS spectra to determine 
the function of the binding versus time. The reaction time was well above 24h, which 
indicates a weak trans-effect of the benzonitrile – Pt complex. As shown in Figure 
5.21 for the example of compound 21, the first and easy accessible binding site is the 
previously discussed and well – known loss of a chloride which leads to the mono – 
adduct 21 – 2’-desoxyguanosine. In the consecutive step, the amine trans to the 
cyano – like bond of the Pt to the benzonitrile residue is broken and can further react 
with another 2’-desoxyguanosine.  
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Figure 5.21 Time – dependant reaction of 21 with 2’-desoxyguanosine. 
The reaction of the compounds follows the classical consecutive reaction profile A -> 
B -> C. The low solubility of 2’-desoxyguanosine prohibited a determination of the 
kinetics, which avoids a pseudo-first order condition in the first part of the reaction. 
The classical experiment with 2’-desoxyguanosine-monophosphate was also carried 
out, but the exposure to compound 20 caused immediate precipitation due to the 
positive charge of the porphyrin.  
 
Scheme 5.6 Observed reaction behavior of cis-diammine-chloro-N-cyano-platinum(II)-porphyrin 
compounds and the corresponding MS spectrum in water with 2’-desoxyguanosine after 24h. 
 
First adduct 
Second adduct 
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5.4.4 Cytotoxicity Studies in Carcinoma Cells 
Most platinum drugs’ cytotoxic effect is due to the formation of DNA – Pt – adducts. 
However, various possible mechanisms are mentioned in literature[187, 191, 238, 319, 345]. 
In vitro measurements of drug concentrations are related to the efficacy of drugs on 
inhibiting biological functions. The concentration of a drug needed to induce 50% cell 
death is called the IC50 value. One gold standard of determining this value is the MTT 
assay, another standard is the trypan blue assay[38, 346]. For our studies to determine 
the IC50 value, we carried out an MTT assay, which is a standard colorimetric assay for 
measuring the activity of enzymes that reduce MTT to formazan upon mitochondrial 
activity. MTT is a yellow colorant (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) that is reduced to purple formazan in the mitochondria 
of living cells. This reduction only takes place when the cells are alive and the 
mitochondrial reductase is active. By comparing the formation of the purple 
formazan, and untreated control cells, the activity of the drugs is monitored. The 
different absorbance of MTT and formazan can be monitored and quantified by using 
an ELISA plate reader to measure the absorbance at 570 nm[347]. 
 
Scheme 5.7 Reduction of MTT to formazan. 
To determine the cytotoxicity of the above mentioned compounds 17 - 22, two 
different human cell lines, the human mama-carcinoma cells MCF-7 and the human 
ovarian cancer cells A2780, were exposed to the porphyrin compounds 17 – 22 under 
different conditions at concentrations ranging from below 0.1 to 200 M.  
MTT 
formazan 
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Figure 5.22 96 well plate MTT assay. The outer wells are controls with no cells (0% survival), the 
second lowest row is occupied with untreated controls (100% survival), and in the internal rows each 
represents the dose response in statistical relevant data (5 experiments) at a given concentration. 
The photodynamic effect of the compounds was monitored by exposing one set of 
the sample plates to light emitted from a water cooled xenon light (to avoid IR 
irradiation) covered with a cutoff filter 600 nm with an intensity of 3200 lux. The light 
was shone vertically on the plates with the help of a mirror in order to equally expose 
all wells in the same fashion. All experiments were carried out twice to avoid 
contamination errors of mistakes of handling the cells to influence the results. All 
graphs show a median of minimally 2 experiments.  
  110 
 
Figure 5.23 The experimental setup for the irradiation of the carcinoma cell lines. The beam of a 
water cooled light source equipped with a cutoff filter <600nm is directed via a mirror to the 96well 
plates in a 90° angle. 
Compound 17, a solely organic porphyrin did show a cytotoxic effect when exposed 
to light after incubation to the cells for 24 hours (green line, Figure 5.24). To 
determine the needed incubation time, two experiments with different incubation 
times were carried out. First, the cell plates were exposed to light after 4 hours with 
no prior exchange of the compound containing medium. This did not show any photo 
effect or enhancement on the cytotoxic effect (brown line). The photo effect only 
occurred, when the compounds could be taken up into the cell which takes about 16 
– 24 hours. As depicted in Figure 5.24, compound 17 showed a phototoxic effect 
when exposed to light. The IC50 value drops to 1 M in case of the MCF7 cell line and 
0.55 M in case of the A2780 cell line. Compared to the values obtained for the 
cytotoxic effects without irradiation to light, this is an increase in cytotoxicity of over 
300%!  The effect was comparable for both cell lines.  
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Figure 5.24 MTT assay excerpt of compound 17. Only the relevant region of the MTT assay is 
shown up to 100% cell death at the corresponding concentration. The data points are the median of 
two MTT assays. The orange line represents the MTT assays with no exposure to light. The brown 
one shows the survival rate of the cells after exposure to light 4 hours after incubation (no washing), 
the green line depicts the amount of living cells after exposure to light 24 hours after incubation 
(and washing) of the cells. 
In another experiment, the cell plate was incubated for 24 hours, then the medium 
was removed and the cells washed with medium to remove traces of compound 
which was not taken up by the cells. Afterwards, fresh, no-porphyrin containing, 
medium was given into the wells and then the plates with the cells were exposed to 
light. Like this, it could be avoided, that a possible photoreaction taking place outside 
of the cells and i.e. producing singlet oxygen could harm the cell membrane and thus 
cause cell death. This exposure to light was carried out at various exposures to light 
(5, 10, 20, 30, and 90 minutes) at a given concentration of 5 M (Figure 5.25). These 
experiments were carried out for compounds 17 and 20. As shown in Graph 5.25, the 
phototoxic effect did not increase during longer exposure times. After 10 minutes, 
the maximum was reached in case of platinated compound 20.  
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Figure 5.25 Various light exposure times of cells treated with either compound 17 (black) or 20 
(red) at 3200 lux. 
For convenience and since the plates could only be irradiated one at a time, 10 
minutes exposure time were chosen to be the preferred exposure time for the 
following experiments.  
A similar toxicity behavior was observed for compound 18, a porphyrin with a central 
copper ion. See below for an overview of the IC50 values and IC90 values (Table 5.4). 
Again, a photodynamic effect is observed. The increase in cytotoxicity is caused by 
the irradiation of light. For both cell lines it is observed that the central copper is 
increasing the cytotoxicity of the compound compared with the metal free 
compound 17. Comparable to compound 17 is also that copper compound 18 can as 
well act as an intercalator into DNA. This can tremendously disturb the biological 
function a block the cell metabolism and eventually lead to apoptotic effects. 
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Figure 5.26 MTT assay excerpt of Cu – compound 18. Only the relevant region of the MTT assay 
is shown up to 100% cell death at the corresponding concentration. The data points are the median 
of two MTT assays. The orange line represents the MTT assays with no exposure to light (top). The 
light red one (bottom) shows the survival rate of the cells after exposure to light 24 hours after 
incubation (and washing) of the cells. 
Zinc porphyrin complex 19 shows a phototoxic effect (Figure 5.27). The non-
platinated compound is also having a cytotoxic effect when no light is applied to the 
cells, but the effect is rather low. Interestingly, cell line A2780 showed a different 
behavior towards compound 19 compared to MCF7 when not irradiated. The 
phototoxicity is again very low (> 1M). Zinc compound 19 is no intercalator due to 
one axial ligand that is fairly strong attached to the central metal ion.[10, 11, 143, 303] It 
can therefore not intercalate into DNA. This compound can, as described in Chapter 
2, bind in a side-on mode towards biological molecules. It can also, being a flat 
molecule, occupy flat areas on the cell membrane causing damage by emerging 
singlet oxygen proximate to phospholipide bilayer. 
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Figure 5.27 MTT assay excerpt of Zn – compound 19. Only the relevant region of the MTT assay 
is shown up to 100% cell death at the corresponding concentration. The data points are the median 
of two MTT assays. The green line represents the MTT assays with no exposure to light. The red 
(MCF7) or light green (A2780) line shows the survival rate of the cells after exposure to light 24 
hours after incubation (and washing) of the cells. 
Compound 20, a metal free porphyrin with a cisplatin residue, is a typical intercalator 
with an additional binding site (Figure 5.28). Interestingly and contrary to its non-
platinated analog compound 17, it does not show any phototoxic effect. It is very 
toxic regardless of light, nevertheless. This proves the proposed accessibility of the Pt 
– residue to biological relevant structures causing lower survival among the cells. The 
combined effect of intercalation and cisplatin – like behavior add up to a very toxic 
compound. Contrary to compound 17, the externally bound platinum compound pulls 
out the electron density (as can also be observed in the absorption spectra) which 
prohibits a photoreaction. 
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Figure 5.28 MTT assay excerpt of Pt – compound 20. Only the relevant region of the MTT assay 
is shown up to 100% cell death at the corresponding concentration. The data points are the median 
of two MTT assays. The grey line represents the MTT assays with no exposure to light. The dark grey 
red one shows the survival rate of the cells after exposure to light 24 hours after incubation (and 
washing) of the cells. 
Copper porphyrin with externally bound cisplatin 21 shows a similar behavior 
towards the two cell lines as copper compound 18 (Figure 5.29). There is a phototoxic 
effect, the cytotoxicity is high (see Table 5.4) and IC50 value is low. The possibilities of 
this compound are multiple ones: a possible binding via the cisplatin residue, an 
intercalation and also a photoactive compound able to induce singlet oxygen. 
Although there is no fluorescence of this compound, the absorption of this 
compound is well defined with a maximum at the Soret band around 430 nm and a 
prominent Q – band at 554 nm. This seems sufficient to excite the porphyrin to its 
singlet state to start the chain reaction to produce singlet oxygen. 
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Figure 5.29 MTT assay excerpt of Cu – compound 21. Only the relevant region of the MTT assay 
is shown up to 100% cell death at the corresponding concentration. The data points are the median 
of two MTT assays. The green line represents the MTT assays with no exposure to light. The yellow 
line shows the survival rate of the cells after exposure to light 24 hours after incubation (and 
washing) of the cells. 
The non-intercalating zinc porphyrin 22 with a cisplatin coordinated on the outer 
sphere of the porphyrin was the most cytotoxic compound when irradiated (Figure 
5.30). The very high cytotoxicity is related to the versatile binding modes this 
compound can participate in. The zinc porphyrin is not an intercalator since the 
axially bound water is preventing an intercalation[11]. The increased accumulation of 
zinc porphyrin in the mitochondria as well as in the cell nucleus was observed in 
preliminary cell uptake studies.  The phototoxic effect was contributing 55 times to 
the cytotoxicity. This compound 22 is a good example of a limited toxicity compound 
triggered to become a highly toxic compound upon light irradiation. One important 
feature is its extraordinary high Q – band around 650 nm which contributes strongly 
to its fluorescence properties. Another effect of this characteristic is, that deeper skin 
sections treated with this compound can be reached to develop its phototoxic effect 
when irradiated with light. Compounds IC50(hv) value of 0.15 M is comparable with 
the most cytotoxic compounds[114, 168, 194, 282, 324, 348]. The combined effect of the 
possibility to bind covalently via the platinum residue to DNA and to strongly evolve 
singlet oxygen resulted in a highly effective weapon against carcinoma cell lines. 
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Figure 5.30 MTT assay excerpt of Pt – compound 22. Only the relevant region of the MTT assay 
is shown up to 100% cell death at the corresponding concentration. The data points are the median 
of two MTT assays. The red line represents the MTT assays with no exposure to light. The light red 
one shows the survival rate of the cells after exposure to light 24 hours after incubation (and 
washing) of the cells. 
An even more elevated cytotoxic effect for compound 22 was observed (Figure 5.31), 
when the counter ion was changed from nitrate to tetrafluoroborate and the 
compound dissolved in the medium with 50l of DMSO. The observed IC50 value upon 
irradiation was down to 0.02 M. It has to be further evaluated, which will be the 
most suitable conditions for a possible treatment of cancer cells (see chapter Outlook 
5.5).   
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Figure 5.31 MTT assay excerpt of Pt – compound 22, with BF4
- as a counter ion instead of the 
previously used NO3
- dissolved in 1% DMSO medium. 
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Cisplatin was chosen as a reference to compare the results and as internal standard 
for the cytotoxic test. It was shown, that the cells used in these experiments showed 
a standard cytotoxicity towards cisplatin as described in literature. To obtain 
comparable data on the behavior of cisplatin upon irradiation, an experiment with 
and without irradiation on the same conditions described before were carried out. In 
both cell lines, the cytotoxicity of the cisplatin was not particularly different upon 
irradiation. A small contrary effect was observed in the MCF7 cell line, in which the 
cisplatin decomposed during irradiation and showed a slightly minor cytotoxic effect 
(see below Figure 5.32, left). 
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Figure 5.32 MTT assay excerpt of cisplatin. Only the relevant region of the MTT assay is shown 
up to 100% cell death at the corresponding concentration. The data points are the median of two 
MTT assays. The green line represents the MTT assays with no exposure to light. The grey one shows 
the survival rate of the cells after exposure to light 24 hours after incubation (and washing) of the 
cells. 
 
5.4.5 Calculated Interactions  
To understand the mechanism of action, a possible model of the interaction between 
17 – 22 and DNA was calculated. It was assumed that the cisplatin residue can 
coordinate as freely as if no porphyrin was coordinated. The model relied on an X-ray 
structure of cisplatin-modified DNA, one NH3 ligand of the Pt complex was replaced 
by porphyrin 20 resulting in a depiction how such an interaction could happen. In 
comparisons studies, different scenarios such as intercalation, coordination and 
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partial side – on interaction were discussed. The distance in between the porphyrin 
and the cisplatin enables the molecule to penetrate deep into the groove and 
coordinate in a classical cross-linking fashion with the bending of the DNA as depicted 
in Figure 5.33. For this type of interaction, cisplatin residue would have to lose one of 
its trans located amine ligands. This is well possible due to the stronger trans-effect 
of the cyano – residue of the porphyrin towards the amine than vice versa.  
 
 
Figure 5.33 Molecule 22 is cross-linking 2 neighboring guanosine residues in this calculated 
model system. Zoom to the coordination site below. 
Compound 22 could as well coordinate to one guanosine residue which would keep 
the helical structure of the DNA intact. This scenario is shown in Figure 5.34. The 
positive charge of the porphyrin causes an electrostatic interaction of the phosphate 
– sugar backbone towards the porphyrin. An intercalation of a zinc porphyrin is not 
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possible due to its strongly coordinated axial ligand. In Figure 5.35, a metal free 
porphyrin is chosen to depict the intercalation by a sterically not hindered porphyrin. 
 
Figure 5.34 Molecule 22 is coordinating to one guanosine residue of B - DNA in this calculated 
model system.  
By shortening the distance in between the porphyrin center and the cisplatin residue, 
it is more likely to also intercalate into DNA (see Figure 5.35). 
 
Figure 5.35 Porphyrin which is directly linked to a cisplatin via its pyridyl residue intercalating 
into DNA (side view). The shortened coordination disfavors a coordination of the platinum by a base.  
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5.5 Conclusion and Outlook  
In the following Table 5.4, an overview of all compounds that were exposed to the 
carcinoma cell lines is listed. The ratio shown in the last column depicts the 
phototoxic effect and its impact on the photo- cytotoxicity – the higher the number 
the higher is the influence.  
MCF7 
      Compound IC50 M) IC90(M) Photoactive h/h (IC50) 
 h h h h   
cisplatin 0.7 1.4 2.3 25 decomposition 0.5 
17 38 1 85 2.5 yes 38 
20 0.6 0.5 1.5 1.2 no 1.2 
18 4 0.45 70 1.5 yes 8.9 
21 2.5 0.7 13 1.3 yes 3.6 
19 11.5 0.5 20 1.35 yes 23 
22 8.5 0.15 60 0.45 yes 57 
 
A2780 
      Compound IC50 (M) IC90(M) Photoactive hv/hv (IC50) 
 h h h h   
cisplatin 0.8 0.65 1.7 1.8 no 1.2 
17 43 0.55 80 1.4 yes 78 
20 0.35 0.15 1 0.4 no 2.3 
18 20 0.65 70 1.7 yes 31 
21 6.5 0.55 60 1.5 yes 12 
19 1.8 0.4 5.6 1.2 yes 4.5 
22 3.2 0.08 10 0.3 yes 40 
Table 5.4 Comparison of the various tested compounds 17 – 22 in both cell lines. Values are 
given for the IC50 and IC90 values as well as for irradiated and a non-irradiated samples. The ratios 
hv/hv for the IC50 values are given to compare the photo effect. 
The goal of this research project was to synthesize conjugates of cisplatin and its 
analogs with photoactive molecules. The idea was to develop a combined chemo- 
and photodynamic therapy on the known basis of porphyrin and cisplatin chemistry. 
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The chosen synthetic concept of this publication has a major shortcoming, since the 
platinum metal centers have only one leaving group. Therefore, mainly the formation 
of mono-adducts to DNA, which are easily repaired, is expected to be formed. 
Preliminary cancer cell toxicity studies with novel conjugates were performed. IC50 
values versus 2 human cancer cell lines down to 0.08 M in the presence of red light 
could be found. The light irradiation increased the toxicity by a factor up to 55 
compared with dark toxicity (factor 78 for porphyrin 21 which has no platinum bound 
to it). The proposal is based upon these exciting initial results. Follow up cell uptake 
studies revealed an accumulation of the porphyrins in the cell nucleus as well as in 
the mitochondria. In further cell uptake studies, time dependent uptake will be 
monitored and the development of toxicity within the cell determined.  
 
Figure 5.36 Schematic Drawing of the interior of a human cell. 
Further studies on this class of porphyrins would include several changes on the link 
in between the porphyrin and the DNA binding platinum residue. In general, this 
should improve the properties of the cytotoxic platinum unit in terms of toxicity and 
selective cancer tissue uptake. Two concepts will be followed: 
- with a rigid linker between the photosensitizer and the platinum center, 
- with a flexible linker between the photosensitizer and the platinum center. 
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Potential biological targets are not easily reachable for rigid linkers and thus a series 
of flexible and variable sizes of Pt linkers will have to be tested (Figure 5.37). A 
cleavable linker containing one or several esters which will regulate the release of the 
platinum unit could be interesting to investigate the effects. Various ester-cisplatin 
analogs are known[267]. 
An expansion of the variety towards different photoactive units linked to a known 
cytotoxic platinum unit can open possibilities to fine tune the properties towards a 
better absorption of light in the tissue. Toxicity and selective cancer tissue uptake are 
a primary focus of the improvements as well. Possibilities are small peptide 
fragments like SV40, a nuclear localization signal (NLS) peptide to guide the molecule 
towards cancer cells[349].  
 
Figure 5.37 Porphyrin-platinum conjugates with a flexible linker to be synthesized and tested for 
their anti-cancer activity. 
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6. Conclusion and outlook 
In the first part of this PhD thesis, the topic was driven by the question whether it 
was possible to locate and signal the Z-DNA conformation in cells. Therefore, a 
number of positively charged porphyrins were synthesized because the interactions 
of porphyrins with various conformations of DNA were studied and documented 
before [11, 88, 90, 99, 100, 124, 138, 145, 350-352].  
The porphyrins synthesized contained different central metal ions such as nickel, 
copper, and zinc to tune their coordination spheres and their spectroscopic 
properties. The synthesis was carried out according to adjusted standard literature 
procedures starting either with the statistical approach formulated by Adler – Longo 
or the building block approach by Lindsey [117, 118, 146, 148, 169, 170, 353-355]. The yields of the 
syntheses for the porphyrins and the metalloporphyrins were expectedly low but 
could be improved after some iteration of the synthetic approaches. Compounds 10, 
11, and 14 were tested for stability in saline and buffered solutions and exposed to 
different DNA model systems starting with DNA building block 5’-GMP followed by 
poly d(GC). The behavior towards different conformations of DNA, especially 
spermine - induced Z-DNA, was examined by CD spectroscopy. Different orders of 
exposures, either the Z-DNA inducing agent was added first followed by the 
treatment with porphyrin or vice versa, was used to simulate a competition between 
the molecules.  
The wide range from flat, no axial containing ligands (H2TMPyP 10, NiTMPyP, 11) to 
square pyramidal (ZnTMPyP, 14) to octahedral (CuTMPyP, 18) metal coordination 
spheres showed a significantly different behavior when reacted with DNA. The 
influences of the metal centers of the porphyrins towards the interaction and thus 
the ability to detect Z-DNA were tremendous. If the molecules can intercalate into 
DNA (H2TMPyP 10, and partly NiTMPyP, 11), the previously Z-conformation flipped 
back into its B-form. Following this finding, DNA exposed to these porphyrins could 
not be transferred into its Z-form. Both molecules showed a tendency to stack 
around the DNA when the vacant intercalation sites are occupied.  
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The experiment revealed as well that the non – intercalating ZnTMPyP, 14 only 
showed a distinct CD signal when exposed to Z-DNA suggesting side-on coordination 
with a substantial stacking of the porphyrins upon increased concentrations. This 
signal was found to be specific only for the Z-form of the DNA since there was only a 
weak electrostatic interaction between B-DNA and compound 14. This makes 
porphyrin 14 a suitable Z-DNA detecting molecule – which we wanted to improve.  
The most prominent difference between the B- and the Z-conformation of DNA is, 
apart from its obvious left- and right-handedness, the different diameters. Zinc 
compound 14 was chosen as the flanking and thus DNA – interacting part in its 
function as a Z-DNA detecting molecule parallel connected to a second zinc 
compound 14 by a rigid bridge which would keep the flanks at a distance of 21 Å. This 
would enable the flanks to embrace only Z-DNA and not B-DNA. The porphyrins 
would be detectable via CD, UV or fluorescence spectroscopy and one could 
determine whether they are wrapped around DNA or just side-on coordinated due to 
its Dexter radius.  
The synthesis of such a highly positively charged molecule was not achieved due to 
the vast differences in solubility of the different building units. Especially the 
synthesis of the bridging unit 4,4'-biphenyl-4,4'-diyldipyridine 35 and reaction with 
the corner unit cisplatin was difficult. Another difficulty was the creation of a tri 
methylated species of a porphyrin which has 4 sides to be methylated. The exchange 
of the lead porphyrin to the novel compound 17, an A3B-type porphyrin with 3 sites 
which are methylatable and one free coordination site, which was synthesized by a 
modified novel procedure introduced by Lindsey solved the problem[148, 149]. The yield 
of the porphyrin synthesis was very low and the purification of the molecule difficult. 
The follow up reactions such as methylation and metallation were straight forward 
and gave high yields.  
A fragment of the proposed lead molecule, one porphyrin 17 coordinated to a 
cisplatin, caught our attention in the progress of this work. Since the exchange of one 
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of the ammonium ligands due to the trans-effect of the de facto cyano – ligand[157] 
was proven before, we tested the ability of this molecule 20 to bind N7 of guanine as 
well as the cytotoxic properties of this and its related metalloporphyrins in two 
human cancer cell lines. The compounds were tested to be stable in bovine serum 
and adhesive to HSA. The surprising results revealed not only that the molecules are 
toxic comparable to cisplatin, but can also be activated upon irradiation of red light to 
become even more toxic. The best IC50 value was achieved by compound 22 being 
0.08 M when irradiated with red, water-cooled light for 10 minutes. This was 40 
times more toxic compared to the non – irradiated sample. All porphyrins showed a 
phototoxic behavior which can be explained by the evolution of singlet oxygen 
derived from the spectral properties in the range from 550 – 680 nm.  
Porphyrins are interesting targeting molecules for determining the different 
conformations of DNA. Combining the aspects of spectroscopic uniqueness, different 
modes of interaction and ability to fine-tune the coordination of the central metal ion 
and thus the spectroscopic properties creates  a challenging but very interesting field 
for future research. Combining the phototoxic findings with the ability to detect Z-
DNA in living cells could shed a new light on the Z-DNA research and produce 
interesting insights of the involvement of Z-DNA in the cell cycle and its properties in 
the metabolism.  
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7. Experimental 
7.1 List of Abbreviations 
Å     Angström 
arom.     Aromatic 
bs     Broad singlet 
bt     Broad triplet 
Calcd.     Calculated 
CD     Circular dichroism 
CDCl3     Deuterated chloroform 
CH2Cl2     Dichloromethane 
CH3CN     Acetonitrile 
cm-1     Unit of wave number (IR) 
CO     Carbon monoxide 
conc.     Concentrated 
Cu     Copper 
CuCl2     Copper chloride 
Cu(NO3)2   Copper nitrate 
Cu(BF4)2   Copper tetrafluoroborate 
D2O     Deuterated water or deuterium oxide 
DMF     N,N-Dimethyl formamide 
DMSO-d6    Deuterated methyl sulfoxide 
DNA     Desoxyribonucleotide acid 
EA     Elemental analysis 
EDTA     Ethylenediaminetetraacetic acid 
EI     Electron impact 
eq.     Equivalent 
ESI     Electrospray ionisation 
Et3N     Triethylamine 
EtOH     Ethanol 
FAB     Fast atom bombardment 
g     Gram 
G     Guanine 
GC     Gas chromatography 
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h     Hour 
H2O     Water 
H2O2     Hydrogen peroxide 
HCl     Hydrochloric acid 
Hepes     4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC     High performance liquid chromatography 
Hz     Hertz 
IR     Infrared 
J     Coupling constant (NMR) 
K2CO3     Potassium carbonate 
KBr     Potassium bromide 
M     Molarity 
m     mol 
m     meta 
Me     Methyl 
MeOH     Methanol 
MeOH-d4    Deuterated methanol 
mg     Milligram 
MgSO4    Magnesium sulfate 
MHz     Megahertz 
ml     Milliliter 
mM     Millimolar 
mmol     Millimole 
mol     Mole 
MS     Mass spectroscopy 
MW     Molecular weight 
N2     Nitrogen gas 
Na     Sodium 
Na2CO3    Sodium carbonate 
Na2SO4    Sodium sulfate 
Ni     Nickel 
nm     nanometer 
NMR     Nuclear magnetic resonance 
ORTEP     Oak Ridge thermal ellipsoid plot 
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p     para 
pH     –log [H+] 
PPh3     Triphenyl phosphine 
ppm     Part per million 
prep.     Preparative 
R.T.     Retention time (HPLC) 
r.t.     Room temperature 
Ref.     Reference 
Rf     Retention factor (TLC) 
s     Singlet 
t     Triplet 
TAE     Ethylenediaminetetracetic acid triethyl ester (Tri-Acetate-
EDTA) 
TFA     Trifluoroacetic acid 
THF     Tetrahydrofuran 
TLC     Thin layer chromatography 
Tris     Tris(hydroxymethyl)aminomethane 
TsCl     Tosyl chloride 
UV-Vis    Ultraviolet-visible 
V     Volt 
Zn     Zinc 
δ     Chemical shift (NMR) 
ε     Extinction coefficient (UV-Vis) 
λ     Wavelength 
ν     wavenumber (IR) 
l     microlitre 
M     Micromolar 
˚C    Degree Celsius 
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7.2 Instrumentation and materials 
All chemical were purchased from Aldrich, Molekula, Frontier Science or Fluka (Buchs, 
CH) and used without further purification. Biomolecules were purchased from 
Amersham Biosciences, Sigma - Aldrich or Operon and used without further 
purification unless otherwise described. 
All the reactions were performed under nitrogen atmosphere unless otherwise 
described. The reactions were monitored by thin layer chromatography (TLC) or HPLC 
(see below). TLC was carried out on 0.25 mm Merck silica gel aluminum plates (60 
F254) or aluminum oxide pre-coated plastic sheets (alox N/UV254) using UV light or 
staining solutions as visualizing agent: 
Staining solutions: 
Schlittler reagent [356]: Solution 1: 1g H2PtCl6 in 6 ml H2O + 20 ml 1N HCl 
Solution 2: 22.5 g KI in 225 ml H2O 
Solutions 1 and 2 were mixed and diluted with H2O to a volume of 1000 ml. 
Ce-P-Mo reagent: 10 g Ce(SO4)2*4H2O + 25 g H3[P(Mo3O10)4] + 60 ml conc. 
H2SO4 + 940 ml H2O. 
Column chromatography was performed on silica gel (particle size 0.040-0.063 mm) 
or aluminum oxide (0.05-0.15 mm, basic pH 9.5 ± 0.5, or neutral pH 7.5 ± 0.5). 
HPLC analyses were performed on a VWR L-2130 system equipped with a diode array 
UV/vis spectrometer L-2430 and the following HPLC column, solvents and gradients: 
Columns:  Machery-Nagel C18 Nucleodur RP (5m particle size, 100 Å pore size) 
Solvent:  0.1% Formic Acid in Water (Solvent A), 10% MeOH in Water (Solvent B) 
Gradient: 1 min 0% B, 0% B to 100% B within 8 min, keep at 100% B for 2 min, 
return to 100% A within 1 min, 2 min 0% B equilibration 
Electrospray Ionization (ESI) Mass spectra were recorded either in the positive or 
negative mode on an Esquire HCT from Bruker (Bremen, Germany). Matrix-assisted 
laser desorption/ionization (MALDI) mass spectra were recorded on a  Bruker 
Autoflex equipped with an ION Tech Ionizator.  
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Gas chromatography-mass spectra (GC-MS) were recorded on a Varian-Chrompack 
CP-3800 gas chromatograph equipped with a Saturn 2000 electron impact mass 
spectrometer (EI-MS). The samples were carried by He through a CP-SIL 8 CB-MS 
column (30 m X 0.25 mm).  
UV/Vis spectra were recorded on a Varian Cary 50 spectrometer equipped with a 
temperature controlled cuvette holder. All experiments were carried out at 25°C if 
not stated otherwise. 
IR spectra were recorded on a Perkin Elmer BX FT-IR spectrometer using samples in 
KBr pellets. 
NMR spectra were recorded on a Varian Mercury 200 MHz or Gemini 300 MHz 
spectrometer. The chemical shifts are relative to residual solvent protons as 
reference. 
Circular dichroism measurements were performed using a Jasco J-810 
spectropolarimeter equipped with a Jasco PFD-4255 Peltier temperature controller. 
Elemental analyses were performed on a Leco CHNS-932 elemental analyzer. 
MTT Assays and fluorescence measurements were carried out on a fluorescence 
spectrophotometer Varian Cary Eclipse equipped with a temperature controlled 
cuvette holder. All experiments were carried out at 37°C. Light source used was a 
slide projector lamp with a cut-off filter at 600 nm.  
Crystallographic data were collected at 183(2) K on an Oxford Diffraction Xcalibur 
system with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) that was graphite-
monochromated. Suitable crystals were covered with oil (Infineum V8512, formerly 
known as Paratone N), mounted on top of a glass fiber and immediately transferred 
to the diffractometer. The program suite CrysAlisPro was used for data collection, 
semi-empirical absorption correction and data reduction.[357] Structures were solved 
with direct methods using SIR97[358] and were refined by full-matrix least-squares 
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methods on F2 with SHELXL-97.[359] The structures were checked for higher symmetry 
with help of the program Platon.[360] Data were collected for Lorentz and polarization 
effects as well as for absorption (numerical). Structures were solved with direct 
methods using SHELXS-97 [361] or SIR97 [358] and were refined by full-matrix least-
squares methods on F2 with SHELXL-97[359].  
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7.3 Synthesis of Porphyrin and their Building Blocks 
Statistic Synthesis of 5,10,15,20-tetraphenylporphyrin (TPP, 1) to 5,10,15,20-
tetrapyridylporphyrin (TPyP, 6) and its intermediates[104, 114, 119, 147, 167, 169, 362, 363] 
Pyrrole (7.0 ml, 100 mmol, freshly distilled), benzaldehyde (7.5 ml, 74 mmol), and 4-
pyridine-carboxaldehyde (2.5 ml, 26 mmol) were refluxed in 250 ml propionic acid for 
1 hour under air. The reaction mixture was cooled and allowed to stand open 
overnight. Filtration and methanol washing afforded 2.74 g of a purple crystalline 
product. TLC (98% CHCl3 / 2% ethanol) showed 6 different products with the 
following Rf-values: 5,10,15,20-tetraphenylporphyrin (TPP, 1) 0.88, 5-pyridyl-
10,15,20-triphenylporphyrin (MPyTPP, 2) 0.6, trans-5,15-dipyridyl-10,20-
diphenylporphyrin (trans-DPyDPP, 3) 0.42, cis-5,10-dipyridyl-15,20-diphenylporphyrin 
(cis-DPyDPP, 4) 0.22, 5,10,15-tripyridyl-20-phenylporphyrin (TPyMPP, 5) 0.12, 
5,10,15,20-tetrapyridylporphyrin (TPyP, 6) 0.08. These isomers were separated by 
silica gel chromatography using 5% isopropanol / 95% dichloromethane solvent 
system which was gradually ending with 100% methanol. After separation, the 
following yields of the resulting porphyrins were obtained: 260 mg TPP, 185 mg 
MPyTPP, 16 mg trans-DPyDPP, 46 mg cis-DPyDPP, 44 mg TPyMPP, 222 mg TPyP. 
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5,10,15,20-tetraphenylporphyrin TPP 1 [C44H30N4, M = 614.75 g/mol], purple powder. 
EA: calculated: C, 85.97; H, 4.92; N, 9.11; found: C, 85.88; H, 4.88; N, 9.20. 1H-NMR 
(200 MHz, CDCl3):  = -2.81 (s, 2H, NHpyrrole), 7.62-7.88 (m, 12 H, m- and p-phenyl), 
8.08-8.32 (m, 8H, o-phenyl), 8.63-8.96 (m, 8H, pyrrole). UV vis spectrum [, nm, in 
CHCl3, ( x 10
4, cm-1M-1)]: 418 (Soret band, 100), 516 (Q1, 20), 550 (Q2, 13), 590 (Q3, 
20), 646 (Q4, 5). MS (ESI): m/z (%) = 614 (100) [M]+, 637 (40) [M+ Na]+.  
5-pyridyl-10,15,20-triphenylporphyrin MPyTPP 2 [C43H29N5, M = 615.24 g/mol], 
purple powder. EA: calculated: C, 83.88; H, 4.75; N, 11.37; found: C, 83.82; H, 4.80; N, 
11.29. 1H-NMR (200 MHz, CDCl3):  = -2.73 (2H, s, NHpyrrole), 7.77 – 7.85 (10 H, m, m- 
and p-phenyl), 8.08 – 8.12 (9H, m, o-phenyl and 3,5-pyridyl), 8.16 – 8.32 (6H, m, 
pyrrole), 9.04 (2H, d, 2,6-pyridyl). MS (ESI): m/z (%) = 615.3 (100) [M]+, 638.7 (20) 
[M+Na]+.  
5,15-dipyridyl-10,20-diphenylporphyrin trans-DPyDPP 3 [C42H28N6, M = 616.17 
g/mol], purple powder. EA: calculated: C, 81.80; H, 4.58; N, 13.63; found: C, 82.00; H, 
4.45; N, 13.77. 1H-NMR (200 MHz, CDCl3):  = -2.86 (2H, s, NHpyrrole), 7.79 (6 H, m, m- 
and p-phenyl), 8.17 - 8.22 (8H, m, o-phenyl and 3,5-pyridyl), 8.90 (8H, d, pyrrole), 9.06 
(4H, d, 2,6-pyridyl). MS (ESI): m/z (%) = 617 (100) [M+H]+, 639 (60) [M+ Na]+, 544 
(30)[M-py]+.  
5,10-dipyridyl-15,20-diphenylporphyrin cis-DPyDPP 4 [C42H28N6, M =  616.17 g/mol], 
purple powder. EA: calculated [M+ HCl + 3 C3H8O]: C, 73.49; H, 6.41; N, 10.08; found: 
C, 73.37; H, 6.46; N, 9.78. 1H-NMR (200 MHz, CDCl3):  = -2.86 (2H, s, NHpyrrole), 7.76 – 
7.81 (6 H, m, m- and p-phenyl), 8.20 – 8.25 (8H, m, o-phenyl and 3,5-pyridyl), 8.90 
(8H, d, pyrrole), 9.06 (4H, d, 2,6-pyridyl). MS (ESI): m/z (%) = 617(100) [M+H]+.  
5,10,15-pyridyl-20-phenylporphyrin TriPyMPP 5 [C41H27N7, M =  617.70 g/mol], 
purple powder. EA: calculated: C, 79.72; H, 4.41; N, 15.87; found: 79.68; H, 4.55; N, 
15.66. 1H-NMR (200 MHz, CDCl3):  = 7.80 – 7.85 (3H, m, m- and p-phenyl), 8.15 – 
8.19 (8H, m, o-phenyl and 3,5-pyridyl), 8.86 (8H, d, pyrrole), 9.07 (6H, d, 2,6-pyridyl). 
MS (ESI): m/z (%) = 618 (100) [M+H]+, 639 (40) [M+ Na]+.  
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5,10,15,20-tetrapyridylporphyrin TPyP 6 [C40H26N8, M = 618.17 g/mol], purple 
powder. EA: calculated: C, 77.65; H, 4.24; N, 18.11; found: C, 77.67; H, 4.17; N, 18.13. 
1H-NMR (200 MHz, CDCl3):  = 8.14 – 8.18 (8H, m, 3,5-pyridyl), 8.82 (8H, d, pyrrole), 
9.04 (8H, d, 2,6-pyridyl). UV vis spectrum [, nm, in CHCl3,]: 418, 512, 546, 588, 646. 
MS (ESI): m/z (%) =618 (100) [M]+. 
 
Statistic Synthesis of 5,10,15,20-tetrapyridylporphyrin (TPyP, 6) to 5,10,15,20-tetra-
para-benzonitrile-porphyrin (TBNP, 7) and its statistic intermediates 
 
 
To a 100 ml round-bottom flask equipped with a magnetic stirring bar, a reflux 
condenser and a dropping funnel (100 ml) attached to the reflux condenser, 2.01g 
(15.3 mmol) 4-cyanobenzaldehyde and 5.16g (46 mmol) pyridine-4-carbaldehyde and 
40ml propionic acid were added. The suspension was heated to reflux (165°C oil 
bath). The suspension turned into a homogeneous solution while heating. Under 
reflux of the propionic acid, 4.13g (61.6 mmol) pyrrole was added drop wise with the 
help of the dropping funnel within 1h. The reflux increased considerably because the 
boiling point of pyrrole is below the boiling point of propionic acid. The reaction was 
stirred for 2h under reflux after complete addition of the pyrrole. The black solution 
was cooled down to room temperature. The propionic acid was evaporated (75°C, 1 
mbar). The crude black solid product was further dried under high vacuum at 70°C for 
24h. The crude product was purified over multiple silica gel columns (gradient 0:100 - 
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2:98 MeOH: CH2Cl2) to afford 85 mg (0.9% yield) of the pure product 7, the other 
fractions were not separated and afforded 143 mg of a porphyrin mixture. 
 
5,10,15-pyridyl-20-para-benzonitrile-porphyrin (7) [C42H26N8, M =  642.23 g/mol], 
HPLC: 10.86 min (100%). EA: calculated: C, 79.58; H, 4.08; N, 16.29; found: C, 79.37; 
H, 4.46; N, 16.38. 1H NMR (CDCl3, 300 MHz): δ 9.06 (d, J = 4.5 Hz, 6H, 2’), 8.87 (s, 4H, 
12, 13, 17, 18), superimposed by 8.85 (d, 2H, 2, 8), 8.80 (d, J = 4.8 Hz, 2H, 3, 7), 8.33 
(d, J = 8.4 Hz, 2H, 1”), 8.16 (d, J = 1.5 Hz, 6H, 3’), 8.09 (d, J = 6.3 Hz, 2H, 2”), –2.92 (s, 
2H, 3”, 4”). MALDI-MS (dithranol) 643.2 [M+H]+. 
trans-5,15-pyridyl-10,20-para-benzonitrile-porphyrin 25, cis-5,10-pyridyl-15,20-para-
benzonitrile-porphyrin 26, 5-pyridyl-10,15,20-para-benzonitrile-porphyrin 27, and 
5,10,15,20-para-benzonitrile-porphyrin 28 were not separated and characterized. 
 
  137 
5,10,15-tri-methylpyridinium-20-pyridyl-porphyrin nitrate (8) 
 
 
5,10,15,20-tetrapyridyl-porphyrin (6) (140 mg, 0.226 mmol) was dissolved in 40 ml 
DMF given into a 100 ml flask and about 10 equivalents of MeI (156 l, 2.18 mmol) 
added. The solution was stirred for 2 – 6 hours at 40°C and followed by HPLC. After a 
ratio between the tetra and tri methylated species of around 4:3 was detected, a 1:1 
mixture of acetone : diethyl ether was added to the solution and the precipitate 
filtered, washed with cold acetone and diethyl ether and charged onto a Amberlyte 
A-26 ion-exchange resin column charged with a saturated solution of NH4NO3 in 
water to exchange the I- ions with NO3
- ions. The resulting solution was dried, weight 
to afford 152 mg and attempted to be separated using the following techniques: 
Preparative HPLC with C18 Nucleosil column: Several flat gradients over the time 
period of 55 min were tested for separation. The separation could not afford pure 
product 8.  
Preparative HPLC with C18 Nucleodur semi preparative column: Several flat gradients 
over the maximum time period of 63 min were tested. The separation could not 
afford pure product 8.  
Semi - Preparative HPLC with a cation exchange column (Machery Nagel, strongly or 
weakly exchanging columns): Several gradients were tested with different buffer 
systems. The separation could not afford pure product 8.  
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Thick Layer Chromatography  (TLC): on a 1.5 or 2 mm TLC silica plate, an aqueous 
solution containing the porphyrin mixture was given and the plate given into a 
developing chamber containing the mobile phase (aqueous solution of ammonium 
nitrate, ethanol, n-butanol; 10:6:1 ). After 35 minutes, the plate was removed and the 
silica containing the different bands cut off the glass. The silica gel was dissolved in 
water/methanol to extract the corresponding porphyrin which was determined by 
HPLC. The separation was moderate, but never clean and always contained the 
corresponding neighboring porphyrins up to 20%[364].  
CPC (Centrifugal Partition Chromatography) was tested with the help of Armen, 
France, because a separation was described in the literature before[120]. Different 
solvent mixtures such as water/n-butanol and aq. propionic acid/n-butanol , were 
tested with this method, but only very few showed a separation behavior. The testing 
will be continued with other solvent mixtures.  
Another approach was carried out by demethylation of the tetra methylated species. 
The demethylating agent was 1-methylimidazole which reacted to 1,3-
dimethylimidazole cation. The reaction was carried out in water and monitored via 
HPLC. A defined mixture of a 4:2 tetra:tri methylated species was obtained 
repeatedly after 3h at 45°C. Upon further reaction, the mixture got more complex. 
The most material was afforded by the thick layer chromatography. The solution was 
lyophilized at 0.2 mbar overnight and afforded a purple product yielding 8 mg (0.1%). 
5,10,15-methylpyridinium-20-pyridyl-porphyrin nitrate, 8 [C45H41N8, M =  663.79 
g/mol], HPLC[343]: 7.21 min (100%). MS (ESI): m/z (%) = 664.7 (100) [M+H]+. 
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5,10,15,20-tetra-methylpyridinium-porphyrin nitrate (10) 
 
5,10,15,20-tetrapyridyl-porphyrin (6) (140 mg, 0.226 mmol) were dissolved in 40 ml 
DMF given into a 100 ml flask and around 10 equivalents of MeI (156 l, 2.18 mmol) 
added. The solution was stirred overnight at 40°C and the process of the reaction 
followed by HPLC. After completion of the reaction, a 1:1 mixture of acetone : diethyl 
ether were added and the precipitate filtered, washed with cold acetone and diethyl 
ether and charged onto a Amberlyte A-26 ion-exchange resin column charged with a 
saturated solution of NH4NO3 in water to exchange the I
- ions with NO3
- ions. The 
resulting solution was lyophilized at 0.2 mbar overnight and afforded a purple 
product yielding 165 mg (95%). 
5,10,15,20-methylpyridinium-porphyrin nitrate (10) [C44H38N12O12, M = 926.85 
g/mol, porphyrin alone 678.32 g/mol], HPLC[343]: 6.65 min (100%). EA: calculated: C, 
57.02; H, 4.13; N, 18.13; found: C, 57.41; H, 4.26; N, 17.89. H-NMR (200 MHz, H2O):  
= -2.76 (2H, s, NHpyrrole), 2.86 – 2.89 (12H, m, methyl) 7.76 – 7.80 (8H, m, m-pyridyl), 
8.19 – 8.23 (8H, m, o-pyridyl), 8.90 (8H, d, pyrrole). MS (ESI): m/z (%) =, 169.7 (100) 
[M(por)]4+, 226.3 (80) [M(por)]3+, 339.4 (30) [M(por)]2+, 678.9 (100) [M(por)]+. UVvis 
spectrum [, nm, in H2O]: 420 (Soret), 515 (Q1), 545 (Q2), 588 (Q3), 624 (Q4). 
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5,10,15-methylpyridinium-20-benzonitrile-porphyrin nitrate (17) 
 
5,10,15-pyridyl-20-para-benzonitrile-porphyrin (7) (200 mg, 0.311 mmol) were 
dissolved in 40 ml DMF given into a 100 ml flask and about 15 equivalents of MeI 
(156 l, 2.18 mmol) added. The solution was stirred overnight at 40°C and followed 
by HPLC. After completion of the reaction, a 1:1 mixture of acetone:diethylether 
were added and the precipitate filtered, washed with cold acetone and diethylether 
and charged onto an Amberlyte A-26 ion-exchange resin column charged with a 
saturated solution of NH4NO3 in water to exchange the I
- ions with NO3
- ions. The 
resulting solution was lyophilized at 0.2 mbar overnight and afforded a purple 
product yielding 245 mg (91%). 
5,10,15-methylpyridinium-20-benzonitrile-porphyrin nitrate (17) [C45H35N11O9, M =  
873.8 g/mol], HPLC[343]: 8.15 min (100%), EA: calculated: C, 61.85; H, 4.04; N, 17.63; 
found: C, 61.66; H, 4.25; N, 17.72. 1H-NMR (200 MHz, H2O, 294 K):  = 2.80 – 2.86 (9 
H, m, methyl), 8.34 (2H, 2 d, 3-cyanobenzol), 8.46 (2H, 2 d, 2-cyanobenzol), 9.30 (6H, 
d, 10-pyridinium), 9.37 – 9.40 (2H, m, 1-pyrrole) 9.42 (2H, d, 2’H-pyrrole of 4-pyrrole 
residue), 9.55 (4H, dd, 2’H-pyrrole of 2- and 3-pyrrole residues). 9.70 (4H, d, 3-
pyridinium of 5,15-pyridinium), 9.75 (2H, d, 3H of 10-pyridinium). MS (ESI): m/z (%) = 
343.3 (100) [M-3NO3-H]
2+, 686.3 [M-3NO3-2H]
+. UV vis spectrum [, nm, in H2O]: 424 
(soret, 100), 516 (Q1, 20), 551 (Q2, 13), 591 (Q3, 20), 644 (Q4, 5). 
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Synthesis of 5-(4-Phenyl)-dipyrromethane (PDP) [169, 363] 
 
10 g (92.8 mmol) 4-phenyl-carboxaldehyde and 84 ml (~1300 mmol) freshly distilled 
pyrrole were combined and the solution was degassed with argon for 10min. The 
reaction was carried out under argon. The reaction solution was heated to 85 °C. 
After 15h the solution was cooled to room temperature. After an additional 4h 
stirring at room temperature the pyrrole was removed in vacuo. The remaining dark 
violet oil was further dried by high vacuum overnight to afford a sticky dark oil which 
was solved in CH2Cl2 and cleaned by filtration over basic Alox (pH=9.5). The main 
fractions were combined to afford 11.9 g of crude product as a black solid. The black 
solid was purified by bulb to bulb distillation to afford 7.84 g colorless crystals (2*10-
2mbar and 210°C). Yield: 34%. The compound was stored at -20 °C.  
5-(4-Phenyl)-dipyrromethane 1H NMR (200MHz, CDCl3): δ 5.46 (s, 1H), 5.88-5.90 (m, 
2H), 6.15-6.19 (m, 2H), 6.72-6.75 (m, 2H), 7.11-7.14 (m, 2H), 8.11 (bs, 2H), 8.49-8.52 
(m, 2H). ESI-MS: m/z (%) 221.6 [M+H] +. EA (calc): C 81.4, H 5.92, N 12.66; (found): C 
81.64, H 5.82, N 12.51. 
 
Synthesis of (4-Pyridyl)-dipyrromethane (PyDP) [167, 169, 363] 
 
A 250ml flask was charged with 10 g (93.4 mmol) 4-pyridine-carboxaldehyde and 84 
ml (~1300 mmol) freshly distilled pyrrole. The resulting yellow solution was degassed 
by bubbling argon through the solution for 10min. The reaction was carried out under 
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nitrogen and the solution heated to 85°C. After 15h, the solution was cooled to room 
temperature. After an additional 4h stirring at room temperature, pyrrole was 
removed in vacuo. The remaining dark violet oil was further dried by high vacuum 
overnight to afford a sticky oil. The oil was solved in CH2Cl2 and cleaned by filtration 
over a basic Alox pad (2 cm height, pH = 9.5). The resulting oil was purified by bulb to 
bulb distillation to afford 6.24 g (25% yield) as colorless crystals (2*10-2mbar and 
210°C). The compound was stored at -20 °C.  
(4-Pyridyl)-dipyrromethane MS (ESI): m/z (%) = 462.3 (100) [3M]+, 245.0 (100) 
[M+Na]+, 223.0 (80) [M+H]+, 156.0 (40) [M-pyrrole]+. The compound was crystallized 
from a chloroform solution. 
 
Figure 7.1 Povray representation of an ORTEP plot of DPyP crystallized from chloroform. 
Ellipsoids are drawn at 50% probability. Hydrogen ions are omitted for clarity. 
 
Synthesis of 5-(4-Methyl-pyridinium)dipyrromethane (MPyDP) [167, 353] 
N+
OH
+
H
N
2
TCA
rt
N2
N+
HNNH
I- I-
 
1.37 g (5.5mmol) Pyridinium-N-methyl-4-carboxaldehyde iodide was added to a 
100ml one-necked round-bottom flask equipped with a magnetic stirring bar. 36.9 g 
(550 mmol) pyrrole was added and the system was degassed by passing nitrogen 
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through the solution. After 5 min, 0.899g (5.5mmol) TCA were added and the flask 
was closed with a plug. Analysis with MS showed almost complete reaction and 
almost no by-product was formed after 20 h stirring at room temperature. The 
pyrrole was removed at room temperature by suction (high vacuum) to afford highly 
viscous brown oil. The crude product was dissolved in CHCl3 and evaporated at room 
temperature to remove remaining pyrrole. 2.834g crude green solid product could be 
obtained consisting of the favored product and the TCA starting material. Because of 
stability reasons the TCA wasn’t separated from the crude material. A theoretical 
yield of 96% (5.28mmol) could be obtained if the TCA was subtracted from the yield. 
1H NMR (200MHz, CDCl3): δ 4.205 (s, 3H), 5.82-5.84 (m, 2H), 6.04-6.09 (m, 2H), 6.73-
6.75 (m, 2H), 7.75-7.76 (d, J = 6.6Hz, 2H), 8.46-8.49 (d, J = 6.6Hz, 2H), 9.43 (bs, 2H) 
ESI-MS: m/z 238.5 [M-I]+ 
 
Synthesis of 5-(4-chloro-pyridyl)dipyrromethane (ClPyDP) [169, 170, 365, 366] 
 
To a two-necked round-bottom flask equipped with 5 g (35.6 mmol) 4-chloro-
benzaldehyde, 59.7 g (62 ml, 890 mol) pyrrole was added. The system was closed 
with a septum and degassed by passing argon through the solution for 10min. Under 
argon atmosphere 0.59 g (5mmol) TFA were added by syringe. After 10 min the now 
brown solution was quenched with 30ml 0.2M aqueous NaOH solution. The brown 
solution cleared up slightly and turned brown-orange. The organic phase was 
separated and extracted with EtOAc and washed twice with water. The combined 
organic phases were evaporated to dryness over night at high vacuum to afford a 
brown solid. The crude product was purified by bulb to bulb distillation (<1*10-3mbar, 
140°C) to afford 4.0 g (44% yield) of the colorless crystals. The colorless crystals were 
  144 
stored at -20 °C. 1H NMR (200MHz, CDCl3): δ 5.44 (s, 1H), 5.90 (s, 2H), 6.16-6.20 (m, 
2H), 6.70-71 (m, 2H), 7.12-7.17 (d, 2H), 7.26-7.32 (m, 2H), 7.88 (s, 1H) 13C NMR (50 
MHz, CDCl3): δ 43.35, 107.43, 108.56, 117.51, 128.73, 129.75, 131.98, 132.73, 140.65 
ESI-MS: m/z 279.5 [M+Na]+ 
 
Synthesis of 5-(4-phenyl)-di-(5-pyrro-1-carboxyphenyl)methane [118, 170, 337, 366-368] 
HNNH
+ 2
O
Cl Argon
MgBr
HNNH
OO
 
A 1l three-necked round-bottom flask, equipped a 100 ml dropping funnel was 
flushed with a constant flow of argon via the reflux condenser. The dropping funnel 
was closed by a septum. 3 g (13.5 mmol) phenyldipyrromethane and 270 ml dry 
toluene were added to the flask. 45 ml (~1.5 M, ~67.2 mmol) of the prior synthesized 
mesitylene magnesia bromide solution were added into the dropping funnel. Under 
an argon atmosphere the mesitylene magnesia bromide solution was added drop 
wise within 20min. The colorless solution in the flask turned slightly black. The 
reaction mixture was cooled down after 30min with external heating (85 °C). The 
dropping funnel was quickly exchanged with another 100ml dropping funnel 
containing 4.7 g (33.6 mmol) benzoylchloride dissolved in 34ml toluene. The 
benzoylchloride solution was added drop wise to the reaction mixture within 10min. 
The mixture turned darker. The reaction was a little exothermic. After an additional 
10min the reaction mixture was quenched with 200 ml saturated aqueous NH4Cl 
solution. The organic phase changed to an intensive red color while the brine phase 
stayed colorless under precipitating white salt crystals. After 35 min stirring the 
solution was extracted. Therefore 270ml EtOAc were added. The organic phase was 
further washed with 200ml brine and 200ml water. The combined organic phases 
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were dried over Na2SO4. The red solution was stored overnight under argon in the 
fridge. Overnight a few colorless needles were formed in the flask. The solvent was 
evaporated under light protection at 25 °C via high vacuum to afford 8.84 g (20.5 
mmol, 153% yield) of dark red oil. The crude product was used directly for the next 
reaction, because of stability reasons. 
 
Figure 7.2 Povray representation of ORTEP plot of 10 crystallized from chloroform. Ellipsoids are 
drawn at 50% probability. Hydrogen ions are omitted for clarity. 
 
Synthesis of tin di-butyl 5-(4-phenyl)-di-(5-pyrro-1-carboxyphenyl)methane [337, 367-
369] 
HNNH
OO
+ Sn
Cl Cl
NEt3
CH2Cl2 NN
OO
Sn
The crude 5-(4-phenyl)-di-(5-pyrro-1-carboxyphenyl)methane (≤5.81 g, ≤13.5 mmol) 
was suspended in 200 ml CH2Cl2. 4 g (40.3 mmol) NEt3 and 4 g (13.4 mmol) SnCl2Bu2 
were added. The suspension was stirred for 30 min at room temperature. The crude 
product was filtered over 70 g silica gel and washed with 0.5 l CH2Cl2. The solvent was 
removed in vacuo to afford 10.8 g crude product. The crude product was purified 
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over a silica column (97.5:2.5 hexane:EtOAc; 1 % NEt3) to afford a total of 5.3 g (8 
mmol, 60 % yield regarding the overall yield of the whole synthesis starting from the 
dipyrromethane). 1H NMR (200MHz, CDCl3): δ 0.66-0.78 (m, 6H), 1.49-1.55 (m, 12H), 
5.60 (s,1H), 6.19 (d, J = 3.6 Hz, 2H), 7.09 (d, J = 3.8 Hz, 2H), 7.20-7.29 (m, 9H), 7.43-
7.61 (m, 6H), 7.88-7.92 (m, 4H), 119Sn NMR (74.5MHz, CDCl3), -269.70 (s) ESI-MS: m/z 
661.2 [M+H]+. 
 
Synthesis of (4-pyridiyl)-di-(5-pyrro-1-carboxyphenyl)methane [337, 367, 368] 
N
HNNH
OO
N
HNNH
+ 2
O
Cl
MgBr
N2
 
A 1l three-necked round-bottom flask, equipped a 100ml dropping funnel was 
flushed with a constant flow of nitrogen via the reflux condenser. The dropping 
funnel was closed by a septum. 3 g (13.4 mmol) 4-pyridinedipyrromethane and 270 
ml dry toluene were added to the flask. The 4-pyridinedipyrromethane was not 
completely soluble. 45 ml (~1.5 M, ~67.2 mmol) of the prior synthesized mesitylene 
magnesia bromide solution were added into the dropping funnel. Under a nitrogen 
atmosphere, the mesitylene magnesia bromide solution was added drop wise within 
10min. The yellow suspension in the flask turned into a dark brown suspension. The 
reaction mixture was heated up to 85 °C. After 60 min the three-necked round-
bottom flask was held into an ultra-sonic bath for a few minutes to obtain smaller 
insoluble crystals. The dropping funnel was quickly exchanged with another 100ml 
dropping funnel containing 4.7 g (33.6 mmol) benzoylchloride dissolved in 34 ml dry 
toluene. The benzoylchloride solution was added drop wise to the reaction mixture 
within 15 min. After an additional 10 min the black reaction solution was quenched 
with 200 ml saturated aqueous NH4Cl solution. After 10 min stirring the solution was 
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extracted with 270 ml EtOAc. The organic phase was further washed with 200 ml 
brine and 200 ml water. The combined organic phases were dried over Na2SO4. The 
brown solution was stored overnight under argon in the fridge. The solvent was 
evaporated under light protection at 30°C in vacuo to afford a dark brown oil. The 
crude product was used directly for the next reaction, because of stability reasons. 
 
Synthesis of tin di-butyl 5-(4-pyridyl)-di-(5-pyrro-1-carboxyphenyl)methane [337, 367, 
368] 
N
HNNH
OO
+ Sn
Cl
Cl NEt3
CH2Cl2
N
NN
OO
Sn
Crude 5-(4-phenyl)-di-(5-pyrro-1-carboxyphenyl)methane (≤5.78 g, ≤13.4 mmol) was 
suspended in 200 ml CH2Cl2. 4 g (40.3 mmol) NEt3 and 4 g (13.4 mmol) SnCl2Bu2 were 
added. The suspension was stirred for 30 min at room temperature. The solvent was 
removed in vacuo to afford 16 g crude product. The crude product was purified over 
a silica column (95:5-8:2 hexane:EtOAc; 1% NEt3) to afford a total of 1.6 g product. 
The analytical results of the product showed discrepancies to the desired product. 1H 
NMR (500MHz, CDCl3): δ 0.64-0.71 (m), 1.08-1.19 (m), 1.26-1.33 (m), 1.42-1.57 (m), 
1.98-2.02 (d), 2.25 (s), 2.52 (bs), 4.79-4.80 (d), 5.00 (s), 5.43 (s), 6.33 (d), 6.48 (d), 
6.79-6.92 (t), 7.12-7.15 (dd), 7.27-7.35 (m), 7.47-7.50 (t), 7.54-7.57 (t), 7.89-7.92 (d) 
13C NMR (126 MHz, CDCl3): δ 13.75, 13.80, 19.86, 20.37, 20.58, 21.02, 24.57, 24.67, 
26.14, 26.45, 27.40, 27.54, 44.99, 115.43, 115.45, 124.32, 128.61, 129.23, 131.82, 
135.99, 136.12, 136.75, 137.89, 149.48, 149.82, 184.57, 184.71. 119Sn NMR (74.5MHz, 
CDCl3): -276.52 (s). 
 
  148 
Synthesis of 5-pyridin-10,15,20-phenyl-porphyrin via 5-(4-phenyl)-di-(5-pyrro-1-
phenolyl)methane  [337, 367, 368] 
NN
OO
Sn
N2
NaBH4
MeOH/THF
HNNH
HOOH
 
HNNH
HOOH
+
N
HNNH
1) Yb(OTf)3
2) DDQ
CH2Cl2
NNH
HNN
N  
A 100ml flask was equipped with 1 g (1.5 mmol) tin di-butyl 5-(4-pyridyl)-di-(5-pyrro-
1-carboxyphenyl)methane. The system was flushed with nitrogen, then 60ml dry 
THF/MeOH (10:1) was added. The 2.27 g (60 mmol) NaBH4 was added rapidly in small 
portions within 10 min. The solution was foaming while and afterwards adding the 
NaBH4. Only a small part of the added NaBH4 was dissolved. TLC indicated complete 
conversion after 1 h 30 min. The reaction was quenched with 100ml saturated 
aqueous NH4Cl solution. Strong foaming lead to a loss of 1/4 to 1/3 of the product. 
The product was extracted once with 100 ml CH2Cl2. The organic phase was dried 
over Na2SO4 and concentrated in vacuo at 40 °C to afford the instable intermediate. 
0.652 g (1.5 mmol) 4-Pyridinedipyrromethane were dissolved in 600 ml CH2Cl2 with 
the help of an ultra-sonic bath. The solution of 600 ml 4-pyridinedipyrromethane was 
added to the intermediate. Under nitrogen (passing through the solution) 1.19 g (1.92 
mmol) Yb(OTf)3 were added. The yellow solution turned black slowly. After 30 min 
1.02 g (4.5 mmol) DDQ was added and the nitrogen disconnected. After 1h stirring at 
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room temperature the solution was filtered over 2cm silica gel pads. The silica pad 
was washed with 500 ml CH2Cl2 (1% TEA) and 500ml CH2Cl2/MeOH (9:1, 1% TEA) to 
afford 217 mg (first 500ml) and 2.79 g (second 500ml) crude product (black sticky tan 
solid). The crude product was purified by silica column (increasing gradient 
CH2Cl2:MeOH 10:0 up to 9:1, 1% TEA). 82 mg (0.13 mmol) pure violet crystals and 
39mg (0.06 mmol) less pure black crystals could be obtained (13% yield). 
1H NMR (200MHz, CDCl3): δ -2.801 (s, 2H), 7.74-7.79 (m, 9H), 8.16-8.24 (m, 8H), 8.79-
8.89 (m, 8H), 9.02-9.05 (m, 2H). ESI-MS: m/z (%) 661.2 (100) [M+HCOOH]+. 
 
 
 
Figure 7.3 Povray representation of ORTEP plot of porphyrin 2 crystallized from a 
chloroform/MeOH mixture. Ellipsoids are drawn at 50% probability. Hydrogen ions are omitted for 
clarity. 
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7.4 Synthesis of Metallo - Porphyrin Complexes 
5,10,15,20-methylpyridinium-nickel(II)-porphyrin nitrate (11) [133, 146, 370-372]  
To a solution of 50 mg (0.058 mmol) 5,10,15,20-methylpyridinium-porphyrin nitrate 
(10) in 25 ml H2O, 14.2 mg (1 eq.) of nickel(II)acetate were added and the solution 
stirred for 24h at 45 °C. The reaction was monitored by HPLC. After the completion of 
the reaction, the solvent was removed in vacuo. The crude product was loaded onto 
an Amberlyte A-26 ion-exchange resin column charged with a saturated solution of 
NH4NO3 in water to obtain the pure nitrate product. Yield: 52 mg, 0.055 mmol, 94%. 
HPLC[343]: 7.28 min (100%), MS calc: 982.2; obtained (ESI+): m/z (%) = 183.6 [M(por)]4+ 
(100),  244.5 [M(por)]3+ (100), 367.1 [M]2+ (40), 352.5 [M-(CH3)2]
2+ (80). 
 
5,10,15,20-methylpyridinium-copper(II)-porphyrin nitrate (12) [133, 146, 370-372] 
To a solution of 50 mg (0.058 mmol) 5,10,15,20-methylpyridinium-porphyrin nitrate 
(10)  in 25 ml H2O, 15.6 mg (1eq.) of copper(II)tetrafluoroborate were added and the 
solution stirred for 24h at 45 °C. The reaction was monitored by HPLC. After the 
completion of the reaction, the solvent was removed in vacuo. The crude product 
was loaded onto an Amberlyte A-26 ion-exchange resin column charged with a 
saturated solution of NH4NO3 in water to exchange the BF4
- ions with NO3
- ions and 
obtain the pure nitrate product. Yield: 49 mg, 0.053 mmol, 98%. 
HPLC[343]: 7.16 min (100%), MS (ESI): m/z (%) = 184.8 [M]4+ (100), 241.4 [M-CH3]
3+ 
(80). 
 
5,10,15,20-methylpyridinium-cobalt(II)-porphyrin nitrate (13) [146, 372] 
To a solution of 50 mg (0.058 mmol) 5,10,15,20-methylpyridinium-porphyrin nitrate 
(10) in 25 ml H2O, 14.2 mg of cobalt(II)acetate were added and the solution stirred for 
24h at 45 °C. The reaction was monitored by HPLC. After the completion of the 
  151 
reaction, the solvent was removed in vacuo. The crude product was loaded onto an 
Amberlyte A-26 ion-exchange resin column charged with a saturated solution of 
NH4NO3 in water to obtain the pure nitrate product. Yield: 50 mg, 0.055 mmol, 96%. 
HPLC[343]: 7.39 min (100%), MS (ESI): m/z (%) = 240.4 [M-CH3]
3+ (100). 
 
5,10,15,20-methylpyridinium-zinc(II)-porphyrin nitrate (14) [133, 146, 371-373] 
To a solution of 50 mg (0.058 mmol) 5,10,15,20-methylpyridinium-porphyrin nitrate 
(10) in 25 ml H2O, 14.2 mg of zinc(II)acetate were added and the solution stirred for 
24h at 45 °C. The reaction was monitored by HPLC. After the completion of the 
reaction, the solvent was removed in vacuo. The crude product was loaded onto an 
Amberlyte A-26 ion-exchange resin column charged with a saturated solution of 
NH4NO3 in water to obtain the pure nitrate product. Yield: 52 mg, 0.056 mmol, 97%. 
HPLC[343]: 7.18 min (100%), MS (ESI): m/z (%) = 185.4 [M]4+ (100)  
 
5,10,15-methylpyridinium-20-para-benzonitrile-copper(II)-porphyrin nitrate (18)  
 
 
To a solution of 17 mg (0.023 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-
porphyrin nitrate (9) in 15 ml H2O, 3.28 mg of Cu(BF4)2 were added and the solution 
stirred at 45 °C. The reaction was monitored by HPLC. After the completion of the 
reaction, the solvent was removed in vacuo. The crude product was loaded onto an 
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Amberlyte A-26 ion-exchange resin column charged with a saturated solution of 
NH4NO3 in water to exchange the BF4
- ions with NO3
- ions and obtain the pure nitrate 
product. Yield: 52 mg, 0.056 mmol, 97%. 
18, [C45H33N11O9Cu, M =  935.36 g/mol]: HPLC
[343]: 8.12 min (100%), MS (ESI): m/z (%) 
= 250.1 [M]3+ (100), 373.9 [M]2+ (90), 748.5 [M(CuPor)] + (40). UVvis spectrum [, nm, 
in H2O]: 315, 424 (Soret, 100), 542 (Q1, 30), 582 (Q2, 13). 
 
5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin nitrate (19) 
 
 
To a solution of 19 mg (0.025 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-
porphyrin nitrate (9) in 15 ml H2O, 3.58 (1.1 eq.) mg of zinc(II)acetate were added and 
the solution stirred at 45 °C. The reaction was monitored by HPLC. After the 
completion of the reaction, the solvent was removed in vacuo. The crude product 
was loaded onto a Amberlyte A-26 ion-exchange resin column charged with a 
saturated solution of NH4NO3 in water to certify the presence of only NO3
- ions. Yield: 
23 mg, 0.024 mmol, 92%. 
19, [C45H33N11O9Zn, M =  937.19 g/mol]: HPLC
[343]: 7.16 min (100%), MS (ESI): m/z (%) 
= 249.7 [M]3+ (100), 274.1 [M]2+ (15). MS (MALDI) m/z (%) = 687.3 [M-Zn]+ (100), 
749.2 [M]+ (70). UVvis spectrum [, nm, in H2O]: 322, 438 (Soret), 563 (Q1), 613 (Q2). 
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cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-porphyrin nitrate (20) 
 
20 mg (0.023 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-porphyrin 
nitrate (17) were given in 25 ml H2O, then 50 ml of a filtered aqueous solution of 6.86 
mg (0.023 mmol) cis-(NH3)2PtCl(NO3) (see platinum building blocks) were added and 
the solution stirred for 16 days at 45 °C in the dark. The reaction was monitored by 
HPLC, and stopped after completion. After cooling the solution to room temperature, 
it was treated with a 0.01 M KCl solution. Then, the solution was dried in vacuo and 
the purple precipitate washed with acetone, iced water and methanol. After 
dissolving it again in water, the solution was lyophilized at 0.2 mbar overnight to 
afford the purple product. Yield: 23 mg, 0.019 mmol, 83%. 
cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-porphyrin nitrate (20) 
[C45H41ClN14O12Pt, M =  1200.43 g/mol]: HPLC
[343]: 7.54 min (100%), gradient 1 and 2. 
MS (ESI): m/z (%) = 229.8 (100) [M-cis(NH3)2PtCl-4NO3]
3+, 233.8 (70) [M-Cl+OH-
4NO3]
4+, 234.9 (40) [M-4NO3]
4+, 316.8 (20) [M-H-4NO3]
3+, 335 (60) [M-H-cis(NH3)2PtCl-
CH3]
2+, 343.5 [M-H-cis(NH3)2PtCl]
2+ (100). MS (MALDI): m = 705.3 (100) [M-
cis(HN3)2PtCl+OH2]
+, 897.2 (5) [M-NH2-Cl-3H]
+. 195Pt-NMR (129 MHz, H2O, 293 K):  = -
2300.56 (Pt(3N)(Cl)). 
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cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-copper(II)-porphyrin 
nitrate (21) 
 
15 mg (0.015 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-copper(II)-
porphyrin nitrate (18) were given in 10 ml H2O, then a filtered aqueous solution of 
3.43 mg (0.0152 mmol) cis-(NH3)2PtCl(NO3) was added and the solution stirred for 12 
days at 40 °C. The reaction was monitored by HPLC. After cooling the solution to 
room temperature, it was treated with a 0.01 M KCl solution. Then, the solution was 
dried in vacuo and the purple precipitate washed with acetone, iced water and 
methanol. After dissolving it again in water, the solution was lyophilized at 0.2 mbar 
overnight to afford the reddish product.  Yield: 16.4 mg, 0.013 mmol, 86%. 
cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-copper(II)-porphyrin 
nitrate (21) [C45H39ClCuN14O12Pt, M =  1261.96 g/mol]: HPLC
[343]: 7.43 min (100%) with 
gradient 1, and 7.77 (96%) with gradient 2. MS (ESI): m/z (%) = 250.3 [M-
cis(NH3)2PtCl]
3+ (100), 373.8 [M-H-cis(NH3)2PtCl]
2+ (50). 195Pt-NMR (129 MHz, H2O, 293 
K):  = -2340.12 (Pt(3N)(Cl)). 
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cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin 
nitrate (22) 
 
30 mg (0.032 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-
porphyrin nitrate (19) were given in 10 ml H2O, then a filtered aqueous solution of 
8.11 mg (0.0342 mmol) cis-(NH3)2PtCl(NO3) was added and the solution stirred for 12 
days at 45 °C. The reaction was monitored by HPLC. After cooling the solution to 
room temperature, it was treated with a 0.01 M KCl solution. Then, the solution was 
dried in vacuo and the purple precipitate washed with acetone, iced water and 
methanol. After dissolving it again in water, the solution was lyophilized at 0.2 mbar 
overnight to afford the purple product.  Yield: 34 mg, 0.027 mmol, 84%. 
cis-(NH3)2PtCl-5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin 
nitrate (22) [C45H39ClN14O12PtZn, M =  1263.80 g/mol]: HPLC
[343]: 7.69 min with 
gradient 1 and 8.14 min with gradient 2 (100%). MS (ESI): m/z (%) = 250.3 [M-
cis(NH3)2PtCl-4NO3]
3+ (100), 251.8 [M-CH3-4NO3]
4+ (30), 253.9 [M-4NO3]
4+ (50), 338.3 
[M-4NO3]
3+ (20), 367.5 [M-cis(NH3)2PtCl-CH3-4NO3]
2+ (40), 375 [M-cis(NH3)2PtCl-
4NO3]
2+ (80). MS (MALDI): m = 770.3 [M+Na-cisPt-4NO3]
+ (100), 897.2 [M+Pt+NH2-3H-
4NO3]
 +(5). 195Pt-NMR (129 MHz, H2O, 293 K):  = -2393.97 (Pt(3N)(Cl)). 
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cis-(NH3)2PtCl-para-benzonitrile 
 
In order to test the affinity and kinetic stability of the Pt-NC coordination, 10 mg (0.04 
mmol) of cis-[(NH3)2PtCl(NO3)] was reacted with the 4.2 l benzonitrile (1eq.) in 10 ml 
n-butanol. The resulting blue solution was stirred for 12 hours in the dark and the 
solvent removed. 11.4 mg of the bluish powder were obtained (0.038 mmol). Yield: 
89%.  
MS (ESI): m/z (%) = 231.1 [Pt-(NH3)2+2H]
+ (10), 266.1  [M-benzonitrile-Cl]+ (10), 367.2  
[M-NO3]
+ (100),  435.2 [M-Cl+benzonitrile-NO3]
+ (10). 
 
7.5 Organic Bridges 
The preset characteristics of the organic bridges were simple – able to coordinate to 
two metal corners on both ends via a nitrogen atom, rigid, keeping the distance and 
innocent towards DNA. Only organic, non-charged and aromatic structures were 
chosen such as the 5,15-pyridyl-porphyrin. In the course of these studies, the simple 
to synthesis 5,15-phenyl-porphyrin was obtained and crystallized from a CHCl3 versus 
hexane vapor diffusion.  The distance in between the both terminal (para) C’s of the 
phenyl was 17.4 Å, which fit perfectly to the above outlined strategy.  
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Figure 7.4 Povray plot of 5,15-phenyl-porphyrin crystallized from a CHCl3 versus hexane vapor 
diffusion. Ellipsoids are drawn at 50% probability. Hydrogen ions are omitted for clarity. 
 
5,15-pyridyl-porphyrin, 29[363] 
 
 120 mg 5-(4-Pyridyl)-dipyrromethane (PyDP, 0.54 mmol) were dissolved in dry CH2Cl2 
(1l) under argon atmosphere. To this solution, trimethyl orthoformate (1.2 eq., 68.7 
mg) was added and the reaction solution cooled to stay below 25 °C for 4 hours. 
Then, trichloroacetic acid was added (10 ml of 0.1 mM solution), after 2 hours, 
pyridine was added to neutralize the solution, then air was bubbled through the 
solution. The solvent was removed and the resulting dark compound purified on a 
silica gel column (3 runs) to yield 68.1 mg of 5,15-pyridyl-porphyrin (32%).  
MS (ESI): m/z (%) = 463.3  [M]+ (100). 1H NMR (200MHz, CDCl3): δ -2.54 (2H, s, inside 
porphyrin NH pyrrole), 7.81 (4H, dd, 3-pyridyl), 8.25 (4H, 2 dd, 3-pyridyl), 9.07 (4H, d, 
pyrrole proximate to 10,20-position), 9.37 (4H, d, pyrrol proximate to 5,15-position), 
10.29 (4H, s, 10,20-porphyrin H). UV vis spectrum [, nm, in CHCl3]: 416 (Soret), 512 
(Q1), 540 (Q2), 585 (Q3). EA calc.: C 77.57, N 18.09, H 4.34; found: C 77.33, N 18.94, H 
4.58.  
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Synthesis of 1,4-bis(4’,4’’-pyridyl)benzene, 30 [374] 
Br Br + N B(OH)22
reflux
 Pd(dppf)2Cl2
Na2CO3
toluene/water
1/1
N N
1
2 3
4
56
1''1'
2''
2'3'
3''
4' 4''
5'
5''6''
6'
 
A 100ml two-necked round-bottom flask was equipped  with 1.65 g (7 mmol) 1,4-
dibrombenzene, 2.73 g (24.5 mmol) pyridine-4-boronic acid, 1.49 g (14 mmol) Na2CO3 
dissolved in 40 ml toluene/water (1:1; degassed by passing nitrogen through the 
solution) and 0.51g (0.7mmol) Pd(dppf)2Cl2. The system was degassed for 15 min by 
passing nitrogen through the suspension. The reaction was heated to reflux and 
allowed to react for 72 h under a nitrogen atmosphere. The solvent was removed in 
vacuo and the resulting residue was extracted with ethyl acetate and washed with 
water (three times). The combined organic phases were dried over anhydrous 
Na2SO4. The Na2SO4 was filtered off. The solvent was evaporated to afford 1.97 g of a 
dark brown solid, which was further purified by silica gel column chromatography 
(CH2Cl2/MeOH(10% NH3) (99:1 V/V up to 97.5:2.5 V/V) to afford a fine grey crystalline 
solid of 1,4-bis(4’,4’’-pyridyl)benzene (Yield: 1.27g, 78%). 
1,4-bis(4’,4’’-pyridyl)benzene. 1H NMR (200MHz, CDCl3): δ 7.53-7.56 (4H, m, H-2, H-3, 
H-5, H-6), 7.8 (4H, s, H-2’, H-2’’, H-6’, H-6’’), 8.69-8.72 (4H, d, J = 5.8Hz, H-3’, H-3’’, H-
5’, H-5’’) 13C NMR (50 MHz, CDCl3): δ 121.6, 127.7, 138.8, 147.3, 150.4 ESI-MS: m/z 
233.1 [M+H]+, 255.5 [M+Na]+ Anal. Calcd (%) for C16H12N2: C 82.73, H 5.21, N 12.06. 
Found: C 82.58, H 5.26, N 11.95. 
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Synthesis of 1,1’-bis(4’’,4’’’-pyridyl)-4,4’-biphenyl, 31 [176]  
Br + N B(OH)22
reflux
 Pd(dppf)2Cl2
Na2CO3
toluene/water
1/1
NBr N
1 1' 1''1'''
2'''
2
2'
2''
3'''
3''
3'
3
4'''
4 4'
4''
5'''
5
5'
5''
6'''
6
6'
6''
 
1.56 g (5mmol) 4,4’-dibromobiphenyl, 2.15 g (17.5 mmol) pyridine-4-boronic acid, 
1.06 g (10 mmol) Na2CO3 dissolved in 40 ml toluene/water (1:1; degassed by passing 
nitrogen trough the solution) and 0.37 g (0.5 mmol) Pd(dppf)2Cl2. were combined in a 
100 ml flask. The system was degassed for 10min with passing nitrogen trough the 
suspension. The reaction was heated to reflux and allowed to react for 72 h under 
nitrogen atmosphere. The solvent was evaporated and the resulting residue was 
extracted with CH2Cl2 and washed with water (three times). The combined organic 
phases were dried over anhydrous Na2SO4. The solvent was evaporated to afford a 
black solid. The crude product was elutriated with MeOH. The MeOH was removed by 
suction and the crystalline residue was washed several times with MeOH to afford 
1.10g (Yield: 71%). 
1,1’-bis(4’’,4’’’-pyridyl)-4,4’-biphenyl. 1H-NMR (200MHz, CDCl3): δ 7.56-7.59 (m, 4H, H-
2’’, H-2’’’, H-6’’, H-6’’’), 7.75-7.80 (m, 8H, H-2, H-2’, H-3, H-3’, H-5, H-5’, H-6, H-6’), 
8.69-8.75 (m, 4H, H-3’’, H-3’’’, H-5’’, H-5’’’) 13C NMR (50 MHz, CDCl3): δ 121.71 (4C, C-
2’’, C-2’’’, C-6’’, C-6’’’), 127.77 (4C, C-3, C-3’, C-5, C-5’), 127.99 (4C, C-2, C-2’, C-6, C-6’), 
137.64 (2C, C-1, C-1’), 141.18 (2C, C-4, C-4’), 147.94 (2C, C-1’’, C-1’’’), 150.53 (4C, C-
3’’, C-3’’’, C-5’’, C-5’’’) ESI-MS: m/z 309.4 [M+H]+. EA calc (%): C22H16N2: C 85.69, H 
5.23, N 9.08. found: C 82.51, H 5.19, N 8.81. 
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Synthesis of 4-(4-bromophenyl)-pyridine [176] 
Br Br + N B(OH)2
reflux
 Pd(dppf)2Cl2
Na2CO3
toluene/water
1/1
N Br
 
A 100ml flask was equipped 1.65 g (7 mmol) 1,4-dibrombenzene, 0.86 g (7 mmol) 
pyridine-4-boronic acid, 0.74 g (7 mmol) Na2CO3 dissolved in 35 ml toluene/water 
(1:1; degassed by passing nitrogen through the solution) and 0.26 g (0.35 mmol) 
Pd(dppf)2Cl2. The system was degassed for 10min by passing nitrogen trough a 
suspension. The reaction was heated to reflux and allowed to react for 104 h under 
nitrogen atmosphere. The solvent was evaporated and the resulting residue was 
extracted with five times 100 ml CH2Cl2 and washed with water (two times). The 
combined organic phases were dried over Na2SO4. The solvent was evaporated to 
afford 1.18 g of a brown solid, which was further purified by alox column 
chromatography (pH=9.5, 1:1 CH2Cl2/EtOAc) to afford a grey crystalline solid (yield, 
294mg, 18%). 
4-(4-bromophenyl)-pyridine. 1H NMR (200MHz, CDCl3): δ 7.43-7.53 (m, 4H), 7.59-7.65 
(m, 2H), 8.65-8.68 (d, 2H) ESI-MS: m/z 234.5 [M+H]+. 
 
4-methylpyridinium-4’-pyridine iodide[375] 
15 mg 4,4’-bipyridine (0.12 mmol) were dissolved in CHCl3 and 1 eq (14.1 mg, 620 l) 
methyliodide at 4°C and stirred for 30 minutes, then allowed to return to room 
temperature. The resulting precipitate was obtained by cooling the solution to -10°C 
and filtering it. Yield 15.2 mg (73 %). MS (ESI): m/z (%) = 171.7 [M] +(100).  
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Figure 7.5 Povray plot of 4-methylpyridinium-4’-pyridide iodine crystallized from a methanol/n-
pentane mixture. Ellipsoids are drawn at 50% probability.  
The crystal structure above was obtained by reacting 4,4’-bipyridine with one 
equivalent of methyliodide in CHCl3 at 4°C and slowly allowing it to reach room 
temperature. The resulting pale yellow crystal was obtained by vapor diffusion of an 
aqueous solution versus dioxane. The two neighboring pyridine rings are twisted 
against each other in a 60° angle for minimal overlap of its dislocated aromatic 
orbitals. The following crystal structure shows one of the decomposition products of 
4-chloropyridinium bromide in methanol and crystallizing the colorless powder from 
water versus dioxane. 
 
Figure 7.6 Povray plot of 1-(4-pyridine)-4-methoxy-pyridinium dibromide crystallized from a 
methanol solution. Ellipsoids are drawn at 50% probability.  
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7.6 Platinum building blocks 
Pt(NH3)2Cl2, Cisplatin 
[156, 376] 
An aqueous solution (120 ml) of 11.95 g (28.8 mmol) K2PtCl4 was treated with 30 ml 
of a saturated solution of potassium iodide (18.8 g, 113.3 mmol) and heated to 40°C 
in 5 minutes and kept at that temperature for another 15 minutes. Then, 30 ml 8N 
NH3 (aq.) were added to generate a yellow crystalline precipitate and a colorless 
solution. After 2h, the precipitate was filtered followed by washing with cooled 
water, MeOH, Et2O and dried at 50°C to yield 12.7 g of a pale yellow crystalline 
powder (88%). This cis-Pt(NH3)2I2 was suspended in 100 ml water and stirred for 30 
min at 80°C with 8.97  g AgNO3 (52.8 mmol). After 90 min at RT and 2.5 h at 4°C 
without stirring, a yellow precipitate of AgI was filtered over a cellite pad. To the 
yellow filtrate, 4.53 g of KCl (60.8 mmol, 2.3 eq) were given and the solution stirred 
for 10 min at 80°C. The solution was left at 4°C overnight, the precipitate filtered, 
washed with cooled water and MeOH, and then dried to yield 6.25 g (20.8 mmol, 
72.4% yield). 
195Pt-NMR (129 MHz, CDCl3, 293 K):  = - 2112.7 (Pt(2N)(2Cl)). EA: calculated: H, 2.02; 
N, 9.34; found: H, 2.08; N, 9.29.  
 
Pt(NH3)2Cl
+NO3, Pt(NH3)2
2+, activated cisplatin 
All platinum compounds were activated by removing one or two equivalents of the 
chlorides with the help of silver ions (from AgNO3, AgBF4, silver(I)acetate). The 
precipitate was removed by centrifugation, filtering through cellite and drying the 
filtrate in vacuo and conserving the powder for a maximum of 2 days at -20°C in the 
dark. In most cases, the filtrate was directly used for the following reaction without 
further analysis or purification assuming 100% yield.   
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Pt(en)I2, Dhara Synthesis
[156] 
An aqueous solution (120 ml) of 11.95 g (28.8 mmol) K2PtCl4 was treated with 30 ml 
of a saturated solution of potassium iodine (18.8 g, 113.3 mmol) and heated to 40°C 
for 5 minutes. The solution turned from light red to dark red to form K2PtI4. To this, 
2.47 ml (34.4 mmol, 1.2 eq) ethylenediamine (en) were added to leave behind 11.5 g 
(28.0 mmol) yellow crystalline Pt(en)I2 and a colorless solution. Isolated yield: 88.1% 
[Pt(en)I2 [C2H8I2N2Pt, M =  508.99 g/mol]. EA: calculated: C, 4.72; H, 1.58; N, 5.50; 
found: C, 4.76; H, 1.28; N, 5.46. 195Pt-NMR (200 MHz, CDCl3):  = -2133.4. MS (ESI): 
m/z (%) = 531.8 (100) [M + Na]+, 469.5 (15) [M – I + MeOH] +. 195Pt-NMR (129 MHz, 
H2O, 293 K):  = -2967.32 (Pt(3N)I). 
 
cis-Pt(en)Cl2
[325, 329, 377, 378] 
200 mg (0.48 mmol) K2PtCl4 and 38.6 l (0.58 mmol, 1.2 eq) ethylenediamine (en) 
were given in 5 ml H2O and the solution heated to 50 °C and stirred for 14 hours in 
the dark. The reaction was stopped and the yellow precipitate filtered to yield 157.2 
mg. Yield: 96%  
cis-Pt(en)Cl2 [C2H8Cl2N2Pt, M =  326.08 g/mol]. EA: calculated: C, 7.37; H, 2.41; N, 
8.59; found: C, 7.37; H, 1.92; N, 8.50. MS (ESI): m/z (%) = 349.1.8 (100) [M + Na] +. 
195Pt-NMR (129 MHz, H2O, 293 K):  = -2123.72 (Pt(3N)(Cl)). 
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7.7 Multi – porphyrin and Platinum Arrays 
cis-Pt(NH3)2(TriMPyP)2 nitrate, 38 
 
 
 
40.9 mg (0.1 mmol) cis-[Pt(NH3)2(DMSO)2](NO3)2 were dissolved in 5 ml chloroform 
and given into a 5 ml chloroform solution containing 155 mg (0.2 mmol) TriMPyP. 
After 1 day of stirring and mild heating to 45 °C, 4 ml of water were added. The 
aqueous solution turned deep green. The two solvents were separated, the aq. 
solution washed with chloroform and dried in vacuo to yield 96 mg (0.055 mmol, 55 
%)  
cis-Pt(NH3)2(TriMPyP)2 nitrate [C86H76O24N26Pt, M = 2051.52 g/mol] HPLC : 6.42 
min[190, 378]. EA: calc. C, 50.32; H, 3.72; N, 17.74; found: C, 50.55; H, 3.58; N, 18.02. MS 
(ESI): m/z (%) = 197.5 [M-8NO3+H2O]
8+  (100), 369.3 [M-8NO3-5CH3]
3+ (90). 
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cis-Pt(NH3)2(MPyTPP)2 nitrate 
 
40 mg (0.12 mmol) cis-Pt(NH3)2Cl2 were dissolved in 5 ml DMSO, 2 eq. AgNO3 (40.8 
mg, 0.24 mmol) were added and stirred for 1 hour. The solution was separated by 
centrifugation from the precipitation, dried in vacuo and the resulting light yellow 
product dissolved in 5 ml dichlormethane. To this solution, 150 mg (0.24 mmol) 
MPyTPP were added and the mixture stirred for 1 day at 42 °C. Yield: 55 % 
cis-Pt(NH3)2(MPyTPP)2 nitrate [C86H64N14O6Pt, M = 1584.6 g/mol] EA: calc. C, 65.19; H, 
4.07; N, 12.37; found: C, 65.22 H, 4.31; N, 12.22. MS (ESI): m/z (%) = 792 [M-NO3]
2+ 
(70). 
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cis-(NH3)2Pt-di-5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin 
nitrate, 35 
 
30 mg (0.02 mmol) 5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin 
nitrate (35) were given in 5 ml H2O, then a filtered aqueous solution of 4.6 mg (0.019 
mmol) cis-(NH3)2Pt(H2O)2 were added and the solution stirred for 10 days at 40 °C. 
The reaction was monitored by HPLC. After cooling the solution to room 
temperature, it was treated with a 0.01 M KCl solution. Then, the solution was dried 
in vacuo and the purple precipitate washed with acetone, iced water and methanol. 
After dissolving it again in water, the solution was lyophilized at 0.2 mbar overnight 
to afford the greenish product.  Yield: 34 mg, 0.028 mmol, 88%.  
cis-(NH3)2Pt-di-5,10,15-methylpyridinium-20-para-benzonitrile-zinc(II)-porphyrin 
nitrate. HPLC: 7.39 min (100%). MS (ESI): m/z (%) = 250.3 [35]3+ (100), 251.8 
[35+Pt(NH3)2+(H2O)]
4+ (30), 253.9 [35+Pt(NH3)2+(H2O)]
4+ (50), 338.3 [M]3+ (20), 367.5 
[35-CH3]
2+ (400), 375 [35]2+ (80). 195Pt-NMR (129 MHz, CDCl3):  = -2662.43. 
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(cis-[Pt(NH3)2Cl]2 5,15-dipyridylporphrin nitrate 
 
An activated cisplatin solution (25mg, 0.1mmol in 30 ml DMF) was added to a 
solution of (23.4 mg, 0.5 eq.) 5,15-dipyridylporphrin in DMF and the solution stirred 
for 3 days. The reaction was followed by TLC. The resulting purple compound was 
soluble in ethanol or dichloromethane, but not in water although it has 2 positive 
charges.  
MS (ESI): m/z (%) = 1081.2 (9.5) [M-Cl]+. 195Pt-NMR (200 MHz, CDCl3):  = -2326.3. 
 
 (cis-[Pt(NH3)2Cl]2 trans-DPyDPP nitrate, reaction of cisplatin with 3. 
An activated cisplatin solution (25mg, 0.1mmol in 30 ml DMF) was added to a 
solution of (30.5 mg, 0.5 eq.) trans-DPyDPP, 3 in DMF and the solution stirred for 3 
days. The reaction was followed by TLC. The resulting purple compound was soluble 
in CHCl3, CH2Cl2, but not in water although it has 2 positive charges located on the 
platinum. The analysis was not conclusive due to solubility issues.  
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[cis-Pd(en)2(4,4’-bipyridyl)]4 nitrate 
[175, 176] 
 
Ta a solution of Pd(en)Cl2 (40 mg, 0.17 mmol) in dry MeOH (5 ml), AgNO3 (57.2 mg, 
0.34 mmol) were added and the precipitate was filtered off. The solvent was 
removed in vacuo and the activated palladium salt dissolved in D2O (4 ml). Then, 4,4’-
bipyridine (21.8 mg, 0.14 mmol) were added and the mixture stirred at 10 °C for 1h. 
The square was isolated as a white precipitate (73.8 g, 41.3 mol) by addition of 
ethanol in 93 % yield.  
1H-NMR (200 MHz, D2O):  8.76 (8H, d, J = 6.6 Hz), 7.77 (8H, d, J = 6.6 Hz), 2.84 (16H, 
d, J = 6.0 Hz).  
 
[cis-Pt(en)2(4,4’-bipyridyl)]4 nitrate 
Ta a solution of Pt(en)I2 (40 mg, 0.08 mmol) in dry MeOH (5 ml), AgNO3 (26.8 mg, 
0.16 mmol) were added and the precipitate was filtered off. The solvent was 
removed in vacuo and the activated palladium salt dissolved in D2O (4 ml). Then, 4,4’-
bipyridine (12.8 mg, 0.08 mmol) were added and the mixture stirred at 10 °C for 1h. 
The square was isolated as a white precipitate (41.6 g, 19.4 mol) by addition of 
ethanol in 95 % yield. 
1H-NMR (200 MHz, D2O):  8.81 (8H, d, J = 6.0 Hz), 7.80 (8H, d, J = 6.0 Hz), 2.76 (16H, 
d, J = 6.2 Hz).  
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7.8 CD titration of poly (dG-dC) - poly (dG-dC) with Cu2+, Ni2+ and Zn2+ 
porphyrins 
7.8.1 UV, Fluorescence, and CD titration of 5’-GMP with (metallo)-porphyrins 
800 l of a 0.1 mM aqueous (1 mM sodium cacodylate buffer solution (pH = 7.0)) 
solution of 5’-GMP were given into a 1ml CD quartz cuvette. To this solution, aliquots 
of a 1 mM solution (buffered sodium cacodylate solution (pH = 7.0) of the 
corresponding (metallo)-porphyrin solution were added. The corresponding 
measurements were carried out in a quartz cuvette with a magnetic stirrer. All 
measurements were taken at 25 °C unless otherwise described. The data obtained 
were processed in Windows Excel and Origin 7.0.  
7.8.2 UV, Fluorescence, and CD titration of poly d(GC) with (metallo)-
porphyrins[379] 
The DNA solution (concentration of approximately 0.1 mM) in an aqueous 1 mM 
sodium cacodylate buffer solution (pH = 7.0) was determined by UV vis spectroscopy 
(260 = 8400 1/cm*M for 1 base)
[379]. To this solution, aliquots of a 1 mM solution 
(buffered sodium cacodylate solution (pH = 7.0) of the corresponding (metallo)-
porphyrin solution were added. The corresponding measurements were carried out 
in a quartz cuvette with or without a magnetic stirrer. All measurements were done 
at 25 °C unless otherwise described. The data obtained were processed in Windows 
Excel and Origin 7.0.  
7.8.3 HPLC Measurements[343] 
Gradient 1 (13 min, for 26 min gradient double the times indicated) starting with 0% methanol in a 0.1% TFA 
aqueous solution ramping up to 100% methanol within 8 minutes, holding at 100% methanol for 2 minutes, 
going back to 100% aqueous solution within 1 minute and washing.  
Gradient 2 (13 min) starting with 0% methanol in a 0.1% TFA and 5% NaCl aqueous solution ramping up to 
100% methanol within 8 minutes, holding at 100% methanol for 2 minutes, going back to 100% aqueous 
solution within 1 minute and washing. 
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7.9  MTT Cytotoxicity Studies 
7.9.1  Cell Lines [380, 381] 
A2780 cell line (human ovarian cancer) were grown in RPMI-1680 (Gibco) 
supplemented with 10% FBS, 60 g mL-1 streptomycin (Gibco) and 60 units (0.66 g 
per unit) penicillin. MCF-7 cell line (human mama-carcinoma) were grown in MEM-
10370 (Gibco) supplemented with 10% FBS, 60 g mL-1 streptomycin (Gibco) and 60 
units (0.66 g per unit) penicillin. HeLa cell line (cervical cancer) is one of the oldest 
and most commonly used human cell lines. The line was grown in DMEM-41966 
(Gibco) supplemented with 10% FBS, 60 g mL-1 streptomycin (Gibco) and 60 units 
(0.66 g per unit) penicillin. 
 
7.9.2  MTT Cytotoxicity assay [38, 347, 382, 383] 
Five hundred cells/well were plated in 96-well plates kept at 5% CO2 at 37 °C, treated 
the next day with various concentrations of cisplatin, porphyrin or Pt-porphyrin 
derivative (17 - 22) with a final volume of 100l. After 18 hours incubation, one set of 
cells treated with 17 - 22 was exposed to light (slide projector, 3200 lux, cut off filter 
>600nm, IR free and water-cooled light source, 10 minutes). After an additional 3 
days, 20 L of MTT solution (5mg/ml, Sigma, in PBS filter-sterilize) were added, the 
plates were incubated for 5 h at 37° C. 100 l of lyses solution were added (10 g SDS, 
25 mL DMF, 25 ml ddH2O, pH <4.7 (phosphate buffer), and the plates were incubated 
overnight at 37 °C. The soluble formazan was quantified at 570 nm using an ELISA 
reader. All specific growth rates are expressed as the mean of quintuplets of three 
independent experiments. 
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7.9.3 Crystallographic Data 
Code, Nr. bs020510, 10 pa071109 pa101107 
Empirical formula  C48H46I4N8O2 C32H22N4 C14H18I2N2O3 
Formula weight  1274.53 462.54 516.10 
Crystal system  Monoclinic Monoclinic Triclinic 
Space group  P21/n P21/c P-1 
a [Å]  17.0290(9)  14.5305(7)  8.0284(2)  
b [Å]  6.7744(5)  16.8710(7)  9.3576(3)  
c [Å]  21.0200(11)  9.6388(4)  12.6851(3)  
 [°]  90 90 104.858(2) 
 [°]  90.731(5) 105.324(4) 103.816(2) 
 [°]  90 90 91.525(2) 
Volume [Å3]  2424.7(3)  2278.89(17)  890.55(4)  
Z 2 4 2 
Density (calculated) [Mg/m3]  1.746  1.348  1.925  
Absorption coefficient [mm-1]  2.617 0.081 3.541 
F(000) 1236 968 492 
Crystal size [mm3]  0.15 x 0.13 x 0.02  0.41 x 0.09 x 0.03  0.34 x 0.06 x 0.06  
Crystal description dark red plate purple needle yellow needle 
Theta range for data 
collection [°]  
3.06 to 25.68 2.59 to 25.35 2.26 to 30.51 
Index ranges -20<=h<=17 
-7<=k<=8 
-25<=l<=22 
-12<=h<=17 
-20<=k<=17 
-11<=l<=9 
-11<=h<=11 
-13<=k<=13 
-17<=l<=18 
Reflections collected 11410 10831 18547 
Independent reflections 4605 [R(int) = 0.0591] 4176 [R(int) = 0.0637] 5437 [R(int) = 0.0275] 
Reflections observed 2821 2149 3818 
Criterion for observation >2sigma(I) >2sigma(I) >2sigma(I) 
Completeness to theta  99.8 % to 25.68°  99.9 % to 25.35°  99.9 % to 30.51°  
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Max. and min. transmission 0.9618 and 0.3990 0.9976 and 0.7168 0.8156 and 0.5132 
Data / restraints / parameters 4605 / 0 / 282 4176 / 0 / 325 5437 / 1 / 207 
Goodness-of-fit on F2 0.967 0.886 1.022 
Final R indices [I>2sigma(I)] R1 = 0.0683 
wR2 = 0.1619 
R1 = 0.0594 
wR2 = 0.1110 
R1 = 0.0296 
wR2 = 0.0588 
R indices (all data) R1 = 0.1079 
wR2 = 0.1729 
R1 = 0.1356 
wR2 = 0.1268 
R1 = 0.0567 
wR2 = 0.0628 
Largest diff. peak and hole 
[e.Å-3]  
2.513 and -0.942 0.223 and -0.361 0.973 and -0.727 
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Name, Nr. pa101209, 2 pa110209 ss191109 
Empirical formula  C43H29N5 C23H33B2Cl3N2O4 C14H13N3 
Formula weight  615.71 529.48 223.27 
Crystal system  Monoclinic Orthorhombic Monoclinic 
Space group  C2 Pna21 P21 
a [Å]  20.042(14)  18.7419(4)  8.1252(5)  
b [Å]  14.977(7)  11.9472(3)  6.1476(2)  
c [Å]  13.605(9)  24.9145(6)  12.0015(6)  
 [°]  90 90 90 
 [°]  131.71(2) 90 100.960(5) 
 [°]  90 90 90 
Volume [Å3]  3049(3)  5578.7(2)  588.55(5)  
Z 4 8 2 
Density (calculated) [Mg/m3]  1.341  1.261  1.260  
Absorption coefficient [mm-1]  0.080 0.359 0.077 
F(000) 1288 2224 236 
Crystal size [mm3]  0.30 x 0.30 x 0.02  0.22 x 0.11 x 0.09  0.43 x 0.13 x 0.10  
Crystal description dark red plate colourless needle colourless needle 
Theta range for data 
collection [°]  
1.92 to 26.37 2.18 to 24.11 2.55 to 30.51 
Index ranges -25<=h<=25 
-16<=k<=16 
-16<=l<=16 
-21<=h<=21 
-13<=k<=13 
-28<=l<=28 
-11<=h<=11 
-8<=k<=8 
-17<=l<=12 
Reflections collected 10871 29488 5796 
Independent reflections 3004 [R(int) = 0.0682] 8641 [R(int) = 0.0764] 1947 [R(int) = 0.0208] 
Reflections observed 2630 4057 1509 
Criterion for observation >2sigma(I) >2sigma(I) >2sigma(I) 
Completeness to theta  92.4 % to 26.37°  99.9 % to 24.11°  99.9 % to 30.51  
Absorption correction None Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Max. and min. transmission  0.9684 and 0.9282 0.9923 and 0.8766 
Data / restraints / parameters 3004 / 1 / 433 8641 / 94 / 629 1947 / 1 / 154 
Goodness-of-fit on F2 1.039 0.806 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0771 
wR2 = 0.2091 
R1 = 0.0528 
wR2 = 0.1078 
R1 = 0.0457 
wR2 = 0.1058 
R indices (all data) R1 = 0.0849 
wR2 = 0.2171 
R1 = 0.1300 
wR2 = 0.1218 
R1 = 0.0603 
wR2 = 0.1109 
Absolute structure parameter  0.13(8)  
Largest diff. peak and hole 
[e.Å-3]  
0.369 and -0.382 0.584 and -0.302 0.190 and -0.162 
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Name, Nr pa301009 ss150110 ss111009 
Empirical formula  C11H11IN2 C11H12Br2N2O C29H22N2O2 
Formula weight  298.12 348.05 430.49 
Crystal system  Orthorhombic Monoclinic Orthorhombic 
Space group  Pbca C2/c Pbca 
a [Å]  16.4984(4)  14.4906(4)  13.3655(3)  
b [Å]  7.40945(16)  10.4674(3)  17.3425(4)  
c [Å]  18.6719(6)  17.1762(7)  19.7854(5)  
 [°]  90 90 90 
 [°]  90 101.806(3) 90 
 [°]  90 90 90 
Volume [Å3]  2282.53(10)  2550.16(15)  4586.10(18)  
Z 8 8 8 
Density (calculated) 
[Mg/m3]  
1.735  1.813  1.247  
Absorption coefficient 
[mm-1]  
2.770 6.339 0.079 
F(000) 1152 1360 1808 
Crystal size [mm3]  0.32 x 0.06 x 0.02  0.17 x 0.06 x 0.04  0.43 x 0.33 x 0.14  
Crystal description colourless needle colourless block colourless prism 
Theta range for data 
collection [°]  
2.51 to 29.13 2.42 to 28.28 2.82 to 27.10 
Index ranges -19<=h<=22 
 -9<=k<=10 
-25<=l<=22 
-19<=h<=19 
-13<=k<=13 
-22<=l<=22 
-17<=h<=17 
-14<=k<=23 
-26<=l<=16 
Reflections collected 11561 14089 19356 
Independent reflections 3066 [R(int) = 0.0554] 3149 [R(int) = 
0.0496] 
5050 [R(int) = 
0.0302] 
Reflections observed 1841 1918 2984 
Criterion for observation >2sigma(I) >2sigma(I) >2sigma(I) 
Completeness to theta  99.9 % to 29.13°  100.0 % to 28.28°  99.9 % to 28.28°  
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Max. and min. transmission 0.9467 and 0.8378 0.7856 and 0.7238 0.9891 and 0.9358 
Data / restraints / 
parameters 
3066 / 0 / 128 3149 / 0 / 146 5679 / 0 / 298 
Goodness-of-fit on F2 0.915 0.822 0.950 
Final R indices [I>2sigma(I)] R1 = 0.0413 
wR2 = 0.0893 
R1 = 0.0325 
wR2 = 0.0485 
R1 = 0.0573 
wR2 = 0.1491 
R indices (all data) R1 = 0.0826 
wR2 = 0.0991 
R1 = 0.0746 
wR2 = 0.0526 
R1 = 0.1183 
wR2 = 0.1671 
Largest diff. peak and hole 
[e.Å-3]  
0.950 and -0.646 0.717 and -0.390 0.553 and -0.155 
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